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A B S T R A C T
Background
Tibolone is a synthetic steroid used for the treatment of menopausal symptoms, on the basis of short-term data suggesting its efficacy.
We considered the balance between the benefits and risks of tibolone.
Objectives
To evaluate the effectiveness and safety of tibolone for treatment of postmenopausal and perimenopausal women.
Search methods
In October 2015, we searched the Gynaecology and Fertility Group (CGF) Specialised Register, the Cochrane Central Register of
Controlled Trials (CENTRAL), MEDLINE, Embase and PsycINFO (from inception), the Cumulative Index to Nursing and Allied
Health Literature (CINAHL) and clinicaltrials.gov. We checked the reference lists in articles retrieved.
Selection criteria
We included randomised controlled trials (RCTs) comparing tibolone versus placebo, oestrogens and/or combined hormone therapy
(HT) in postmenopausal and perimenopausal women.
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Data collection and analysis
We used standard methodological procedures of The Cochrane Collaboration. Primary outcomes were vasomotor symptoms, unsched-
uled vaginal bleeding and long-term adverse events. We evaluated safety outcomes and bleeding in studies including women either with
or without menopausal symptoms.
Main results
We included 46 RCTs (19,976 women). Most RCTs evaluated tibolone for treating menopausal vasomotor symptoms. Some had other
objectives, such as assessment of bleeding patterns, endometrial safety, bone health, sexuality and safety in women with a history of
breast cancer. Two included women with uterine leiomyoma or lupus erythematosus.
Tibolone versus placebo
Vasomotor symptoms
Tibolone was more effective than placebo (standard mean difference (SMD) -0.99, 95% confidence interval (CI) -1.10 to -0.89; seven
RCTs; 1657 women; moderate-quality evidence), but removing trials at high risk of attrition bias attenuated this effect (SMD -0.61,
95% CI -0.73 to -0.49; odds ratio (OR) 0.33, 85% CI 0.27 to 0.41). This suggests that if 67% of women taking placebo experience
vasomotor symptoms, between 35% and 45% of women taking tibolone will do so.
Unscheduled bleeding
Tibolone was associated with greater likelihood of bleeding (OR 2.79, 95% CI 2.10 to 3.70; nine RCTs; 7814 women; I2 = 43%;
moderate-quality evidence). This suggests that if 18% of women taking placebo experience unscheduled bleeding, between 31% and
44% of women taking tibolone will do so.
Long-term adverse events
Most of the studies reporting these outcomes provided follow-up of two to three years (range three months to three years).
Breast cancer
We found no evidence of differences between groups among women with no history of breast cancer (OR 0.52, 95% CI 0.21 to 1.25;
four RCTs; 5500 women; I2= 17%; very low-quality evidence). Among women with a history of breast cancer, tibolone was associated
with increased risk (OR 1.5, 95% CI 1.21 to 1.85; two RCTs; 3165 women; moderate-quality evidence).
Cerebrovascular events
We found no conclusive evidence of differences between groups in cerebrovascular events (OR 1.74, 95% CI 0.99 to 3.04; four RCTs;
7930 women; I2 = 0%; very low-quality evidence). We obtained most data from a single RCT (n = 4506) of osteoporotic women aged
60 to 85 years, which was stopped prematurely for increased risk of stroke.
Other outcomes
Evidence on other outcomes was of low or very low quality, with no clear evidence of any differences between the groups. Effect
estimates were as follows:
• Endometrial cancer: OR 2.04, 95% CI 0.79 to 5.24; nine RCTs; 8504 women; I2 = 0%.
• Cardiovascular events: OR 1.38, 95% CI 0.84 to 2.27; four RCTs; 8401 women; I2 = 0%.
• Venous thromboembolic events: OR 0.85, 95% CI 0.37 to 1.97; 9176 women; I2 = 0%.
• Mortality from any cause: OR 1.06, 95% CI 0.79 to 1.41; four RCTs; 8242 women; I2 = 0%.
Tibolone versus combined HT
Vasomotor symptoms
Combined HT was more effective than tibolone (SMD 0.17, 95% CI 0.06 to 0.28; OR 1.36, 95% CI 1.11 to 1.66; nine studies; 1336
women; moderate-quality evidence). This result was robust to a sensitivity analysis that excluded trials with high risk of attrition bias,
suggesting a slightly greater disadvantage of tibolone (SMD 0.25, 95% CI 0.09 to 0.41; OR 1.57, 95% CI 1.18 to 2.10). This suggests
that if 7% of women taking combined HT experience vasomotor symptoms, between 8% and 14% of women taking tibolone will do
so.
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Unscheduled bleeding
Tibolone was associated with a lower rate of bleeding (OR 0.32, 95% CI 0.24 to 0.41; 16 RCTs; 6438 women; I2 = 72%; moderate-
quality evidence). This suggests that if 47% of women taking combined HT experience unscheduled bleeding, between 18% and 27%
of women taking tibolone will do so.
Long-term adverse events
Most studies reporting these outcomes provided follow-up of two to three years (range three months to three years). Evidence was of
very low quality, with no clear evidence of any differences between the groups. Effect estimates were as follows:
• Endometrial cancer: OR 1.47, 95% CI 0.23 to 9.33; five RCTs; 3689 women; I2 = 0%.
• Breast cancer: OR 1.69, 95% CI 0.78 to 3.67; five RCTs; 4835 women; I2 = 0%.
• Venous thromboembolic events: OR 0.44, 95% CI 0.09 to 2.14; four RCTs; 4529 women; I2 = 0%.
• Cardiovascular events: OR 0.63, 95% CI 0.24 to 1.66; two RCTs; 3794 women; I2 = 0%.
• Cerebrovascular events: OR 0.76, 95% CI 0.16 to 3.66; four RCTs; 4562 women; I2 = 0%.
• Mortality from any cause: only one event reported (two RCTs; 970 women).
Authors’ conclusions
Moderate-quality evidence suggests that tibolone is more effective than placebo but less effective than HT in reducing menopausal
vasomotor symptoms, and that tibolone is associated with a higher rate of unscheduled bleeding than placebo but with a lower rate
than HT.
Compared with placebo, tibolone increases recurrent breast cancer rates in women with a history of breast cancer, and may increase
stroke rates in women over 60 years of age. No evidence indicates that tibolone increases the risk of other long-term adverse events, or
that it differs from HT with respect to long-term safety.
Much of the evidence was of low or very low quality. Limitations included high risk of bias and imprecision. Most studies were financed
by drug manufacturers or failed to disclose their funding source.
P L A I N L A N G U A G E S U M M A R Y
Short-term and long-term effects of tibolone in postmenopausal women
Review question
Cochrane review authors aimed to evaluate the effectiveness and safety of tibolone for treatment of postmenopausal and perimenopausal
women.
Background
Tibolone is an available option for the treatment of menopausal symptoms, and short-term data suggest its efficacy. However, healthcare
providers must consider the balance between benefits and risks of tibolone, as concerns have arisen about breast and endometrial cancer
and stroke.
Study characteristics
We included 46 randomised controlled trials (RCTs), which included 19,976 postmenopausal women. Most studies evaluated tibolone
for treatment of menopausal vasomotor symptoms. Some studies reported other objectives: Four RCTs aimed to assess endometrial
safety, four bleeding patterns, five bone loss or fracture prevention, one sexual outcomes and three safety in women with a history of
breast cancer; two studies examined use of tibolone in women with fibroids or lupus erythematosus. The evidence is current to October
2015.
Key results
Moderate-quality evidence suggests that tibolone is more effective than placebo and less effective than combined hormone therapy
(HT) in reducing vasomotor symptoms in postmenopausal women. Data suggest that if 67% of women taking placebo experience
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vasomotor symptoms, then between 35% and 45% of women taking tibolone will do so; and if 7% of women taking combined HT
experience vasomotor symptoms, then between 8% and 14% of women taking tibolone will do so. Moderate-quality evidence also
suggests that tibolone is associated with a higher rate of unscheduled bleeding than placebo, but a lower rate than HT.
Compared with placebo, tibolone increases the risk of recurrent breast cancer in women with a history of breast cancer, and may increase
the risk of stroke in women over 60 years of age. No evidence suggests that tibolone increases the risk of other serious adverse events,
and no evidence shows differences between tibolone and HT with respect to long-term adverse events. Nearly all evidence on adverse
events was of very low quality, and reported events were scarce.
Quality of the evidence
Much of the evidence obtained was of low or very low quality. Limitations included high risk of bias in the included trials, very low
event rates and potential conflicts of interest. Twenty-six of the studies were financed by drug manufacturers, and another 14 studies
failed to disclose their source of funding.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Tibolone compared with placebo: vasomotor symptoms
Population: postmenopausal women with vasomotor symptoms
Settings: outpat ient or community
Intervention: t ibolone
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Tibolone
Vasomotor symptoms
(all doses)
Follow-up: 12 weeks to
1 year
670 per 1000 400 per 1000
(350 to 450)
OR 0.33
(0.27 to 0.41)
842
(5 RCTs)
⊕⊕©©
moderatea
Three studies at high
risk of attrit ion bias
were excluded f rom this
analysis. Inclusion of
these studies was asso-
ciated with stronger ef -
fect of t ibolone but with
extreme heterogeneity
(I2= 97%)
* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI)
CI: conf idence interval; OR: odds rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: We are very uncertain about the est imate
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B A C K G R O U N D
Description of the condition
Hot flushes are among the most characteristic clinical symptoms
of menopause (Politi 2008); they are probably caused by labil-
ity in the hypothalamic thermoregulatory centre induced by re-
duction of oestrogen and progesterone levels (Freedman 1995).
Hot flushes and sweats of increasing severity can occur during the
night, leading to sleep problems (Porter 1996). Hot flushes and
sweats are described as vasomotor symptoms.
Many postmenopausal women report a variety of symptoms such
as vaginal dryness (Suckling 2006), sexual discomfort, urinary in-
continence (Cody 2012) and frequent urinary infection, proba-
bly resulting from the natural decline of oestrogen levels (Speroff
2004).
All symptoms tend to fluctuate, and their perceived severity varies
greatly among individuals, with some reporting intense discomfort
and a substantial reduction in quality of life.
Researchers have successfully used oestrogens and progestogens to
ameliorate vasomotor (MacLennan 2004) and vaginal symptoms
(Suckling 2006), anxiety and lowmood (NCC-WCH2015). Uri-
nary tract infections are less clearly influenced by combined hor-
mone therapy (HT) (Soc Obstetr Gynaecol Canada 2014).
Description of the intervention
Tibolone (Livial®, ORG OD 14) is a synthetic steroid widely
prescribed to postmenopausal women in Europe.
How the intervention might work
After its commercialisation, tibolone gained some popularity for
combining oestrogenic and progestogen actions. Its mechanism
of action is not well known, although many studies, most spon-
sored by the drug manufacturer, indicate that the drug undergoes
different tissue-selective metabolic transformations and may exert
weak oestrogen, progestogen and/or androgen activities (Modelska
2002). The oestrogenic effects, exerted mainly in brain, bone and
vaginal tissues, are weaker on the endometrium, where the drug is
transformed into progestogenmetabolites. In breast tissue, limited
conversion of oestrone to oestradiol may reduce the oestrogenic ef-
fects. In brain and liver, tibolone seems to have androgenic effects.
Some randomised controlled clinical trials (RCTs) have suggested
that tibolone decreases vasomotor symptoms and ameliorates vagi-
nal dryness and discomfort, but results are not consistent. AnRCT
published in 2009 (Kenemans 2009) highlighted that tibolone
increases recurrence of breast cancer, revealing a contraindication
for women with a history of breast cancer. Although the drug is
thought to have a possible role in preserving bone mineral density,
control of osteoporosis is not a recommended indication.
Why it is important to do this review
The safety profile of tibolone has not been well defined, and tri-
als evaluating its use to treat patients with vasomotor symptoms
usually provide follow-up periods that are too short for assessment
of potential long-term adverse events such as increased risk of en-
dometrial (Beral 2005) and breast (Kenemans 2009; Beral 2003)
cancer and of cardiovascular events (Cummings 2008). For this
reason, safety has been evaluated in a wider population, and RCTs
including women who did not take tibolone for symptomatic re-
lief have been considered.
O B J E C T I V E S
To evaluate the effectiveness and safety of tibolone for treatment
of postmenopausal and perimenopausal women.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs). We did not include quasi-
randomised and cross-over trials.
Types of participants
Menopausal and perimenopausal women with or without vaso-
motor and/or genital symptoms, defined as women with surgical
menopause or with spontaneous menopause, or women who had
menstruated irregularly over the past 12 months.
Types of interventions
• Tibolone use versus placebo
• Tibolone use versus oestrogens
• Tibolone use versus combined HT (referring to two
different formulations: sequential combined and continuous
combined)
This review did not consider tibolone use versus no treatment.
Types of outcome measures
Primary outcomes
• Vasomotor symptoms measured as occurrences or through
scales, defined as any otherwise unexplained sensation of
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flushing/sweating experienced by the participant. We included
studies that measured hot flushes (with or without night sweats),
provided that they measured hot flushes as an outcome of
efficacy in populations including symptomatic women
• Unscheduled bleeding (vaginal bleeding and/or spotting)
• Long-term adverse events: endometrial cancer, breast
cancer, venous thromboembolic events, cardiovascular events,
cerebrovascular events, mortality from any cause
Secondary outcomes
• Insomnia (frequency or continuous outcome)
• Genital symptoms: vaginal dryness and painful sexual
intercourse (measured as frequency or severity), vaginal infection
(inflammation of the vagina usually related to one of three
infectious conditions: bacterial vaginosis, vulvovaginal
candidiasis, trichomoniasis), urinary tract infection
• Endometrial hyperplasia
We measured all outcomes other than vasomotor symptoms in
women with or without vasomotor symptoms.
We included studies assessing at least one of these specific out-
comes, even if they did not report useable data. We excluded stud-
ies not assessing such outcomes.
Search methods for identification of studies
Electronic searches
We searched for all relevant published and unpublished RCTs,
without language restriction, and in consultation with the
Cochrane Gynaecology and Fertility Group (CGF) Information
Specialist.
We searched the CGF Specialised Register (formerly known as the
Menstrual Disorders and Subfertility Group Specialised Register),
the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, Embase, PsycINFO and the Cumulative Index to
Nursing and Allied Health Literature (CINAHL), from inception
until 15 October 2015, using the strategies shown in Appendix 1,
Appendix 2, Appendix 3, Appendix 4, Appendix 5 and Appendix
6. For the search of clinicaltrials.gov, we used “tibolone” as a key-
word. We contacted individual researchers and the current man-
ufacturer of tibolone to ask them to identify unpublished and on-
going trials.
Searching other resources
We contacted individual researchers working in relevant fields (gy-
naecology, endocrinology) and the current manufacturer of ti-
bolone (Merck Sharp & Dome) to check for additional relevant
references and unpublished and ongoing trials. We also checked
the reference lists of all studies identified by the above methods.
Data collection and analysis
Selection of studies
Four review authors (GF, EP, SM, SB) independently screened
the titles and abstracts of articles found in the search for inclu-
sion. We searched for outcomes of interest in the full texts, even if
they had not been reported in the abstracts. We resolved disagree-
ments by discussion and by consultation with two additional re-
view authors (VB, a gynaecologist; and EM, an endocrinologist).
We sought further information from study authors who published
papers containing insufficient information to permit a decision
about eligibility. We recorded reasons for excluding studies after
debate and agreement.
Data extraction and management
Five review authors (GF, EP, SM, SB, JW) independently ex-
tracted details of study design, participants, interventions, follow-
up, quality components, efficacy outcomes and adverse events.
Three other review authors (VB, a gynaecologist; EM, an endocri-
nologist; and AMM, a cardiologist) resolved discrepancies regard-
ing extraction of quantitative data or risk of bias assessment of
RCTs. When a trial was presented in abstract form, we sought
further information by searching the Internet, by contacting study
authors and by checking for the next best available resource or
publication. We contacted study authors for further insight on
study design and results, when we considered this necessary. For
studies with more than one publication, we extracted data from
all publications, but we considered the final or updated version of
each trial to be the primary reference.
We extracted the following information from the studies included
in the review (see also Characteristics of included studies table).
Trial characteristics
• Randomisation
• Allocation concealment
• Trial design: multi-centre or single-centre
• Number of women randomised, excluded and analysed
• Duration, timing and location of the trial
• Source of funding and conflicts of interest
Baseline characteristics of studied groups
• Definition and duration of preexisting menopausal
condition
• Age of the women
• Previously administered treatment(s)
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Interventions
• Type of intervention and control
• Dose regimen
• Treatment duration
Outcomes
• Outcomes reported
• Definitions of outcomes
• The way outcomes were measured
• Timing of outcome measurement
If data were reported only in figures, we used Microsoft Power-
Point to extract data from the figures. We opened the figure in the
software and overlaid a grid. We drew horizontal or vertical lines
as needed, and we ‘snapped’ (aligned) them to this grid, to ensure
that they were parallel/perpendicular to the plot axes, as required.
We could move lines drawn in the software vertically and horizon-
tally, so we could read off the value corresponding to a given data
point in a scatterplot or the height of a bar in a bar chart against
the appropriate axis. A single review author (JW) extracted data
from figures.
Assessment of risk of bias in included studies
We assessed risk of bias of included trials by taking six components
into account: generation of the allocation sequence (participant
randomisation), allocation concealment, blinding (or masking)
of participants and personnel, blinding of outcome assessment,
completeness of follow-up (attrition bias) and selective reporting.
We used the following definitions when assessing risk of bias.
Generation of the allocation sequence
• Adequate: if the allocation sequence was generated by a
computer or by a random number table. We considered drawing
of lots, tossing of a coin, shuffling of cards or throwing of die as
adequate if a person not otherwise involved in recruitment of
participants performed the procedure
• Unclear: if the trial was described as randomised, but the
method used for generation of the allocation sequence was not
described
• Inadequate: if a system involving dates, names or
admittance numbers was used for allocation of women. We
excluded these studies, known as quasi-randomised, from the
present review
We also excluded trials with alternating allocation.
Allocation concealment
• Adequate: if allocation of women involved a central,
independent unit; an on-site locked computer; identical
appearing numbered drug bottles or containers prepared by an
independent pharmacist or investigator; or sealed, opaque
envelopes
• Unclear: if the trial was described as randomised but the
method used to conceal the allocation was not described
• Inadequate: if the allocation sequence was known to
investigators who assigned participants, envelopes were unsealed
or transparent or the study was quasi-randomised
Blinding (or masking) of participants and personnel
• Adequate: if the trial was described as double-blind and the
method of blinding involved identical placebo or active drugs,
particularly:
◦ double-blind (method described and use of a
placebo(s) or dummy technique meant neither the participant
nor the care provider or assessor knew which treatment was
given)
◦ single-blind (participant, care provider or assessor was
aware of the treatment given)
• Unclear: if the trial was described as double-blind or single-
blind but the method of blinding was not described
• Not performed: if the trial was open-label (all parties aware
of treatment)
Blinding of outcome assessment
• Adequate: if in the absence of blinding of outcome
assessment, review authors judged that outcome measurement
was not likely to be influenced by lack of blinding; or if blinding
of outcome assessment was ensured and it was unlikely that
blinding could have been broken
• Unclear: if information was insufficient to permit
judgement of ‘low risk’ or ‘high risk’, or if the study did not
address this outcome
• Inadequate: if no blinding of outcome assessment occurred
and outcome measurement was likely to be influenced by lack of
blinding; or if blinding of outcome assessment was present but
blinding could have been broken, and if outcome measurement
was likely to be influenced by lack of blinding
Completeness of follow-up (attrition bias)
• Adequate: if numbers and reasons for dropouts and
withdrawals in all intervention groups were described and 90%
or more of randomised participants were included in the analysis;
or if it was specified that no dropouts or withdrawals occurred
• Unclear: if the report gave the impression that no dropouts
or withdrawals occurred but this was not specifically stated
• Inadequate: if less than 90% of randomised participants
were included in the analysis; or numbers or reasons for dropouts
and withdrawals were not provided
We contacted the authors of primary trial reports when necessary
to request clarification of data and to obtain missing information.
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Selective reporting
• Adequate: if the study protocol was available and all of the
study’s prespecified (primary and secondary) outcomes of interest
in the review were reported in the prespecified way
• Unclear: if information was insufficient to permit
judgement of ‘low risk’ or ‘high risk’
• Inadequate: if not all of the study’s prespecified primary
outcomes were reported; if one or more primary outcomes were
reported via measurements, analysis methods or subsets of data
(e.g. subscales) that were not prespecified; if one or more
reported primary outcomes were not prespecified (unless clear
justification for their reporting was provided, such as an
unexpected adverse effect); if one or more outcomes of interest in
the review were reported incompletely and could not be included
in a meta-analysis; or if the study report failed to include results
for a key outcome that would have been expected to be reported
for such a study
Measures of treatment effect
We evaluated efficacy and safety outcomes by considering the
number of women in the control and intervention groups of each
study experiencing at least one event (dichotomous outcomes) to
calculate Mantel-Haenszel odds ratios (DerSimonian 1986) with
95% confidence intervals (CIs), or (for continuous outcomes)
mean scores, standard deviations and the number of women in
each group, using the inverse variance method. The primary out-
come ‘vasomotor symptoms’ and the secondary outcomes vaginal
dryness and sleep were exceptions; we reported these outcomes as
binary or continuous variables - the first two using several scales.
Accordingly, we converted all treatment effect estimates from bi-
nary or continuous variables to standardised mean differences
(SMDs), as this permitted pooling of these variants in ameta-anal-
ysis. Pooled SMDs computed in this manner can be transformed
and interpreted as odds ratios, at the cost of information related
to symptom severity (Higgins 2011).
Unit of analysis issues
This systematic review considered only RCTs. The unit of analysis
in each RCT was the women who were randomised to one of the
treatment arms. For vaginal bleeding, we considered endometrial
hyperplasia and endometrial cancer only in women with a uterus.
Dealing with missing data
We analysed data on an intention-to-treat basis as far as possible by
including all randomised participants in the groups to which they
were allocated. Missing data in included studies compromised re-
alisation of this strategy. Moreover, options to rectify the matter
were limited in the absence of individual participant data. Accord-
ingly, we took the approach of penalising trials with notable rates
of attrition in the risk of bias assessment and conducting sensitiv-
ity analyses that were restricted to trials with low risk of bias in
this domain. We incorporated these sensitivity analyses into our
conclusions.
Assessment of heterogeneity
We included in the meta-analysis all outcomes reported by indi-
vidual studies, noting heterogeneity by using Chi2 and I2 statis-
tics (Higgins 2002). We stated that the Chi2 statistic was statisti-
cally significant if P < 0.10. The I2statistic indicated the percent
of variability due to between-study (or interstudy) variability, as
opposed to within-study (or intrastudy) variability.We considered
an I2value greater than 50% to be large (Higgins 2002). When
statistically significant heterogeneity existed, we conducted a care-
ful clinical review of the data to seek the source of such hetero-
geneity and to decide whether statistical combining of trials was
warranted.
Assessment of reporting biases
We graphically assessed publication bias by using contour-en-
hanced funnel plots.
Data synthesis
Weused a random-effects model, except for vasomotor symptoms,
vaginal dryness and sleep, for which we combined data from di-
chotomous and continuous outcomes in a fixed-effect model by
converting all treatment effect estimates to standardised mean dif-
ferences (SMDs). We deemed this necessary because the key as-
sumption of random-effects meta-analysis - that all observed treat-
ment effects represent realisations from a common underlying dis-
tribution - did not appear to be warranted, given the diversity of
outcome reporting scales used. Poor reporting standards required
that we impute standard deviations for several studies reporting
on menopausal symptoms to combine their results; we calculated
all effect sizes and corresponding standard errors by using the
metaphor package (Viechtbauer 2010) in R (R Core Team 2015).
If results for this outcome were available at several time points, we
used results corresponding to the longest period of use. Table 1 and
Table 2 provide details of methods used in analyses of menopausal
symptoms and vaginal dryness, as well as reasons for exclusion of
several RCTs from these meta-analyses.
We sought the following comparisons.
• Tibolone use, stratified by dose, versus placebo.
• Tibolone use, stratified by dose, versus oestrogens.
• Tibolone use, stratified by dose, versus combined HT.
To avoid multiple-counting of a control group in RevMan, we
split the numbers of events and of exposed participants in studies
with multiple arms, depending on the number of comparisons,
as suggested in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011; see paragraph 16.5.4). We did not
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perform this procedure in cases of rare events (e.g. when one or
three cases should have been split) or when estimated odds ratios
differed by more than 0.05 from the non-stratified analysis. In
the latter case, we combined intervention groups (e.g. different
doses of tibolone) to create a single pair-wise comparison versus
the control group.
Subgroup analysis and investigation of heterogeneity
We stratified results according to tibolone dose. Two of the largest
RCTs, which assessed the occurrence of breast cancer and cardio-
cerebrovascular events, selected very specific and heterogeneous
populations; therefore, we considered that it would be informative
to present results on breast cancer separately for women who had
a history of breast cancer and those who had no such history, and
results on cardiovascular and cerebrovascular events that distin-
guished women younger than and over 60 years of age. We did
not prespecify these subgroup analyses.
Sensitivity analysis
We conducted sensitivity analyses of the primary outcome to de-
termine whether conclusions were robust to arbitrary decisions
regarding eligibility and analysis. In performing these analyses, we
considered whether conclusions would have differed if:
• eligibility had been restricted to studies without high risk of
attrition bias; and
• eligibility had been further restricted to studies that used
validated scales to measure vasomotor symptoms.
Overall quality of the body of evidence - Summary of
findings table
We used GRADEPRO software and methods of The Cochrane
Collaboration to prepare a Summary of findings table (Higgins
2011). This table portrayed the overall quality of the body of
evidence for main review outcomes (occurrence of vasomotor
symptoms, vaginal bleeding, breast cancer, endometrial cancer, ve-
nous thromboembolic events, cardiovascular events, cerebrovas-
cular events and mortality from any cause) and main comparisons
(tibolone vs placebo, tibolone vs HT) on the basis of GRADE
criteria (study limitations (i.e. risk of bias), consistency of effect,
imprecision, indirectness and publication bias). We justified, doc-
umented and incorporated Judgements about evidence quality
(high, moderate, low or very low) into the reporting of results for
each outcome.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
The original systematic search performed in 2011 through seven
databases produced 540 records (after duplicates were removed).
After selecting 57 papers of potential interest from their titles and
abstracts, we eventually included 33 RCTs. Two of these articles
(Ziaei 2010; Ziaei 2010b) appeared to report different outcomes
for the same study; we have amalgamated these and counted them
as a single study in the 2016 update.
We performed additional searches in 2015: we initially selected 62
additional abstracts and found 14 additional RCTs, plus another
publication (Bots 2006) for one of the studies already included
(Langer 2006). (See Figure 1 for study flow.) We have included in
this update six studies that were excluded in the previous version of
the review (see Differences between protocol and review). There-
fore this review update includes a total of 46 studies (32 studies
from the previous version of the review, six that were excluded
from the previous version of the review and eight new studies).
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Figure 1. Study flow diagram.
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Of these newly included reports, five (Bouchard 2012; Gupta
2013; Jacobsen 2012; Morais-Socorro 2012; Polisseni 2013) were
published since 2012, and three (Baracat 2002; Doren 1999;
Wender 2004)were cited among references provided in other stud-
ies. We asked drug manufacturers, as well as authors of conference
proceedings, about possibly unpublished studies but obtained no
information on this.
Included studies
Study design and setting
We included 46 RCTs of parallel design; 18 were multi-centre
studies.
Participants
All selected RCTs included postmenopausal or perimenopausal
women (n = 19,976), and in most of these RCTs, all or some par-
ticipants had menopausal symptoms. A few studies did not clearly
specify whether women were symptomatic, or whether investiga-
tors had other reasons to test the effectiveness of tibolone. Among
these, five RCTs (Archer 2007; Hänggi 1997; Doren 1999; Okon
2005; Wender 2004) were carried out with the main objective
to assess endometrial safety associated with the use of tibolone,
and four RCTs (Elfituri 2005; Huber 2002; Winkler 2000; Ziaei
2010) had as their main objective assessment of bleeding patterns.
Five of the included RCTs (Cummings 2008; Gallagher 2001;
Jacobsen 2012; Langer 2006; Roux 2002) assessed effects of ti-
bolone on bone loss in postmenopausal women, in addition to
its safety profile and its effects on menopausal symptoms. One
study (Cummings 2008) also evaluated the reduction in fractures
among women with osteoporosis.
Three RCTs (Kenemans 2009; Kroiss 2005; Kubista 2007) specif-
ically studied individuals with breast cancer: Kenemans 2009
assessed the recurrence of breast cancer in women with vaso-
motor symptoms who were previously treated surgically; Kroiss
2005 evaluated the safety profile of tibolone administered to post-
menopausal women after breast cancer surgery to prevent, relieve
or delay the occurrence of menopausal symptoms; Kubista 2007
assessed the safety of 14-day tibolone treatment of breast tissue in
patients with invasive cancer without metastatic spread, and we
included this study because an ischaemic stroke occurred.
Among populations with specific characteristics other than
menopausal symptoms, one RCT (de Aloysio 1998) selected pa-
tients with uterine leiomyomas to assess the effects of tibolone on
bleeding patterns. Another RCT (Vieira 2009) assessed the fre-
quency of flares in patients with lupus erythematosus.
Most of the included RCTs studied women in natural menopause
only, although a few studies also included women without a
uterus. In these cases, investigators evaluated endometrial out-
comes (bleeding, hyperplasia, cancer) only in women with an in-
tact uterus.
The mean age of women in most of the selected studies was be-
tween 52 and 55 years. In two trials (Cummings 2008; Jacobsen
2012) that selected women older than 60 years of age, researchers
observed much higher means, whereas in one trial (Elfituri
2005) on Lybian women with natural or surgical menopause, the
mean age of participants was lower (44 years). Mean time since
menopause ranged from 1.5 to 17 years.
All but three of the selected RCTs included fewer than 1000 par-
ticipants. Each of the three largest RCTs (Archer 2007; Cummings
2008; Kenemans 2009) actually included more than 3000 partic-
ipants. Follow-up periods ranged from two weeks to four years.
Interventions
The included studies administered oral tibolone (usually 2.5 mg
daily: range 0.625 mg to 5 mg daily) compared with placebo,
unopposed oestrogen or combined HT, as detailed below. Unless
otherwise stated, doses were daily and progesterone was continu-
ous. Several studies included more than one comparator.
• Placebo (17 RCTs): Benedek-Jaszmann 1987, Berning
2000, Bouchard 2012, Cummings 2008, Gallagher 2001,
Hudita 2003, Jacobsen 2012, Kenemans 2009, Kroiss 2005,
Kubista 2007, Landgren 2002, Meeuwsen 2002, Morais-Socorro
2012, Swanson 2006, Vieira 2009, Volpe 1986, Wender 2004
• Unopposed oestrogen (three RCTs)
◦ Conjugated equine oestrogen (CEE) 0.0625 (Gupta
2013)
◦ Oestriol 2 to 4 mg (Volpe 1986)
◦ 17β-Oestradiol patch 50 µg (Mendoza 2000)
• Combined HT (28 RCTs)
◦ CEE 0.625 mg plus medroxyprogesterone acetate 2.5
to 5 mg (Archer 2007;Baracat 2002;de Aloysio 1998;Huber
2002;Kökçü 2000;Langer 2006;Uygur 2005;Wu 2001;Ziaei
2010)
◦ Oestradiol valerate 2 mg and norethisterone 0.7 to
2mg (Al-Azzawi 1999;Okon 2005)
◦ Oestradiol 50 µg + norethisterone acetate (140
microgr) in the form of a transdermal patch (Nijland 2009)
◦ Oestradiol valerate 2 mg plus dienogest 2 mg
(Osmana ao lu 2006)
◦ Oestradiol 2 mg + oestriol 1 mg/d + norethindrone
acetate 1 mg/d (Winkler 2000)
◦ Oestradiol 1 to 2 mg plus norethindrone 0.5 to 1 mg
(Polisseni 2013;Roux 2002)
◦ 17β-Oestradiol 1 to 2 mg + norethisterone 0.5 to 1
mg (Doren 1999;Hammar 1998;Hammar 2007;Nappi
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2006a;Nathorst-Böös 1997)
◦ Oestradiol 2 mg + medrogestone 10 mg (Egarter
1996)
◦ CEE 0.625 mg plus sequential 150 µg norgestrel
(Ross 1999)
◦ CEE 0.625 mg plus sequential medroxyprogesterone 5
mg (Siseles 1995)
◦ CEE 0.625 mg plus sequential norethisterone 5 mg
(Siseles 1995;Volpe 1986)
◦ CEE 0.625 mg + sequential cyproterone acetate 12.5
mg/d (Volpe 1986)
◦ Oestradiol valerate 2 mg plus sequential cyproterone
acetate 12.5 mg (Volpe 1986)
◦ Oestradiol valerate 2 mg plus sequential
norethisterone 5 mg (Volpe 1986)
◦ 17β-Oestradiol oral 2 mg or patch 50 µg plus
sequential oral dydrogesterone 10 mg (Elfituri 2005;Hänggi
1997)
◦ 17β-Oestradiol patch 50 µg plus sequential
norethisterone 0.25 mg (Mendoza 2002)
◦ Transdermal β-oestradiol patch 50 µg plus micronised
natural progesterone 200 mg twice a week (Mendoza 2002)
Outcomes
Of 46 RCTs, 23 evaluated the effectiveness of tibolone for treat-
ment of vasomotor symptoms in symptomatic women, mea-
sured as occurrence (Kökçü 2000; Meeuwsen 2002), as frequency
(Bouchard 2012; Hammar 2007; Landgren 2002; Swanson 2006)
or with the use of scales (Benedek-Jaszmann 1987; Elfituri 2005;
Hammar 1998; Huber 2002; Hudita 2003;Morais-Socorro 2012;
Polisseni 2013; Wu 2001; Ziaei 2010). Data from eight other
RCTs (Al-Azzawi 1999; Baracat 2002; Egarter 1996; Ross 1999;
Siseles 1995; Vieira 2009; Volpe 1986; Wender 2004) that evalu-
ated vasomotor symptoms were unsuitable for analysis (see Table
1 for detailed explanations).
• Twenty-eight of 46 RCTs evaluated unscheduled bleeding
(24 could be considered for meta-analyses).
• Ten of 46 RCTs evaluated breast cancer.
• Thirteen of 46 RCTs evaluated endometrial cancer.
• Nine of 46 RCTs evaluated venous thromboembolic events.
• Five of 46 RCTs evaluated cardiovascular events.
• Eight of 46 RCTs evaluated cerebrovascular events.
• Six of 46 RCTs evaluated mortality from any cause.
• Nine of 46 RCTs evaluated endometrial hyperplasia (extra
one is Volpe 1986).
• Sixteen of 46 RCTs evaluated vaginal dryness and painful
sexual intercourse (seven could be considered for meta-analyses)
(extra ones are Mendoza 2000 and Uygur 2005).
• Four of 46 RCTs evaluated insomnia.
• Two of 46 RCTs evaluated vaginal infection.
• One of 46 RCTs evaluated urinary tract infection.
Excluded studies
We excluded 24 studies from the review. Following are the most
common reasons for exclusion (occurring inmore than one RCT).
• Three of 24 were not randomised.
• Fifteen of 24 did not assess outcomes of interest.
• Four of 24 did not include a comparator of interest.
Risk of bias in included studies
See also Characteristics of included studies, Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
TwentyRCTsdescribed adequatemethods of sequence generation;
we rated them as having low risk of bias in this domain. We rated
25 studies as having unclear risk. We rated one study (Wu 2001)
as having high risk of bias; investigators stated they allocated to
treatment groups randomly selected pairs of two women.
Allocation concealment
Most of the selectedRCTs provided no information regarding allo-
cation concealment. Only 10 of 46 RCTs specified that researchers
used a system for concealing allocation (low risk of bias): an inter-
active voice response system in five RCTs, another computerised
system (the Almedica Drug Labelling System; Almedica, Parsip-
pany, NJ, USA) in one RCT and opaque envelopes in four RCTs.
We rated remaining studies as having unclear risk of bias.
Blinding
Performance bias
In 22 out of 46 RCTs, participants and/or personnel were blinded
(low risk of bias). Fourteen RCTs were open trials or blinding
appeared unlikely (high risk of bias), and 10 provided insufficient
or no information by which this domain could be assessed (unclear
risk).
Detection bias
We considered risk of bias as low in 25 of 46 RCTs, whereas 10
RCTs did not provide enough information for assessment, and we
rated 13 studies as having high risk of bias in this domain.
Incomplete outcome data
We considered 17 of 46 RCTs to have low risk of attrition bias.
Several RCTs reported some reasons for concern (lack of inten-
tion-to-treat analysis, loss to follow-up with no reasons specified).
In particular, investigators gave no clear reasons for excluding par-
ticipants from treatment and/or evaluation in six RCTs (rated as
having unclear risk), and more than 10% of participants were lost
to follow-up in 23 RCTs (rated as having high risk).
Selective reporting
Only nine of 46 study protocols were available; we judged risk of
selective reporting bias as low in all of these studies, as they reported
expected outcomes of interest for this review, or they reported data
on adverse events that were not indicated in the study protocol but
could be expected in the study report. We rated all other studies
as having unclear risk.
Other potential sources of bias
The drug producer sponsored most of the RCTs, and its employ-
ees often authored the articles. We rated 26 as having high risk
of bias and 10 unclear risk. Just six of 46 RCTs appeared truly
independent, and we rated them as having low risk of bias in this
domain.
Effects of interventions
See: Summary of findings for the main comparison Tibolone
compared with placebo for treatment of vasomotor symptoms
in postmenopausal women; Summary of findings 2 Tibolone
compared with placebo for postmenopausal women: adverse
events; Summary of findings 3 Tibolone compared with
combined HT for treatment of vasomotor symptoms in
postmenopausal women; Summary of findings 4 Tibolone
compared with combined HT for postmenopausal women:
adverse events
Tibolone versus placebo
Primary outcomes
Vasomotor symptoms
Eight RCTs reported useable data on this outcome; three other
RCTs reported data that could not be used (see Table 1). A sub-
stantial effect of tibolone on vasomotor symptoms compared with
placebo is suggested (see Analysis 1.1 and Figure 4), with a pooled
estimate of the SMD of -0.99 (95% CI -1.10 to -0.89; n = 1657;
I2 = 96%; moderate-quality evidence). Multiplying this by the
pooled standard deviation from Hammar 1998 (0.76) suggests
that tibolone could improve vasomotor symptoms by around 0.75
(0.7 to 0.8) points on a 5-point severity scale. A sensitivity anal-
ysis (see Analysis 1.15) excluding three RCTs with attrition bias
(Benedek-Jaszmann 1987; Hudita 2003; Morais-Socorro 2012 -
the latter two also have very large estimates) still shows an effect
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of tibolone, with reduced heterogeneity and effect size (SMD -
0.61, 95% CI -0.73 to -0.49; I2 = 54%). The corresponding odds
ratio (OR) is 0.33 (95% CI 0.27 to 0.41). These estimates can
be translated to meaningful scales; multiplying the SMD by the
pooled standard deviation from Hammar 1998 (0.76) suggests
that tibolone could improve vasomotor symptoms by around 0.5
(0.4 to 0.6) points on a 5-point severity scale; this probably would
not constitute a clinically meaningful effect.
Figure 4. Forest plot of comparison: 1 Tibolone versus placebo, outcome: 1.1 Vasomotor symptoms.
Subgroup analysis by dose
We found strong evidence (P < 0.00001) of differences between
subgroups defined by tibolone dose, although this was diminished
when we removed trials with high risk of attrition bias, which were
likely to provide overestimates (P = 0.04). Furthermore, once we
removed these trials, we noted the suggestion of a dose-response
relationship (Analysis 1.15; Figure 5), although trials were too few
to allow formal investigation of this through meta-regression.
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Figure 5. Forest plot of comparison: 1 Tibolone versus placebo, outcome: 1.15 Sensitivity analysis -
Vasomotor symptoms without trials with high risk of attrition bias.
Subgroup analysis by duration
Wenoted some scope, albeit limited, for review authors to consider
the impact of treatment duration on the effect; estimates from
four of the included studies (Bouchard 2012; Landgren 2002;
Morais-Socorro 2012; Swanson 2006) corresponded to 12 weeks,
from one (Hudita 2003) to 24 weeks, from one (Ziaei 2010) to six
months and from one (Benedek-Jaszmann 1987) to 12 months.
All seven studies appeared in the stratum corresponding to a dose
of 2.5 mg/d. Accordingly, we were able to look at estimates in
this stratum to see whether duration modified the treatment ef-
fect when dose was held constant. As we recalled the high risk of
attrition bias in Hudita 2003 andMorais-Socorro 2012, we noted
that no such relationship was evident; neither the estimate from
Benedek-Jaszmann 1987 (12 months) nor that from Ziaei 2010
(six months) was notably different from the 12 week estimates.
Unscheduled bleeding
Nine RCTs reported this outcome (Analysis 1.2). Unscheduled
bleeding was more likely to occur in the tibolone group (OR 2.79,
95% CI 2.10 to 3.70; nine RCTs; n = 7814; I2 = 43%; moderate-
quality evidence). This suggests that if 18% of women taking
placebo experience unscheduled bleeding, then between 31% and
44% of women taking tibolone will do so. Statistical significance
persisted if we excluded the two largest RCTs (Cummings 2008;
Kenemans 2009), which provided 47% of the total weight and
about 85% of the population of interest.
Subgroup analysis by dose
Results were stratified by dose (2.5 and 1.25 mg daily). Effect
estimates were similar in the two groups.
Long-term adverse events
Endometrial cancer
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Eight RCTs reported this outcome (Analysis 1.3). We found no
evidence of a difference between groups, although the event rate
was low, with 16 cases reported in the tibolone arms and five in
the placebo arms (OR 2.04, 95% CI 0.79 to 5.24; eight RCTs;
8504 women; I2 = 0%; very low-quality evidence).
Evidence suggests that if one woman in a thousand taking placebo
develops endometrial cancer, then between one and six women in
a thousand who take tibolone may do so. Seven and four cases, re-
spectively, occurred in Kenemans 2009 (with 2.5mg/d; n = 3133),
and four versus zero cases in Cummings 2008 (with 1.25 mg; n =
3519). Fifteen cases (11 in tibolone arms vs four in placebo arms)
occurred in studies recruiting younger postmenopausal women
(average age < 55 years).
Breast cancer
Six RCTs assessed this outcome: four in women without a history
of breast cancer (Analysis 1.4) and two in women with a history
of breast cancer (Analysis 1.5).
Among women without a history of breast cancer, we found no
evidence of a difference between groups (OR 0.52, 95% CI 0.21
to 1.25; four RCTs; 5500 women; I2 = 17%; very low-quality
evidence).
Among women with a history of breast cancer, we noted increased
risk in the tibolone group (OR 1.5, 95% CI 1.21 to 1.85; two
RCTs; 3165 women; moderate-quality evidence). All events oc-
curred in the largest of the studies (Kenemans 2009), which ad-
ministered 2.5 mg/d of tibolone and was stopped prematurely ow-
ing to increased risk in the intervention group.
Venous thromboembolic events
Five RCTs assessed this outcome; three of them (Cummings 2008;
Kenemans 2009; Landgren 2002) reported the occurrence of
events (Analysis 1.6). We found no evidence of a difference be-
tween groups (OR 0.85, 95% CI 0.37 to 1.97; n = 9176; I2 = 0%;
very low-quality evidence).
Ten cases (seven in tibolone arms vs three in placebo arms) of a
total of 24 occurred in studies recruiting younger postmenopausal
women (average age < 55).
Cardiovascular events
We found no evidence of a difference between groups (OR 1.38,
95% CI 0.84 to 2.27; four RCTs; n = 8401; I2 = 0%; very low-
quality evidence; Analysis 1.7).
The four RCTs assessing this outcome involved women of very
different age groups (Cummings 2008, mean age 68; Jacobsen
2012, mean age 74; Kenemans 2009, mean age 53 years; Langer
2006, mean age 59), but we observed no statistical heterogeneity
between these studies.
Cerebrovascular events
Four RCTs assessed this outcome (Analysis 1.8) and provided no
conclusive evidence of a difference between groups (OR1.74, 95%
CI 0.99 to 3.04; four RCTs; n = 7930; I2 = 0%).
One RCT (Cummings 2008; n = 4506), which selected osteo-
porotic women aged 60 to 85 years, provided most of the data;
this trial was stopped prematurely for increased risk of stroke with
1.25 mg/d of tibolone (28 vs 13 cases; OR 2.18, 95% CI 1.12
to 4.21). Among women younger than 60 years old (Kenemans
2009), five cases occurred in each group (OR 0.99, 95% CI 0.29
to 3.42; n = 3133).
Mortality from any cause
Four RCTs assessed this outcome, and three reported events
(Analysis 1.9), providing no evidence of a difference between
groups (OR 1.06, 95% CI 0.79 to 1.41; five RCTs; n = 8242; I2
= 0%; low-quality evidence).
Secondary outcomes
Insomnia
Three RCTs reported insomnia or “sleep” (Analysis 1.10).
Results suggested an advantage of tibolone over placebo related to
insomnia or quality of sleep (SMD -0.19, 95% CI -0.38 to 0.00;
three RCTs; n = 3432; I2 = 0%).
Genital symptoms
Vaginal dryness
Three RCTs (Hudita 2003; Kenemans 2009; Ziaei 2010) reported
useable data on this outcome (see Analysis 1.11 and Table 2),
suggesting an advantage of tibolone over placebo for vaginal dry-
ness, although this would barely be evident if the two arms from
Hudita 2003, which had a high dropout rate, were excluded. The
SMD(95%CI) includingHudita 2003 was -0.66 (-0.90 to -0.43),
which corresponds to improvement on a 0 to 3 severity score of 0.6
(0.4 to 0.8) points with a standard deviation (SD) of 0.89. This
probably would not amount to a clinically meaningful difference.
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Vaginal infection
Two RCTs reported this outcome (Analysis 1.12). The rate of
vaginal infection was higher in the tibolone group (OR 2.50, 95%
CI 1.24 to 5.06; two RCTs; n = 7639; I2 = 88%). The direction of
effect was consistent, but considerable statistical heterogeneity was
probably due todifferences in the population studied (osteoporotic
women aged 60 to 85 years in Cummings 2008, and younger
women who had experienced breast cancer in Kenemans 2009).
Urinary tract infection
One RCT (Kenemans 2009) reported this outcome (Analysis
1.13) and revealed no evidence of a difference between groups
(OR 0.70, 95% CI 0.46 to 1.06; one RCT; n = 3133).
Endometrial hyperplasia
Four RCTs assessed this outcome, and two reported events
(Analysis 1.14), providing no evidence of a difference between
groups, although results revealed only seven events in total (OR
1.20, 95% CI 0.23 to 6.25; n = 4518; I2 = 0%).
Tibolone versus oestrogens
Primary outcomes
Two RCTs (Gupta 2013; Mendoza 2002) compared tibolone ver-
sus oestrogens and reported data on three outcomes (vasomotor
symptoms, vaginal dryness and painful sexual intercourse, insom-
nia).
Vasomotor symptoms
We found no evidence of a difference between groups (OR 1.23,
95% CI 0.35 to 4.34; two RCTs; n = 108; I2 = 0%; low-quality
evidence), although the small number of events observed meant
that large effects in either direction could not be ruled out. See
Analysis 2.1 and Figure 6.
Figure 6. Forest plot of comparison: 2 Tibolone versus oestrogens, outcome: 2.1 Vasomotor symptoms.
Secondary outcomes
Insomnia
No events occurred in either group (Analysis 2.2).
Genital symptoms
Vaginal dryness and painful sexual intercourse
We found no evidence of a difference between groups (OR 0.32,
95% CI 0.01 to 8.25; one RCT; n = 50), although the estimate
was so imprecise as to be completely uninformative (Analysis 2.3).
Tibolone versus combined HT
Primary outcomes
Vasomotor symptoms
Nine RCTs reported useable data on this outcome, and five other
RCTs provided data that could not be used (see Table 1). Results
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suggested a small disadvantage of tibolone compared with com-
bined HT (see Analysis 3.1 and Figure 7), with a pooled esti-
mate of the SMD of 0.17 (95% CI 0.06 to 0.28; n = 1336; I2
= 67%; moderate-quality evidence). Multiplying this estimate by
the pooled standard deviation fromHammar 1998 (0.76) suggests
that combinedHT improves vasomotor symptoms by around 0.15
(0.08 to 0.23) compared with tibolone on a 5-point severity scale.
The corresponding OR was 1.36 (95% CI 1.11 to 1.66). A sen-
sitivity analysis (see Analysis 3.11) excluding five RCTs with high
attrition bias provided slightly larger but similar estimates (SMD
0.25, 95% CI 0.09 to 0.41; I2 = 0%). A further sensitivity anal-
ysis excluding the latter five RCTs plus Hammar 1998 (using a
non-validated scale) revealed no evidence of a difference between
treatments because the estimate lacked precision once other stud-
ies were excluded (see Analysis 3.12).
Figure 7. Forest plot of comparison: 3 Tibolone versus combined HT, outcome: 3.1 Vasomotor symptoms.
Subgroup analysis by duration
Duration of treatment in this comparison ranged from 12 weeks
to 12 months, while dose was the same in all studies (2.5 mg/d);
therefore, a tentative investigation of the impact of treatment du-
ration on treatment effect could be undertaken. Althoughwe iden-
tified too few studies to permit a formal analysis (e.g. using meta-
regression), we were able to order the studies according to dura-
tion so as to inspect whether a trend in the size of the SMDs was
suggested (Analysis 3.13). However, we observed no clear trend,
and consequently found no evidence that the difference between
tibolone and HT varies according to the duration of treatment.
Unscheduled bleeding
Seventeen RCTs reported this outcome: 15 compared tibolone
with continuous combined HT, two with continuous sequential
HT (Analysis 3.2). The latter studies included cases of bleeding if
they had been reported as side effects by study authors.
Tibolonewas associatedwith fewer breakthrough events than com-
bined HT (OR 0.32, 95% CI 0.24 to 0.41; 16 RCTs; n = 6438; I
2 = 72%; low-quality evidence), suggesting that if 47% of women
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taking combined HT experience unscheduled bleeding, then be-
tween 18% and 27% of those taking tibolone will do so. High
heterogeneity was attributable in part to an RCT (Nijland 2009)
in which HT was delivered in patch form, and also to a difference
between dose subgroups, as noted below.
Statistical significance persisted if we excluded the largest RCT
(Archer 2007, which provided about half of the population of
interest).
One RCT (Okon 2005) reported this outcome as days of bleeding
over one year of follow-up. Study authors reported no significant
differences between groups.
Subgroup analysis by dose
We stratified results by dose, revealing a statistically significant dif-
ference between 2.5 mg and 1.25 mg subgroups (test for subgroup
differences: Chi² = 7.28; df = 1 (P = 0.007); I² = 86.3%), which
suggested that the lower dose of tibolone was associated with a
more beneficial effect when compared with HT (OR 0.21, 95%
CI 0.16 to 0.26; two RCTs; n = 1718; I2 = 0%).
Long-term adverse events
Endometrial cancer
Five RCTs reported this outcome (Analysis 3.3). Few events oc-
curred (two cases in tibolone arms vs one in combined HT arms in
three trials), and investigators provided no evidence of a difference
between groups (OR 1.47, 95% CI 0.23 to 9.33; five RCTs; n =
3689; I2 = 0%; very low-quality evidence).
Breast cancer
Five RCTs assessed this outcome (Analysis 3.4). All included
women without a history of breast cancer. Few events occurred
(17 cases in tibolone arms vs 10 in combined HT arms), and
researchers provided no evidence of a difference between groups
(OR 1.69, 95% CI 0.78 to 3.67; n = 4835; I2 = 0%; very low-
quality evidence).
Twenty-two cases (13 in tibolone arms vs nine in placebo arms)
occurred in studies recruiting younger postmenopausal women
(average age < 55).
Venous thromboembolic events
Four RCTs assessed this outcome (Analysis 3.5). Few events oc-
curred (one case of pulmonary embolism in tibolone arms vs two
cases of pulmonary embolism and three of deep venous thrombo-
sis in combined HT arms), and researchers provided no evidence
of a difference between groups (OR 0.44, 95% CI 0.09 to 2.14;
four RCTs; n = 4529; I2 = 0%; very low-quality evidence).
Cardiovascular events
Two RCTs assessed this outcome (Archer 2007; Langer 2006).
Few events occurred (seven in tibolone arms vs 11 in combined
HT arms), and results showed no evidence of a difference between
groups (OR 0.63, 95% CI 0.24 to 1.66; two RCTs; n = 3794; I2
= 0%; very low-quality evidence; Analysis 3.6). The mean age of
women in these RCTs was less than 60 years.
Cerebrovascular events
Four RCTs assessed this outcome (Analysis 3.7). Few events oc-
curred (two cases in tibolone arms vs four cases in combined HT
arms), and data show no evidence of a difference between groups
(pooled OR 0.76, 95% CI 0.16 to 3.66; four RCTs; n = 4562; I
2 = 0%; very low-quality evidence). The mean age of women in
these RCTs was less than 60 years.
Mortality from any cause
Two RCTs (Langer 2006; Nijland 2009; n = 970) reported this
outcome, with only one case noted in the tibolone arm (Analysis
3.8).
Secondary outcomes
Insomnia
Just one RCT (Egarter 1996) used a validated scale (a domain of
the Kupperman Index) to assess this outcome but provided no
data suitable for analysis (SD was not reported and could not be
calculated sensibly via the information provided). The publication
reported no evidence of a difference between tibolone and com-
bined HT.
Genital symptoms
Vaginal dryness and painful sexual intercourse
Evidence at face value suggested little or no difference between
tibolone and combined HT in relation to vaginal dryness (SMD
0.02, 95% CI -0.12 to 0.17; seven RCTs; n = 1098; moderate-
quality evidence; Analysis 3.10).
Mendoza 2000 (n = 76) also measured painful sexual intercourse
as an outcome but provided no data suitable for analysis; study
authors reported no significant difference between groups.
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Similarly, Nathorst-Böös 1997 evaluated dyspareunia but pro-
vided no data suitable for analysis, and study authors reported that
they found no evidence of a difference between groups.
Vaginal infection
None of the selected RCTs reported useable data on this outcome
Urinary tract infection
None of the selected RCTs reported useable data on this outcome.
Endometrial hyperplasia
Five RCTs assessed this outcome (Analysis 3.9), reporting few
events (zero cases in tibolone arms vs three cases in the combined
HT arm) and no evidence of a difference between groups (OR
0.35, 95% CI 0.05 to 2.21; five RCTs; n = 2846; I2 = 0%).
Sensitivity analyses
Aside from sensitivity analyses performed for evaluation of vaso-
motor symptoms, as described above (see Results 1.1 and 3.1),
review authors performed sensitivity analyses for primary out-
comes, considering alternative scenarios in participants lost to fol-
low-up. We performed three analyses on placebo-controlled RCTs
(specifically on venous thromboembolic events and breast can-
cer in women who had or had no history of breast cancer) and
two on combined HT controlled RCTs (specifically on unsched-
uled bleeding and vasomotor symptoms). None of these analyses
showed differences in terms of direction of effect and statistical
significance.
Assessment of review-wide reporting bias
Funnel plot analyses were not helpful to review authors in assess-
ing the presence of publication bias, given the relative scarcity of
studies and data. Vasomotor symptoms and unscheduled bleeding
were the only outcomes with sufficient RCTs to permit such an
assessment, which revealed no evidence of bias for this outcome.
As for the other outcomes, we cannot exclude the occurrence of
publication bias because the drug manufacturer, who sponsored
almost all of the published RCTs, was asked for possibly unpub-
lished data but provided no written response.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Tibolone compared with placebo: adverse events
Population: postmenopausal women with or without vasomotor symptoms
Settings: outpat ient or community
Intervention: t ibolone
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Tibolone
Endometrial cancer (all
doses)
Follow-up: 1 to 3 years
(median 1)
See comment OR 2.04
(0.79 to 5.24)
8504
(9 studies)
⊕©©©
very lowa,b,c
Events very rare in both
groups. Total of 21
events: 16/ 4486 in t i-
bolone group, 5/ 4018 in
placebo group
Breast
cancer; women without
previous breast cancer
(all doses)
Follow-up: 12 weeks to
3 years
4 per 1000 1 per 1000
(1 to 5)
OR 0.52
(0.21 to 1.25)
5500
(4 studies)
⊕©©©
very lowa,b
In women with a history
of breast cancer, risk in-
creased in the t ibolone
group at 1 to 2.75 years’
follow up: OR 1.50 (1.21
to 1.85, 2 RCTs, 3165
women, moderate-qual-
ity evidence )
Unscheduled bleeding
(all doses)
Follow-up: 1 to 3 years
(median 2)
177 per 1000 374 per 1000
(310 to 442)
OR 2.79
(2.1 to 3.7)
7814
(9 studies)
⊕⊕©©
moderated
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Venous thromboem-
bolic events (clinical
evaluation) all doses
Follow-up: 1 to 2.75
years (median 1.5)
See comment OR 0.85
(0.37 to 1.97)
9176
(5 studies)
⊕©©©
very lowa,b,c
Events very rare in both
groups. Total of 24
events: 12/ 5054 in t i-
bolone group, 12/ 4122
in placebo group
Cardiovascular events
(all doses)
Follow-up: 2 to 3 years
(median 2.75)
10 per 1000 13 per 1000
(8 to 22)
1.38
(0.84 to 2.27)
8401
(4 studies)
⊕©©©
very lowa,b,c
⊕©©©
very lowa,b,c
Cerebrovascular
events (all doses)
Follow-up: 14 days to 2.
8 years
5 per 1000 8 per 1000
(4 to 14)
OR 1.74
(0.99 to 3.04)
7930
(4 studies)
⊕©©©
very lowa,b
M ortality from any
cause (all doses)
Follow-up: 1 to 3 years
(median 2.77)
10 per 1000 10 per 1000
(8 to 14)
OR 1.06
(0.79 to 1.41)
8242
(4 studies)
⊕⊕©©
lowb,e
* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI)
CI: conf idence interval; OR: odds rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: We are very uncertain about the est imate
aDowngraded two levels for very serious risk of bias: poor report ing of study methods, high attrit ion and/ or potent ial conf lict
of interest in most studies
bDowngraded one level for serious imprecision: low event rate. Findings compatible with meaningful benef it in one or both
arms, or with no ef fect
cDowngraded one level for serious risk of low applicability: Some studies compare doses of t ibolone that have not been
marketed (although downgrading has no ef fect on rat ing, as study already rated very low)2
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dDowngraded one level for serious risk of bias: poor report ing of study methods and potent ial conf lict of interest in most
studies
eDowngraded one level for potent ial conf lict of interest (funding by pharmaceut ical companies)
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Tibolone compared with combined HT for postmenopausal women: vasomotor symptoms
Population: postmenopausal women with vasomotor symptoms
Settings: outpat ient or community
Intervention: t ibolone
Comparison: combined HT
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Combined HT Tibolone
Vasomotor symptoms
(tibolone 2.5 mg/ d)
Follow-up: 3 to 12
months
70 per 1000 110 per 1000
(80 to 140)
OR 1.57
(1.18 to 2.1)
646
(4 studies)
⊕©©©
moderatea
From a sensit ivity anal-
ysis excluding studies
with high risk of at-
trit ion bias. An inclu-
sive analysis (9 stud-
ies, 1336 part icipants)
suggests a sim ilar but
slight ly reduced disad-
vantage of t ibolone (OR
(95% CI) 1.36 (1.11 to
1.66))
* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI)
CI: conf idence interval; OR: odds rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: We are very uncertain about the est imate
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aDowngraded one level for serious risk of bias: poor report ing of study methods and potent ial conf lict of interest in all studies.
Ef fect est imate robust to a sensit ivity analysis excluding studies at high risk of attrit ion bias
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Tibolone compared with combined HT for postmenopausal women: adverse events
Population: postmenopausal women with or without vasomotor symptoms
Settings: outpat ient or community
Intervention: t ibolone
Comparison: combined HT
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Combined HT Tibolone
Unscheduled bleeding
(all doses)
Follow-up: 3 to 36
months (median 12)
474 per 1000 224 per 1000
(178 to 270)
OR 0.32
(0.24 to 0.41)
6438
(16 studies)
⊕⊕©©
moderatea
Endometrial cancer (all
doses)
Follow-up: 6.8 to 36
months (median 12)
See comments OR 1.47
(0.23 to 9.33)
3689
(5 studies)
⊕©©©
very lowb,c
Events very rare in
both groups. Total of
3 events: 2/ 1826 in t i-
bolone group, 1/ 1863 in
combined HT group
Breast
cancer; women without
previous breast cancer
(all doses)
Follow-up: 6.8 to 36
months (median 24)
3 per 1000 6 per 1000
(3 to 13)
OR 1.69
(0.78 to 3.67)
4835
(5 studies)
⊕©©©
very lowb,c
Venous thromboem-
bolic events (clinical
evaluation; all doses)
Follow-up: 6.8 to 24
months (median 12)
3 per 1000 1 per 1000
(0 to 6)
OR 0.44
(0.09 to 2.14)
4529
(4 studies)
⊕©©©
very lowb,c
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Cardiovascular events
(all doses)
Follow-up: 2 to 3 years
17 per 1000 10 per 1000
(4 to 27)
OR 0.63
(0.24 to 1.66)
3794
(2 studies)
⊕©©©
very lowb,c
Cerebrovascular event
(all doses)
Follow-up: 3.4 to 24
(median 9.4) months
1 per 1000 1 per 1000
(0 to 3)
OR 0.76
(0.16 to 3.66)
4562
(4 studies)
⊕©©©
very lowb,c
M ortality from any
cause (tibolone 2.5
mg/ d)
Follow-up: 3.4 to 24
(median 9.4) months
See comments OR 3.05
(0.12 to 75.2)
970
(2 studies)
⊕©©©
very lowb,c
Only 1 event (in t ibolone
group): 1/ 485 vs 0/ 485
* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI)
CI: conf idence interval; OR: odds rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: We are very uncertain about the est imate
aDowngraded one level for serious risk of bias: poor report ing of study methods and potent ial conf lict of interest in some
studies
bDowngraded two levels for very serious risk of bias: poor report ing of study methods and potent ial conf lict of interest in
some studies
cDowngraded one level for serious imprecision: low event rate. Findings compatible with meaningful benef it in one or both
arms, or with no ef fect
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D I S C U S S I O N
Summary of main results
For this review, we retrieved randomised controlled trials (RCTs)
comparing tibolone versus placebo and versus combined hormone
therapy (HT). We identified only three RCTs comparing tibolone
versus oestrogens without progestogens (Gupta 2013; Mendoza
2000;Volpe 1986), andonly twoof thesewere suitable for analysis.
The addition of progestogens is considered important for lowering
the risk of endometrial carcinoma in women with a uterus.
Effectiveness in treatment of menopausal symptoms
Our findings suggest that tibolone reduces vasomotor symptoms
compared with placebo and is less effective than combined HT.
The clinical relevance of observed differences is disputable - es-
pecially for comparison versus combined HT - as their magni-
tude is limited. It should be noted that the quality of evidence for
this outcome was moderate. In particular, attrition bias and use
of non-validated scales were frequently observed, as was statistical
heterogeneity, although sensitivity analyses excluding RCTs with
high risk of attrition bias confirmed both statistical significance
and direction of effects. Available evidence suggests at most amod-
est effect of tibolone on insomnia and vaginal dryness compared
with placebo. No clinically relevant differences are apparent be-
tween tibolone and combined HT in relation to vaginal dryness
outcomes.
Short-term safety
This review suggests that tibolone has a better bleeding profile
than combined HT and is associated with more numerous break-
through bleeding events than placebo.
Evidence is scarce and unclear on vaginal and urinary tract infec-
tions. Only two RCTs (Cummings 2008; Kenemans 2009) pro-
vided data on vaginal infection. Cummings 2008 performed cer-
vical cytological smears annually in women with a cervix, whereas
Kenemans 2009 provided no information on diagnostic tech-
nique. Both RCTs suggested that tibolone increases vaginal infec-
tion and provided no information on specific aetiologic agents.
Only one study reported urinary tract infections.
Long-term safety
For this systematic review, we found few RCTs providing data that
could be used to assess the long-term safety of tibolone. Nearly
all of the evidence on adverse events was of very low quality, and
events were scarce.
Available evidence indicates that compared with placebo, tibolone
increases the risk of recurrent breast cancer inwomenwith a history
of breast cancer, and may increase the risk of stroke among women
over 60 years of age. No evidence suggests that tibolone increases
the risk of other long-term adverse events, and no evidence reveals
a difference between tibolone and HT with respect to long-term
adverse events.
In particular, the LIBERATE study (Kenemans 2009) confirmed
that tibolone could significantly increase breast cancer among
high-risk women who were surgically treated within five years for
breast cancer (for whom usual oestrogen and combined HT ther-
apies were contraindicated) and who were using adjuvant therapy
and/or chemotherapy in about seven cases out of 10. A daily dose
of 2.5 mg led to an average of 15 extra recurrences each year for
every 1000 women. It is a matter of concern that more than 70%
of recurrence events were distant metastases, ultimately leading to
death. This study failed to confirm the initial hypothesis of non-
inferiority of tibolone versus placebo for breast cancer risk, and
was stopped after 3.1 years.
The latter findings sharply contrast with results from the LIFT
study (Cummings 2008), in which 1.25 mg of tibolone, admin-
istered to osteoporotic women to reduce the risk of vertebral frac-
ture, slightly but significantly reduced new-onset breast cancer
(about two fewer cases for every 1000 women each year). How-
ever, the absolute number of events in this study was low (six
for tibolone vs 19 for placebo, for a total population of about
4500 women between 60 and 85 years of age). We should also
note that LIFT researchers used half of the recommended dose for
menopausal symptoms in women over 60 years of age (mean age
68). TheMillionWomen Study (Beral 2011) suggested that breast
cancer risk may be greater in women starting hormonal therapies
within five years of menopause.
Populations for the LIBERATE and LIFT studies were too differ-
ent for results to be combined meaningfully, and populations in
both studies are not a typical target for HT addressing menopausal
symptoms, so transferability of their results is a matter of concern.
Other RCTs have not added useful data for better assessment of
the breast cancer hypothesis. We should consider that follow-up
in available RCTs was between 12 weeks and three years, which
may be too short a period for a drug therapy to induce cancer,
except for the LIBERATE study, in which high-risk women were
treated and the study was powered for assessment of breast cancer
recurrence.
We found 13 RCTs reporting on endometrial cancer, which oc-
curred in only seven of these trials. Its incidence was low (most
cases occurred in placebo-controlled trials - 15 cases in tibolone
arms vs five cases in placebo arms - most in Kenemans 2009), so
that the hypothesis emerging from observational studies of greater
risk with tibolone could not be confirmed. In this case, we should
also consider that study follow-up ranged between 12 weeks and
three years - an inadequate duration for a drug therapy to induce
cancer.
Data on cerebrovascular events provide some suggestion of higher
risk of stroke with tibolone versus placebo. This result was driven
by the LIFT study (Cummings 2008), which recruited women
over 60 years of age and stopped after 33months for such an unex-
pected difference of 2.3 more events every 1000 women per year,
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which was even greater during the first year of treatment. These
data are consistent with data from systematic reviews of RCTs
testing combined HT therapies versus placebo; among those, a
Cochrane review (Sanchez 2005) including 10 RCTs with a to-
tal of 24,283 women randomised to hormone therapy (HT) or
placebo for an average of five years (risk ratio (RR) for stroke 1.25,
95% confidence interval (CI) 1.07 to 1.45). As for RCTs directly
comparing tibolone versus combined HT, our review did not show
differences between treatments, but data were scant. Unpublished
data from the Million Women Study (available as rapid response;
Beral 2007) had suggested higher risk of fatal stroke with tibolone
versus other hormonal therapies (RR 1.58, 95% CI 1.06 to 2.37).
Our review provides no evidence of an increase in cardiovascular
events with tibolone versus placebo, whereas data on thromboem-
bolic events are very scant and unhelpful. As for combined HT,
Sanchez 2005 found no increase in cardiovascular events and total
mortality with HT but reported an increase in thromboembolic
events. Randomised controlled trials directly comparing tibolone
versus combined HT have provided few data and have revealed no
statistically significant differences.
Last, two large RCTs (Cummings 2008; Kenemans 2009), which
included higher-risk women than were included in other studies
(for previous cancer or more advanced age), provided most of the
data on mortality, revealing no statistically significant differences
or trends.
Summary of benefits and harms
Moderate-quality evidence suggests that tibolone is more effec-
tive than placebo and less effective overall than combined HT in
reducing postmenopausal symptoms, although the magnitude of
observed differences is low. Tibolone provides a clear advantage
in terms of less vaginal bleeding, but available data from RCTs on
its long-term safety compared with other hormonal therapies are
insufficient.
We found no evidence that tibolone increases the risk of serious
adverse events for women taking it over a short term to treat va-
somotor symptoms, provided they have had no history of breast
cancer, but data are scarce andmore evidence is required. Evidence
indicates that tibolone is associated with increased risk of serious
adverse events when used in other contexts. Tibolone leads to in-
creased risk of breast cancer among women with a history of breast
cancer and appears to increase the risk of stroke in older women.
Data on endometrial cancer are inconclusive.
Overall completeness and applicability of
evidence
Moderate-quality evidence on symptomatic relief may limit its ap-
plicability and clinical relevance. Very little evidence is available
on the risks of breast and endometrial cancer in women typically
treated formenopausal symptoms. In addition to this, we foundno
unpublished studies and did not obtain such information from the
drug manufacturer. It should be highlighted that absence of publi-
cation bias is unusual in therapeutic areas with strong commercial
interests, especially as almost all of the published RCTs were spon-
sored by the drug manufacturer (Bekelman 2003; Lexchin 2003).
Most of the included RCTs assessed effects of tibolone 2.5 mg -
the most frequently used dose. Therapeutic schemes and doses of
active controls (combined HT) also reflect those normally used.
Most of the selected RCTs included postmenopausal women with
menopausal symptoms. Two of the largest RCTs, which strongly
influenced results on several outcomes, included very specific pop-
ulations (patients with breast cancer and those with osteoporosis,
respectively), and findings of these studies are of limited applica-
bility to women taking tibolone for menopausal symptoms.
Quality of the evidence
We rated the quality of the evidence for the primary outcome of
our review ‘vasomotor symptoms’ as moderate for comparisons of
tibolone versus placebo and combined HT, and very low for the
comparison against oestrogens. We consider the quality to be very
low for the comparison versus oestrogen because we identified only
two small studies, both of which were compromised by attrition
bias. Given that dropout in these studies is very likely to be infor-
mative (women with poorer responses will be more likely to drop
out), attrition could be fatal to the validity of a trial. In relation to
comparisons against combined HT and placebo, we have identi-
fied weaknesses in many of the individual studies. However, on the
basis of our sensitivity analyses, we believe we can be reasonably
confident in our conclusions related to vasomotor symptoms, for
the following reasons.
First, many of the relevant studies in these comparisons are sub-
ject to attrition bias, which, as noted above, could undermine the
validity of a trial. However, we have shown that our conclusions
are quite robust if we include only studies without high risk of
attrition bias. Another concern is the matter of poor reporting in
these studies. This is a matter of concern because we had to make
some assumptions about variance in some studies, and we had to
pool outcomes measured on different scales. However, although
this may have had some impact on the exact size (and precision) of
the estimate, it is probably unlikely that we arrived at estimates in
the wrong direction (i.e. it is unlikely that placebo is actually better
than tibolone, or that HT is worse than tibolone, with respect to
vasomotor symptoms). Heterogeneity among studies is notable,
but for the comparison versus placebo, we appear to explain much
of it as the result of dose effects and artificially large estimates
due to attrition bias in several studies. Substantial heterogeneity
remains for the comparison versus HT, which we cannot explain;
we see no evidence of a difference in treatment effectiveness ac-
cording to treatment duration, and considerable variation remains
after studies with high risk of attrition bias were excluded. One
study (Hammar 1998) dominates this comparison: It is reason-
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ably sized and appears to be of fair quality (given its use of a non-
validated measurement scale). This study has a conflict of interest,
as the manufacturer of tibolone is involved. However, the estimate
from this trial actually suggests a disadvantage of tibolone, so the
conflict of interest is not really a concern. Many of the other in-
cluded studies have similar conflicts of interest. However, specific
concerns in relation to this would involve selective reporting and
publication bias, and we would expect these to manifest as arti-
ficial exaggeration of the benefits of tibolone. We have ended up
concluding that tibolone is inferior to HT in relation to vasomo-
tor symptoms; it seems unlikely that companies would be hiding
studies or analyses that showed tibolone as superior to HT, so it is
unlikely that our conclusion would change if we discovered new
studies. These biases may have affected our estimate of the effect
of tibolone compared with placebo, although we tentatively note
that trials with no apparent conflict of interest also demonstrated
benefit in relation to vasomotor symptoms (tentatively, because
these studies are themselves subject to other sources of bias). In
summary, although the individual studies have weaknesses, we be-
lieve we can be fairly confident in our conclusions related to va-
somotor symptoms, given the collective evidence. Although the
exact size and precision of our estimates could change in light of
further research, we believe that our clinical conclusions are rea-
sonably unlikely to do so. In our view, this warrants a GRADE
assessment of moderate quality.
We would similarly assess the quality of the evidence for the out-
come unscheduled bleeding. We found no evidence for the com-
parison against oestrogens, but we would consider the evidence
to be of moderate quality when taken collectively for the compar-
isons against placebo and combined HT, because estimates from
studies with conflicts of interest and showing attrition bias appear
to be generally similar to those from studies not revealing these
weaknesses. We have rated the quality of evidence related to other
adverse events as very low, as the result of low or very low event
rates, leading to imprecision in our estimates and a corresponding
inability to comment on the effects of tibolone on these endpoints.
Potential biases in the review process
As stated above, we asked the drugmanufacturer, which sponsored
almost all of the published RCTs, to provide possibly unpublished
data but received no written response. Funnel plot analyses did
not help review authors in assessing the presence of publication
bias, given the relative scarcity of studies and data, although we
were able to produce such plots for both unscheduled bleeding
and vasomotor symptoms, and these suggested no obvious bias.
Agreements and disagreements with other
studies or reviews
Use of tibolone for the treatment of menopausal symptoms has
never been supported by demonstrated advantages over oestro-
gens and combined HT therapies, such as lower risks of breast
and endometrial cancer. On the contrary, observational data from
the Million Women Study (Beral 2003; Beral 2005) suggested
greater risk of breast cancer (RR 1.45, 95% CI 1.25 to 1.68) and
endometrial cancer (RR 1.79, 95% CI 1.43 to 2.25) versus non-
users of HT, and two more recent RCTs included in this review
(Cummings 2008; Kenemans 2009) have raised concerns about
the benefit/risk profile of this drug. The latter two trials targeted
very specific populations (women over 60 years of age and women
who had already had breast cancer), and their results are not easily
generalisable, although it may be wise to apply a precautionary
principle and not exclude the possibility of safety problems for
other groups. It should be noted that the Food and Drug Admin-
istration rejected the application for the registration of tibolone in
the United States, although the reason for this is unknown.
With regard to the effectiveness of tibolone for treating
menopausal symptoms, the effectiveness of combined HT over
placebo has been shown more convincingly (MacLennan 2004).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Moderate-quality evidence suggests that tibolone is more effective
than placebo and is less effective than combined hormone therapy
(HT) in treating vasomotor symptoms. Tibolone is associatedwith
a higher rate of unscheduled bleeding than placebo but a lower
rate than combined HT.
Compared with placebo, tibolone increases the risk of recurrent
breast cancer in women with a history of breast cancer, and may
increase the risk of stroke in women over 60 years of age. No
evidence indicates that tibolone increases the risk of other long-
term adverse events, and no evidence has revealed a difference
between tibolone andHTwith respect to long-term adverse events.
Many of the included randomised controlled trials (RCTs) were
of low or very low quality. Limitations included high risk of bias
in the included trials, very low event rates and potential conflicts
of interest. Twenty-four studies were financed by drug manufac-
turers, and another 10 failed to disclose their source of funding.
Implications for research
This review may reveal a systematic misunderstanding of RCT
methods in this field, with study authors routinelymisinterpreting
their own trials. In particular, trial authors frequently interpret
change from baseline in a study arm as evidence of a treatment
effect. Change from baseline within a treatment group, even if
statistically significant, can never be interpreted in this way; even
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in the absence of any effect of treatment at all, the appearance of
improvement would be due to the twin spectres of variation in
repeated responses of any given individual and so-called regression
to the mean, whereby subsequent measurements will tend to be
closer to the population average compared with relatively severe
baseline measurements introduced by a study’s inclusion criteria.
Patient-reported outcomemeasures, such as those commonly used
in this field, are particularly susceptible to these phenomena. Itmay
help researchers to consider the fact that, were it possible to make
a conclusion of treatment effectiveness based on the evolution of a
single group, no comparator group, and therefore no RCT, would
be required. Researchers should keep this in mind before making
erroneous inferences that may be used as the basis for clinical
decision making.
Other areas of statistical weakness in these trials include poor
methods for handling missing outcome data due to dropout and
for analysing longitudinal outcomes. In relation to the former, we
found that it was common to ignore participants who had dropped
out or to carry their last observation forward for analysis. These
approaches may introduce serious bias if a patient is more or less
likely to drop out depending on her symptoms. Researchers should
instead employ such appropriate methods as multiple imputation
(Sterne 2009). In relation to longitudinal analysis, researchers gen-
erally analysed separately mean responses at each of several time
points. This is problematic because it both ignores the variation
in patterns of response over time and increases the possibility of
false-positive results due to multiple testing. Researchers instead
should employ linear mixed models for which statistical exper-
tise is available (Diggle 1994), or should perform analyses based
on summary measures of longitudinal responses when it is not
(Matthews 1990).
Finally, we would appeal to researchers to adhere to CONSORT
guidelines when reporting RCTs. Reporting was poor in the in-
cluded studies, representing a considerable obstacle to meta-anal-
ysis in this review.
In this specific clinical area, well-designed comparative RCTs are
needed to better assess whether, in women with troublesome
menopausal symptomswho use short-term therapies, tibolone is as
effective as combined HT in relieving symptoms. Although no ev-
idence indicates that use of tibolone for up to three years increases
the risk of serious adverse events in younger postmenopausal
women without a history of breast cancer, observational studies
and RCTs in other populations have raised serious doubts on the
risks of long-term use of both tibolone and combined HT. There-
fore, RCTs realised to better clarify the comparative safety of these
drugs would be unethical. A systematic review of observational
studies may be warranted to improve our understanding in this
regard.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Al-Azzawi 1999
Methods Randomised open-label controlled trial
Participants 235 healthy women with intact uteri, ≥ 12 months postmenopausal (mean 61 months)
, with serum FSH exceeding 20 IU/L. None of the women enrolled in the study had
received hormone therapy during the 3 months before enrolment. Mean age: 54 years
Interventions • Tibolone 2.5 mg/d
• Micronised oestradiol valerate 2 mg/d + norethisterone 0.7 mg/d
Administered for 1 year
Outcomes Vaginal bleeding (0 to 3 months), menopausal symptoms, pulmonary embolism
Notes Commented on menopausal symptoms that were assessed according to the Greene
menopausal symptoms scale but provided no data onwomenwho completed≥ 3months
of treatment
12-Month data on vaginal bleeding not available. Cumulative data available only for the
first 3 months
Timing: unclear
Location: unclear (UK?)
Multi-centre: 15 sites
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified but, given the nature of the out-
comes assessed, evaluation likely to be “ob-
jective”. Open design may affect evaluation
of climacteric symptoms, but these were not
taken into consideration (score)
Incomplete outcome data (attrition bias)
All outcomes
High risk Number of participants analysed was vari-
able for different outcomes and throughout
the study, depending on the number of com-
pleted diaries. Cumulative 12-month inci-
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Al-Azzawi 1999 (Continued)
dence of vaginal bleeding not available
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk Financed by the drugmanufacturer. Study au-
thors have conflicts of interest
Archer 2007
Methods Randomised controlled trial
Participants 3240 postmenopausal healthy women, with an intact uterus and with a screening biopsy
classified as atrophic or inactive endometrium and a double-layer endometrial thick-
ness ≤ 6 mm as assessed by transvaginal ultrasonography (TVUS). Mean time since
menopause: 4.5 years. Mean age: 54.4 years
Interventions • Tibolone 2.5 mg/d
• Tibolone 1.25 mg/d
• Continuous combined conjugated equine oestrogen 0.625 mg/d plus
medroxyprogesterone acetate 2.5 mg/d
Administered for 2 years
Outcomes Unscheduled bleeding, breast cancer, endometrial cancer, endometrial hyperplasia, ovar-
ian cancer, cardiovascular events, cerebrovascular events, thromboembolic events
Notes Timing: not reported
Location: USA, Europe, Chile
Multi-centre:146 centres
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No details on random generation of the allocation se-
quence, but use of an interactive voice response system
should keep risk of selection bias very low
Allocation concealment (selection bias) Low risk Interactive voice response system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-dummy method
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified but, given the nature of outcomes assessed,
their evaluation is likely to be “objective”
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Archer 2007 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk No information on withdrawals/dropouts
Selective reporting (reporting bias) Low risk No difference between study protocol and assessed out-
comes
Conflict of interest High risk Financed by the drug manufacturer; some study authors
are employees of the drug manufacturer
Baracat 2002
Methods Randomised controlled trial; open label, multi-centre
Participants 85 generally healthy postmenopausal women, with an intact uterus, in menopause for
≥ 4 years, absence of endometrial hyperplasia, mean age 52 years
Interventions • Tibolone 2.5 mg/d
• CEE/MPA 0.625 mg/5.0 mg/d
For 13 treatment cycles, each of 28 days
Outcomes Hot flushes, unscheduled bleeding, vaginal dryness, painful intercourse, endometrial
hyperplasia
Notes Timing: not available
Location: Brasil
Multi-centre: number of sites not specified
Hot flushes not measured with a validated score (frequency and intensity of hot flushes
for each participant in each cycle were calculated as the sum of the mean # of hot flushes
per day multiplied by the respective score (1 = mild, 2 = moderate, 3 = severe)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Describe: “the randomization was per-
formed in balanced blocks of ten subjects
using the table of aleatory numbers; each
study center received 20 envelopes with the
number of the subject and respective code
(treatment group)” (p 62)
Allocation concealment (selection bias) Low risk Describe: “the randomization was per-
formed in balanced blocks of ten subjects
using the table of aleatory numbers; each
study center received 20 envelopes with the
number of the subject and respective code
(treatment group)” (p 62)
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Baracat 2002 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Describe: open-label design
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Describe: participants unblinded to treat-
ment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Describe: similar rates of discontinuation,
reasons given
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk Describe: sponsored by manufacturer of
CEE/MPA
Benedek-Jaszmann 1987
Methods Parallel-group RCT
Participants 60 healthy postmenopausal women 44 to 61 years old, with hot flushes, who had un-
dergone natural or surgical menopause and were experiencing hot flushes and associated
symptoms
Interventions • Tibolone 2.5 mg/d
• Placebo 1 tablet/d
Administered for 1 year
Outcomes Hot flushes, insomnia
Following scoring system used for clinical parameters: absent = 0, mild = 1, moderate =
2, strong = 3
Notes Menopausal symptoms measured on a non-validated scale
Timing: unclear
Trial location: Netherlands
Multi-centre: no; single site
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
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Benedek-Jaszmann 1987 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study authors state that the trial is double-blind and that iden-
tical-looking placebo tablets have been used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes evaluated through a questionnaire with insufficient
information to judge whether outcomemeasurement could have
been influenced
Incomplete outcome data (attrition bias)
All outcomes
High risk 17/60 participants dropped out. Unclear how many were ran-
domised to each group
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest Unclear risk No information provided
Berning 2000
Methods Randomised placebo-controlled trial
Participants 94 healthy non-smoking women, 1 to 3 years following spontaneous menopause (mean
22 months), with body mass index < 27 kg/m2, free of diseases or medication known to
influence calcium metabolism or to contraindicate the trial medication. Mean age: 53
years
Interventions • Tibolone 2.5 mg/d
• Tibolone 1.25 mg/d
• Placebo
Administered for 2 years
Outcomes Vaginal bleeding
Notes Timing: unclear
Location: Netherlands
Multi-centre: number of sites not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear what “random medication number”
means
Allocation concealment (selection bias) Unclear risk Method not specified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Although study authors do not state whether
trial is double-blind or single-blind, they used
identical looking interventions and a placebo
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Berning 2000 (Continued)
control
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given the nature of the out-
come assessed, evaluation is likely to be “objec-
tive”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Bleeding: all randomised participants assessed
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk Financed by the drug manufacturer. Study au-
thors have conflicts of interest
Bouchard 2012
Methods Randomised double-blind placebo-controlled trial
Participants 485 postmenopausal women 40 to 65 years of age, seeking treatment for hot flushes,
who had completed their last natural menstrual period 12 months before screening (or
had a follicle-stimulating hormone (FSH) level 40 mIU/mL). Women had intact uterus,
BMI ≤ 34 and minimum of 7 moderate and severe hot flushes per day, or 50 moderate
and severe hot flushes per week, recorded for 7 consecutive days during screening. Mean
age: 53.6 years
Interventions Tibolone 2.5 mg/d, placebo, desvenlafaxine 100 mg/d (not considered in meta-analyses)
Outcomes Hot flushes (frequency), hot flushes (severity, through the Greene climacteric scale),
uterine bleeding, endometrial cancer
Notes Multi-centre trial (35 sites in Europe, 2 sites in South Africa, 1 site in Mexico)
Timing: unclear
Follow-up: 12 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study authors declare that this is a double-
blind trial but do not provide information
on blinding methods
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Bouchard 2012 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2 participants in each of tibolone and
placebo groups not assessed for taking
study medications for less than 5 days
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk Study sponsored byWyeth; 4 study authors
are formerWyeth or current Pfizer employ-
ees
Cummings 2008
Methods Randomised placebo-controlled trial
Participants 4538 women between 60 and 85 years of age (mean 68) who had bone mineral density
T score≤−2.5 at the hip or lumbar spine or T score ≤−2.0 with radiological evidence
of vertebral fracture
Interventions • Tibolone 1.25 mg/d
• Placebo
Administered for 34 months (median)
Outcomes Vaginal bleeding, vaginal infection, endometrial cancer and endometrial hyperplasia,
breast cancer, stroke, coronary heart disease, venous thromboembolism, mortality from
any cause
Notes Timing: July 2001 to Feb 2006, when trial was stopped because increased risk of stroke
was identified
Location: Europe, the Americas
Multi-centre: 80 sites in 22 countries
All participants received 2 to 4 tablets of calcium + vit D daily
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No details on random generation of the alloca-
tion sequence, but use of an interactive voice re-
sponse system should keep risk of selection bias
very low
Allocation concealment (selection bias) Low risk Centralised interactive voice response system
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Cummings 2008 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled and identical looking inter-
ventions
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given the nature of outcomes
assessed, their evaluation is likely to be “objec-
tive”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 32 of 4538 participants not evaluated for not
receiving any dose of the interventions under
study
Selective reporting (reporting bias) Low risk Study reported data on outcomes as indicated
in the protocol. Additional data on vaginal
bleeding, vaginal infection, endometrial can-
cer and endometrial hyperplasia, breast cancer,
stroke, coronary heart disease, venous throm-
boembolism and mortality from any cause were
available in the study publication and were in-
cluded in this review
Conflict of interest High risk Financed by the drug manufacturer. Study au-
thors have conflicts of interest
de Aloysio 1998
Methods Randomised controlled trial
Participants 50 women, 13 to 30 months since menopause (mean 20 months); 1 to 4 submucous
or intramural asymptomatic uterine leiomyomas (with longest diameter ranging from
3 to 8 cm); body mass index (BMI) < 28; without blood coagulation disease; without
endometrial pathology. Mean age: 51 years
Interventions • Tibolone 2.5 mg/d
• Conjugated equine oestrogens (CEE), 0.625 mg/d plus medroxyprogesterone
acetate (MPA), 5 mg/d
Administered for twelve 28-day cycles
Outcomes Irregular bleeding, endometrial hyperplasia
Notes Bleeding measured as incidence of bleeding cycles/number of cycles
Timing and trial location unclear
Multi-centre: no information provided
Risk of bias
Bias Authors’ judgement Support for judgement
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de Aloysio 1998 (Continued)
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given the nature of the outcome as-
sessed (endometrial hyperplasia), its evaluation is likely
to be “objective”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 3 participants excluded from analysis for non-compliance
(reasons not related to the study but not better specified)
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest Unclear risk Not financed by drug manufacturer; other conflicts of
interest not stated
Doren 1999
Methods Randomised double-blind placebo-controlled study
Participants 98 healthy postmenopausal women, with intact uterus (mean age 56 years), mean BMI
25 kg/m2, mean time since menopause 6 years
Interventions • Tibolone 2.5 mg/d
• 17beta-oestradiol + NETA (2 + 1 mg/d)
For 12 months
Outcomes Unscheduled bleeding
Notes Timing: unclear
Location: Netherlands; single centre
Hot flashes and sleeplessness reported as adverse events, each by 1 participant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Describe: no details on randomisation
Allocation concealment (selection bias) Unclear risk Describe: no details given
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Doren 1999 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Describe: participants blinded but no de-
tails on personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Describe: participants recorded bleeding
episodes in a diary
Incomplete outcome data (attrition bias)
All outcomes
Low risk Describe: reasons for withdrawal explained
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk Describe: study sponsored bymanufacturer
of tibolone; employer among study authors
Egarter 1996
Methods Randomised controlled trial
Participants 129 women with physiological menopause (for ≥ 12 months), mean age 53 years
Interventions • Tibolone 2.5 mg/d
• Oestradiol 2 mg + medrogestone 2 × 5 mg/d for 12 days/mo
For 6 months
Outcomes Unscheduled bleeding, severity of menopausal symptoms (hot flashes, insomnia, vaginal
dryness)
Notes Data on unscheduled bleeding reported in a graph but number of events unclear
Timing: not reported
Location: Austria
Multi-centre: 5 sites
To register severity of climacteric symptoms, a modified Kupperman Index was used
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label
49Short-term and long-term effects of tibolone in postmenopausal women (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Egarter 1996 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants lost to follow-up: 19.4% in tibolone group,
34.6% in combined HT group
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest Unclear risk Not reported
Elfituri 2005
Methods Randomised controlled trial
Participants 100 healthy Lybian women with a uterus, with natural or surgical menopause, with
menopausal symptoms. All had received no previous oestrogen and/or progestogen in
preceding 12 months. 1 to 9 years since menopause (mean 2 years). Mean age 44.3 years
Interventions • Tibolone 2.5 mg/d
• 17beta-oestradiol 2 mg sequentially combined with dydrogesterone 10 mg
For 1 year
Outcomes Unscheduled bleeding, endometrial cancer, vasomotor symptoms quantified as none (0)
, mild (1), moderate (2) and severe (3)
Notes Timing: not reported
Location: Lybia
Multi-centre: no; single site
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given the nature of outcomes assessed,
their evaluation is likely to be “objective”
50Short-term and long-term effects of tibolone in postmenopausal women (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Elfituri 2005 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons given for withdrawals/dropouts (2 women)
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest Unclear risk Not reported
Gallagher 2001
Methods Pooled data from 1 randomised placebo-controlled trials
Participants 770 healthy postmenopausal Caucasian or Asian women, mean duration of menopause
2.5 years, without osteoporosis (BMD of lumbar vertebrae within 2 standard deviations
of age-matched mean). Mean age: 52.4 years
Interventions • Tibolone 0.3 mg/d
• Tibolone 0.625 mg/d
• Tibolone 1.25 mg/d
• Tibolone 2.5 mg/d
• Placebo
For 2 years. All groups also received 500 mg/d of calcium
Outcomes Hot flashes, endometrial hyperplasia, endometrial cancer, thromboembolic events
Notes Timing: not reported
Location: USA
Multi-centre: more than 20 centres per study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Defined by study authors as randomised
but no details given on random sequence
generation
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical appearing tibolone and placebo
tablets
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given the nature of out-
comes assessed, their evaluation is likely to
be “objective”
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Gallagher 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 85% of randomised participants analysed
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk Financed by drug manufacturer, no decla-
ration of conflicts of interest
Gupta 2013
Methods Randomised controlled trial
Participants 100 asymptomatic patients (no menopausal symptoms) with surgical menopause 3 days
earlier (total abdominal hysterectomy with bilateral salpingo-oophorectomy)
Interventions Tibolone 2.5 mg/d; CEE 0.625 mg; DHEA 25 mg/d (all administered orally); no treat-
ment. Latter 2 arms not considered in the meta-analysis
Outcomes Vasomotor symptoms (occurrence of hot flushes and night sweats), insomnia (occur-
rence), vaginal dryness
Notes Trial location: India (single centre)
Follow-up: 12 months
Timing: 2005
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This RCT is presumably an open trial - includes a “no
treatment” arm
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
High risk Study authors acknowledged losses to follow-up, but total
number of lost participants is unclear
Selective reporting (reporting bias) Unclear risk Study protocol not available
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Gupta 2013 (Continued)
Conflict of interest Unclear risk No information provided
Hammar 1998
Methods Randomised double-blind controlled trial
Participants 437 women with menopausal symptoms, in good physical and mental health, ≥ 1 year
since last menstrual bleeding, menopausal symptoms, intact uterus, body mass index
(BMI) < 30 kg/m2. Mean age 55 years
Interventions • Tibolone 2.5 mg/d
• 17β-Oestradiol 2 mg plus norethisterone acetate 1 mg (E2/NETA)
Administered for 48 weeks
Outcomes Vaginal bleeding (more than 1 sanitary napkin per day)/spotting (just 1 sanitary napkin
per day), hot flushes (1 = none, 2 = light, 3 = moderate, 4 = severe, 5 = very severe),
sweating, vaginal dryness, endometrial cancer, breast cancer, cerebrovascular events
Notes Timing: June 1992 to Feb 1995
Location: Denmark, Norway, Sweden
Multi-centre: 44 sites
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specified
Allocation concealment (selection bias) Low risk Opaque sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given the nature of out-
comes eventually assessed, their evaluation
is likely to be “objective”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 14/437 participants not assessed for lack of
post-baseline assessment
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk Financed by drug manufacturer. Study au-
thors have conflicts of interest
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Hammar 2007
Methods Randomised controlled trial
Participants 572 postmenopausal healthy women with an intact uterus, with or without vasomotor
symptoms. Mean age 55 years. Time since menopause 5 years. Mean number of hot
flashes at baseline 5.8
Interventions • Tibolone 2.5 mg/d
• 17-beta-oestradiol 1 mg + norethisterone acetate 0.5 mg/d
Administered for 48 weeks
Outcomes Unscheduled vaginal bleeding or spotting, hot flashes, thromboembolic events, breast
cancer
Notes Hot flashes measured as median number per treatment period and reported as graph
Timing: from November 2002 to March 2005
Location: 7 Northern European countries
Multi-centre: 32 centres
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Restricted block-wise randomisation (1:1 ratio within
each specific site). No details on random generation of
the allocation sequence, but use of an interactive voice
response system should keep risk of selection bias very
low
Allocation concealment (selection bias) Low risk Automatic interactive voice response system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy method
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators, study site personnel and participants re-
mained blinded until after database was locked
Incomplete outcome data (attrition bias)
All outcomes
High risk 87% of randomised participants analysed but reasons for
withdrawals/dropouts not given
Selective reporting (reporting bias) Low risk Outcomes assessed in the study and of specific interest
for the review had been indicated in the protocol
Conflict of interest High risk Financed by the drug producer. One study author was
an employee of the drug producer
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Huber 2002
Methods Randomised controlled trial
Participants 502 postmenopausal women, with last menstrual period ≥ 12 months previously,
younger than 65 years of age (mean age 55). If the date of natural menopause could not
be established because of hormonal treatment, participants had to be ≥ 53 years of age
and must have been receiving hormonal therapy for ≥ 2 years; if applicable, hormone
therapy had to end with a progestogen phase. All participants were required to have an
intact uterus and a body mass index (BMI) of 18 to 29 kg/m2
Interventions • Tibolone 2.5 mg/d
• Conjugated equine oestrogens 0.625 mg continuously combined with
medroxyprogesterone acetate 5 mg (CEE-MPA)/d
Administered for 12 months
Outcomes Vaginal bleeding/spotting (defined as requiring sanitary protection with more than 1
sanitary pad per day vs just 1 or none), dyspareunia, severity of VM symptoms, stroke,
pulmonary embolism
Notes Severity of VM symptoms quantified as none = 0, light = 1, moderate = 2, severe = 3,
very severe = 4
Timing: Feb 1996 to June 1998
Location: Austria, Denmark, Spain, Sweden, Switzerland, UK
Multi-centre: 37 sites
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given the nature of outcomes assessed
and/or self-evaluation by blind patients, their evaluation
is likely to be “objective”
Incomplete outcome data (attrition bias)
All outcomes
High risk Several participants (about 80, depending on different
outcomes) were excluded from final analyses for adverse
events and insufficient compliance/efficacy
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk Financed by the drug producer. One study author was
the employee of a drug producer
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Hudita 2003
Methods Randomised placebo-controlled trial
Participants 162 healthy, non-obese, postmenopausal women (with evidence of ≥ 12 months of
amenorrhoea with levels of FSH > 30 mlU/mL and of 17β-oestradiol < 50 pg/mL),
between 40 and 65 years of age (mean age 55), with an intact uterus
Interventions • Tibolone 2.5 mg/d
• Tibolone 1.25 mg/d
• Placebo
Administered for 24 weeks
Outcomes Vaginal bleeding and spotting, hot flushes, sweating, vaginal dryness
Notes Used a non-validated scale to assess menopausal symptoms; they were reported also as
frequency reduction from baseline
Timing: unclear
Location: Romania
Multi-centre: no; single site
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Defined as “double-blind” but no other specific
information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided about assessment of
vaginal bleeding; unclear if trial is truly “double-
blind”
Incomplete outcome data (attrition bias)
All outcomes
High risk 42/162 participants not analysed because of ad-
verse events, loss to follow-up, lack of efficacy,
etc
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest Unclear risk Not reported
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Hänggi 1997
Methods Randomised controlled trial
Participants 140 healthy early postmenopausal women between 45 and 55 years of age (mean age
52) with an amenorrhoeic interval >12 months or serum FSH > 30 IU/L. In addition,
women > 55 years of age were included if they had a menopausal age < 5 years
Interventions • Tibolone 2.5 mg/d
• Micronised 17β-oestradiol, orally 2 mg/d continuously plus sequential
dydrogesterone orally 10 mg/d for 14 days every 4 weeks
• 17β-oestradiol patch releasing 50 micrograms/d continuously plus sequential
dydrogesterone orally 10 mg/d for 14 days every 4 weeks
Administered for 24 months
Outcomes Endometrial hyperplasia, endometrial cancer, breast cancer
Notes No-treatment arm with 35 women not considered (as stated in our protocol; moreover
they were not randomised)
Timing: unclear
Location: Switzerland
Multi-centre: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open trial because women in 1 study arm were treated
with an oestrogen patch
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given the nature of outcomes assessed,
their evaluation is likely to be “objective”
Incomplete outcome data (attrition bias)
All outcomes
High risk 55/105 (after 12 months) and 46/105 (after 24 months)
participants were evaluated through endometrial biopsy.
Reasons why remaining women were not assessed were
not specified
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk Sponsored by the drugmanufacturer. Study authors’ con-
flicts of interest not reported
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Jacobsen 2012
Methods Randomised double-blind double-dummy placebo-controlled trial
Participants 318 community-living women > 70 years of age
Interventions Tibolone 1.25 mg/d, placebo, raloxifene 60 mg/d (not considered in the meta-analysis)
for 24 months
Outcomes Cardiovascular events (TIA; cerebrovascular events; myocardial infarction)
Notes Trial location: Netherlands (single centre)
Timing: July 2003 to Jan 2008
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation with computer-gen-
erated list of random numbers
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind trial; study authors declared
that use of double dummy blinded partic-
ipants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
High risk Substantial losses to follow-up (already >
20% at 3 months)
Selective reporting (reporting bias) Low risk Study reported data on outcomes as indi-
cated in the protocol. Additional data on
cardiovascular and cerebrovascular events
available in the study publication and in-
cluded in this review
Conflict of interest Low risk Sponsored by the Dutch Organization for
Health Research and Development. Study
authors declare that they have no conflicts
of interest
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Kenemans 2009
Methods Randomised placebo-controlled non-inferiority trial
Participants 3148 postmenopausal women with vasomotor symptoms, in menopause for ≥ 12
months, who were surgically treated for breast cancer (T1-3, N0-2, M0) within the
previous 5 years; excluded women with endometrial abnormalities at transvaginal ultra-
sonography. Mean time since menopause 6.2 years. Mean age 52.7 years. At study entry,
67% of participants were using tamoxifen
Interventions • Tibolone 2.5 mg/d
• Placebo
Administered for 2.75 years
Outcomes Unscheduled bleeding, vulvovaginal dryness, vaginal infection, urinary tract infection,
insomnia, recurrence of breast cancer, endometrial cancer, venous thromboembolic
events, cardiovascular and cerebrovascular events, mortality
Notes Women who did not have adequate relief of their vasomotor symptoms were allowed
to use concomitant non-hormonal medication, such as soy products, clonidine and
antidepressants
Timing: from June 2002 to July 2007 (study prematurely interrupted for safety reasons)
Location: USA, Europe, Asia, Australia
Multi-centre: 245 centres
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done by use of a cen-
tralised interactive voice response system,
stratified by centre, with a block size of 4
Allocation concealment (selection bias) Low risk Centralised interactive voice response sys-
tem
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind fashion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given the nature of out-
comes assessed, their evaluation is likely to
be “objective”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 98% of randomised participants were anal-
ysed; reasons given for withdrawals/drop-
outs
Selective reporting (reporting bias) Low risk Data on all outcomes indicated in the pro-
tocol were eventually available in the study
publication
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Kenemans 2009 (Continued)
Conflict of interest High risk Financed by the drug producer. Some study
authors with conflicts of interest
Kroiss 2005
Methods Randomised placebo-controlled trial
Participants 70 postmenopausal women (hospital outpatients; < 75 years old; body mass index 18 to
30 kg/m2) with newly diagnosed and histologically confirmed invasive or non-invasive
early-stage breast cancer (< stage IIb), for which they were to receive surgical treatment
(conservation therapy or modified radical mastectomy) followed by tamoxifen (20 mg/
d). The women were required to have had their last natural menstrual period > 1 year
before diagnosis of breast cancer (mean time since menopause 107 months) and to have
a serum oestradiol concentration < 30 pg/mL. Mean age 58 years
Interventions • Tibolone 2.5 mg
• Placebo
Administered for 12 months
Outcomes Vaginal bleeding/spotting, endometrial hyperplasia, endometrial cancer, recurrence of
breast cancer, hot flushes, sweating, vaginal dryness
Notes Menopausal symptoms were evaluated as frequency reduction from baseline (for partici-
pants who could be evaluated) and as mean change in number and severity from baseline.
No data available on vaginal dryness
Timing: July 1996 to July 2000
Location: unclear
Multi-centre: described as multi-centre trial but unclear number and locations of sites
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Automated randomassignment usingADLS sys-
tem
Allocation concealment (selection bias) Low risk Automated randomassignment usingADLS sys-
tem
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled, double-blind (identical
medication)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given the nature of outcomes
assessed, their evaluation is likely to be “objec-
tive”
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Kroiss 2005 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/35 participants in the placebo group did not
receive study treatment
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk Two study authors were employees of the drug
manufacturer
Kubista 2007
Methods Randomised placebo-controlled trial
Participants 102 postmenopausal womenwith initially stage I or II, oestrogen receptor-positive (ER+)
, previously untreated, core-biopsy proven, invasive breast cancer without evidence of
metastatic spread; any endocrine or enzymemodulator therapy was stopped≥ 3 months
before randomisation. Mean age 65 years. Mean time since menopause 17 years
Interventions • Tibolone 2.5 mg
• Placebo
Administered for 14 days
Outcomes Ischaemic stroke, breast tumoural markers
Notes Tumoural markers (surrogate outcome) measured as median/mean
Timing: March 2003 to April 2005
Location: unclear
Multi-centre: 14 sites in 5 countries (not provided)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled and defined as “double-
blind” (1 pill administered per day)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given the nature of the out-
come assessed (stroke), its evaluation is likely to
be “objective”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Stroke evaluated referring to the “all subject
treated group”
61Short-term and long-term effects of tibolone in postmenopausal women (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kubista 2007 (Continued)
Selective reporting (reporting bias) Low risk Some of the outcomes indicated in the protocol
were assessed and reported in the study publica-
tion. Those not reported were of no interest for
the review. Additional data on ischaemic stroke
were available in the study publication and were
included in this review
Conflict of interest High risk Financed by the drug manufacturer. Two study
authors were employees of the drug manufac-
turer
Kökçü 2000
Methods Randomised controlled trial
Participants 50 women in spontaneous menopause ≥ 1 year (mean 25 months), still sexually active
with a partner with no sexual problems, did not have any gynaecological surgery and
had no absolute contraindication for HRT. Mean age 52 years
Interventions • Tibolone 2.5 mg/d
• Conjugated oestrogens (CE) 0.625 mg/d plus medroxyprogesterone acetate
(MPA) 2.5 mg/d
Administered for 1 year
Outcomes Vaginal dryness/dyspareunia, vasomotor symptoms, irregular spotting/bleeding
Notes Timing: unclear
Location: Turkey
Multi-centre: no; single site
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specified
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study authors did not specify whether study drugs were
identical looking. They stated that (1) the trial was single-
blind; and (2) the women did not have any previous
knowledge and did not receive any information on the
possible effects on sexual function of the study drugs. It is
then unclear whether they were intended as “blind” just
because they were not provided any information
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Kökçü 2000 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not specified (and not clear whether the women were
blind)
Incomplete outcome data (attrition bias)
All outcomes
High risk 6/50 women were not evaluated for not attending visits
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest Unclear risk No information about funding or study authors’ conflicts
of interest
Landgren 2002
Methods Randomised placebo-controlled trial
Participants 775 women with a uterus between 40 and 60 years (mean 52 years), with absence of
spontaneous vaginal bleeding for ≥ 10 months and presence of menopausal symptoms
(≥ 1 moderate to severe hot flush per day). Body weight had to be between 80% and
130% of ideal body weight. Mean time since menopause 35 months
Interventions • Tibolone 5 mg/d
• Tibolone 2.5 mg/d
• Tibolone 1.25 mg/d
• Tibolone 0.625 mg/d
• Placebo
Administered for 12 weeks
Outcomes Hot flashes, sweats, vaginal bleeding, thromboembolic events
Notes Menopausal symptoms were evaluated as intensity and as frequency for participants with
a decrease from baseline of 3 or more hot flushes and sweats per day; vaginal bleeding
reported only on a graph
Timing: March 1994 to July 1995
Location: Sweden, Netherlands, Finland, Norway
Multi-centre: 28 sites (9 in Sweden; 8 in Netherlands; 7 in Finland; 4 in Norway)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not explained how the randomisation list was
generated
Allocation concealment (selection bias) Unclear risk Not specified whether assignment of the corre-
sponding number on the randomisation list was
concealed
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Landgren 2002 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled, double-blind (use of identi-
cal tablets)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given the nature of the out-
come assessed (thromboembolism), its evalua-
tion is likely to be “objective”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 30 of 770 participants who started treatment
were not evaluable (reasons not specified)
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk 3 out of 4 study authors were employees of the
drug producer
Langer 2006
Methods Randomised placebo-controlled trial
Participants 866 healthy postmenopausal women (45 to 79 years of age with a body mass index > 19
and < 32 kg/m2) who had been amenorrhoeic for≥ 1 year (mean time since menopause
11 years), with or without intact uterus. If the date of final menstruation was unclear,
the woman was to have used hormone therapy (HT) for > 2 years and had to be > 53
years old or fulfil the US Food and Drug Administration (FDA) criteria for menopause
(serum oestradiol ≤ 20pg/mL [or 73 pmol/L] and follicle-stimulating hormone ≥ 40
mIU/mL). Mean age 59 years
Interventions • Tibolone 2.5mg/d
• 0.625 mg continuous combined conjugated equine oestrogen and 2.5 mg
medroxyprogesterone acetate (CEE/MPA)
• Placebo
Administered for 3 years (39 cycles of 28 days)
CF336 study numbers
Outcomes Vaginal bleeding (requiring more than 1 sanitary napkin or tampon per day), vaginal
spotting (requiring just 1 sanitary napkin or tampon per day), breast cancer, cardiovas-
cular events, mortality from any cause, endometrial cancer
• For bleeding outcomes: reported in 97% (689/707) of women with a uterus
• For endometrial cancer: only 50% (351/707) of randomised women with a uterus
had baseline biopsy, and only 33% had endpoint biopsy
• For other outcomes: 70% completed 3 years of follow-up with treatment, but
total proportion of women followed up for other adverse events unclear
Notes Data on endometrial cancer considered in separate publication
Timing: unclear
Location: United States and Europe
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Langer 2006 (Continued)
Multi-centre: 11 sites (6 in the United States, 5 in Europe)
All participants also received oral calcium (500 mg/d)
707/857 women taking ≥ 1 dose of study medication had intact uterus
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No information provided in the published arti-
cle. In a private communication, the main study
author assured that study treatments were allo-
cated through random codes generated by a cen-
tral co-ordinating group
Allocation concealment (selection bias) Unclear risk In another published article describing the study
methods (Bots ML; Cont Clin Trials 2003;24:
752-75), it is stated: “code numbers were as-
signed to subjects in the order of their randomi-
sation in the trial, that is, the first subject re-
ceived the first number (the lowest), the second
subject received the next number in sequence,
and so on”. This specification made the alloca-
tion concealment issue unclear, but in a private
communication, the main study author assured
that such process was concealed to investigators
but provided no further details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled with double-dummy tech-
nique
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given the nature of outcomes
assessed, their evaluation is likely to be “objec-
tive”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of women not completing the trial and
with no assessment of outcomes of interest is
unclear
Selective reporting (reporting bias) Low risk Study reported data on outcomes as indicated in
the protocol. Additional data on breast and en-
dometrial cancer, cardiovascular events andmor-
tality from any cause available in the study pub-
lication and included in this review
Conflict of interest High risk Financed by the drug manufacturer. One study
author was an employee of the drug manufac-
turer
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Meeuwsen 2002
Methods Randomised placebo-controlled trial
Participants 85 healthy postmenopausal women, who were ≥ 1 year and at maximum 15 years after
natural menopause. Mean age 54.2 years
Interventions • Tibolone 2.5mg/d
• Placebo
Administered for 1 year
Outcomes Vasomotor symptoms, unscheduled bleeding and sleep
Notes Timing: not reported
Location: Netherlands
Multi-centre: no; single site
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not explained how the randomisation list was
generated
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Tablets of identical appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given the nature of the out-
come assessed, its evaluation is likely to be “ob-
jective”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons given for withdrawals (4 women)
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk Drug manufacturer was involved in the trial
(random sequence generation was performed by
the drug manufacturer)
Mendoza 2000
Methods Parallel-group RCT
Participants 76 hysterectomised women < 50 years old. Excluded if had had any previous malig-
nant gynaecological process, oestrogen-producing tumour, endocrinological ormetabolic
problems, cardiovascular disease, uncontrolled hypertension, active hepatic disease, se-
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Mendoza 2000 (Continued)
rious skin illness, intestinal sickness or chronic obstructive respiratory disease. Patients
with psychiatric problems or receiving anxiolytic or antidepressive drugs were also ex-
cluded
Unclear whether all women were symptomatic
Interventions • Tibolone 2.5 mg per day (n = 38)
• Transdermic 17β-oestradiol 50 micrograms per day (n = 38)
Administered for 1 year
Outcomes Climacteric symptoms through a modified version of the Kupperman Index
Vasomotor symptoms measured as frequently (2), occasionally (1) or never (0)
Reports binary measure of “reduction in vasomotor symptoms”
Dyspareunia reported as part of a composite outcome of sexual symptoms (“behavioural
changes”), which included libido
Notes Timing: Feb 1, 1995, to January 31, 1996
Trial location: Nicaragua
Multi-centre: no; single site
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers with simple blind randomisation
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No mention of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding of participants and personnel not stated and therefore
unlikely
Incomplete outcome data (attrition bias)
All outcomes
High risk 14/76 participants interrupted or changed therapy, or were lost
to follow-up; 6/76 did not start therapy
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest Unclear risk No information provided
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Mendoza 2002
Methods Randomised controlled trial
Participants 165 women with intact uterus younger than 60 years (mean 50 years), who had been
amenorrhoeic for 1 to 5 years (mean 22.3 months). Women who had had a hysterectomy
or had received hormone treatment in the 3 months before the trial were excluded, as
were those with a history of a malignant gynaecological process, oestrogen-producing
tumour or obesity (body mass index > 32)
Interventions • Tibolone 2.5 mg/d
• Cyclical combined regimen of transdermal oestrogen and progestogen:
transdermal patch of 17β-oestradiol 50 µg/d during 14 days and transdermal patch of
17β-oestradiol 50 µg/d plus 0.25 mg/d of norethisterone acetate during the following
14 days
• Intermittent progesterone regimen: transdermal 17β-oestradiol 50 µg/d and oral
micronised natural progesterone 200 mg twice a week
For 1 year
Outcomes Irregular bleeding, vasomotor symptoms frequency 0 = never, 1 = occasionally, 2 =
frequently
Notes Data on vasomotor symptoms expressed as number of women with reduced symptoms
Timing: September 1996 to April 1998
Location: Spain
Multi-centre: no; single site
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done following a table of random
numbers
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Defined as “simple-blind”, but no details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given the nature of outcomes assessed,
their evaluation is likely to be “objective”
Incomplete outcome data (attrition bias)
All outcomes
High risk 32/165 women did not start HRT, no reasons given
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest Unclear risk Not reported
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Morais-Socorro 2012
Methods Randomised double-blind placebo-controlled trial
Participants 65 women between 40 and 55 years of age, with menstrual irregularity during the
previous 6 months but fewer than 12 months of amenorrhoea, presence of a uterus
without anomalies in an initial vaginal ultrasonography evaluation and an endometrial
thickness measurement ≤ 10 mm; Kupperman Menopausal Index (KMI) score ≥ 14
points. Mean age 48.5 years
Interventions Tibolone 2.5 mg/d, placebo for 12 weeks
Outcomes Greene scale (vasomotor symptoms), Kupperman Index, vaginal bleeding-spotting
(based on number of days of uninterrupted bleeding and number of pads or tampons/d
required)
Notes Trial location: Brazil (unclear if multi-centre)
Timing: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study authors declare that this is a double-
blind trial but do not provide information
on blinding methods
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
High risk 10% and 14% dropout in tibolone and
placebo arms, respectively
Selective reporting (reporting bias) Low risk Some of the outcomes indicated in the
protocol (Kupperman Index, Greene scale)
were assessed and reported in the study
publication. Those not reported were of no
interest for this review. Additional informa-
tion on vaginal bleeding-spottingwas avail-
able in the study publication and was con-
sidered for this review
Conflict of interest Low risk Supported by grant from the CNPq
(Conselho Nacional de Desenvolvimento
Científico eTecnológico - “NationalCoun-
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sel of Technological and Scientific Devel-
opment”)
Nappi 2006a
Methods Randomised controlled trial
Participants 40 women with menopausal symptoms and primary headache (migraine without
aura [MwA] and ETTH) of premenopausal onset (history ≥ 10 years), spontaneous
menopausal status ≥ 12 months (mean 18 months) with follicle-stimulating hormone
levels > 30 IU/L, age between 51 and 55 years (mean age 53 years), body mass index >
19 and < 30 kg/m2
Interventions • Tibolone 2.5 mg/d
• 1 mg 17β-oestradiol + 0.5 mg norethisterone acetate
Administered for 6 months
Outcomes Vaginal bleeding/spotting, vasomotor symptoms, vaginal dryness
Notes Women had been using symptomatic medications and headache drug prophylaxis ≥ 3
months before entering the study
Results on vasomotor symptoms and vaginal dryness (evaluated using Greene scale)
available only as a graph
Timing: unclear
Location: Italy
Multi-centre: no information provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list of numbers
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is stated that outcome measures were evaluated by a
blind study author, although it is not clear whether this
referred to the database level or to the clinical assessment
of outcomes, which was not likely to be conducted in a
blind fashion
Incomplete outcome data (attrition bias)
All outcomes
Low risk Study authors state that all women completed the study
following appropriate evaluation
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Nappi 2006a (Continued)
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest Low risk Supported by a grant from the ItalianMinistry of Health.
No conflicts of interest reported
Nathorst-Böös 1997
Methods Randomised controlled trial
Participants 437 healthy women, ≥ 1 year postmenopausal or had been using hormone replacement
therapy (HRT) > 2 years.Women were older than 53 years at entry and had been without
HRT for longer than 1 month. All had had hot flushes and sweating, had a body mass
index < 30 and had an intact uterus
Interventions • Tibolone 2.5 mg/d
• 17β-oestradiol 2 mg/d and norethisterone acetate 1 mg/d
Administered for 12 months
Outcomes Vaginal dryness and pain during sexual intercourse as score at baseline and as differences
between pretreatment and post-treatment
Notes Timing: unclear
Location : Denmark, Norway, Sweden
Unclear number of sites, but locations in 3 Scandinavian countries
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list and codes
Allocation concealment (selection bias) Low risk Sealed envelope containing the code
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, double-dummy not specified
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Subjective outcomes (McCoy’s Sex Scale Questionnaire)
that may be subject to bias in the absence of double-blind
(double-dummy not specified)
Incomplete outcome data (attrition bias)
All outcomes
High risk 264/437 (60.4%) completed all assessments (baseline, at
24 and 48 weeks)
Selective reporting (reporting bias) Unclear risk Study protocol not available
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Nathorst-Böös 1997 (Continued)
Conflict of interest Unclear risk Unclear risk: not specified
Nijland 2009
Methods Randomised controlled trial
Participants 403 healthy women who had undergone natural menopause, with an intact uterus and
with female sexual dysfunction associated with sexuality-related personal distress. Mean
age 55.8 years
Interventions • Tibolone 2.5 mg/d
• Estradiol (50 microgr) + norethisterone acetate (140 microgr) in the form of a
transdermal patch
Administered for 24 weeks
Outcomes Unscheduled bleeding, cerebrovascular events, mortality from any cause
Notes Timing: June 2004 to November 2005
Location: Europa, USA, Australia
Multi-centre: 29 centres
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised automatic interactive voice response sys-
tem was used
Allocation concealment (selection bias) Low risk Computerised automatic interactive voice response sys-
tem was used, and treatment assignment was stored elec-
tronically
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-dummy fashion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors blinded to treatment assignment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 6% to 10% were not analysed for unspecified protocol
violations
Selective reporting (reporting bias) Low risk Some outcomes indicated in the protocol (vaginal bleed-
ing and spotting rate) were assessed and reported in the
study publication. Those not reported were of no interest
for this review. Additional information on cerebrovascu-
lar events and mortality from any cause was available in
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the study publication and was considered for this review
Conflict of interest High risk Study sponsored by the drug manufacturer, and some
study authors were employees of the drug firm
Okon 2005
Methods Parallel RCT
Participants 30 postmenopausal women with an intact uterus, requesting HT, who had had ≥ 12
months of amenorrhoea with plasma follicle-stimulating hormone (FSH) > 20 IU/L; <
65 years old
Interventions Tibolone 2.5 mg daily
2 mg micronised oestradiol valerate and norethisterone acetate 0.7 mg daily for 12
months
Outcomes Irregular bleeding - reported as days of bleeding over 1 year
Notes Timing: unclear
Single centre
UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not described
Allocation concealment (selection bias) Unclear risk Method of sequence allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not mentioned
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding not mentioned
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 19/30 women included in analysis (5 in tibolone group
and 6 in HT group withdrew; 1 was excluded from analysis)
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk Funded by pharmaceutical company
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Osmana ao lu 2006
Methods Randomised controlled trial
Participants 165 naturally postmenopausal women; absence of menstruation > 1 year; FSH≥ 30 IU/
L; not undergone any gynaecological operation; no absolute contraindication for HT.
Mean age 50 years
Interventions • Tibolone 2.5 mg/d
• Oestradiol valerate 2 mg plus dienogest 2 mg/d
Administered for 6 months
Outcomes Lubrication and pain during sexual intercourse as score at baseline and at post treatment
Notes Only 107 women were considered in the analyses (excluding women assigned to “no
treatment”)
Even if not specified in the protocol, lubrication has been evaluated as a measure of
vaginal dryness
Timing: unclear
Location: Turkey?
Multi-centre: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specified
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study authors declare that the study is single-blind (par-
ticipant), but in some cases, women were given doctor
samples from drug companies
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes were evaluated through a self-administered
questionnaire, but it is unclear whether participating
women were blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7/165 participants without follow-up data
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest Low risk Study authors declare that they did not receive external
funding and that they do not have conflicts of interest
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Polisseni 2013
Methods Randomised double-blind controlled trial
Participants 174 postmenopausal women between 45 and 60 years of age with moderate or pro-
nounced vasomotor symptoms and a Blatt-Kupperman menopausal index (BKMI) ≥
20 points, with no treatment for menopausal symptoms in the past 6 months
Interventions Tibolone 2.5 mg/d; 1 mg oestradiol + 0.5 mg norethindrone acetate; 50 mg calcium
carbonate and 200 UI vitamin D3 (not considered in the meta-analysis)
Outcomes Vasomotor symptoms, insomnia (measured through theWomen’sHealthQuestionnaire)
Notes Trial location: Brazil (single centre)
Follow-up: 12 weeks
Timing: June 2009 to June 2011
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list of random num-
bers
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind trial; study authors declared
that all capsules appeared identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
High risk 47 participants lost to follow-up (with
differential attrition among groups); only
treatedwomen appear to have been assessed
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest Low risk Study authors declare that they have no
conflicts of interest
Ross 1999
Methods Parallel-group RCT
Participants 36 perimenopausal women (amenorrhoea ≥ 3 months), > 45 years old, with no past
psychotic history nor current use of antidepressants or psychotherapeutic agents. All
participants “suffering from menopausal symptoms and requesting HRT”
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Ross 1999 (Continued)
Interventions • Tibolone 2.5 mg/d
• 0.625 mg conjugated oestrogens daily for 28 days, plus 150 µg norgestrel daily on days
17 to 28
Administered for 12 weeks
Outcomes Women’s Health Questionnaire (subscales on vasomotor symptoms, sleep )
Greene’s Climacteric Scale (subscale on vasomotor symptoms)
Notes Timing: unclear
Trial location: Scotland
Multi-centre: no; single site
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by pre-generated, sequential randomisation lists
Allocation concealment (selection bias) Low risk Used a block size of 10, and each packetwas given a code number.
Copies of the code were kept in opaque sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study authors state that some of the women knew which drug
they were on. Therefore, it is likely that clinicians/researchers
had been unblinded too
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Incomplete blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 22% of participants withdrew (2 in tibolone group and 6 in HT
group)
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk Study funded by Organon
Roux 2002
Methods Randomised controlled trial
Participants 225 healthy women with physiological menopause (time since menopause 3.9 years,
mean age 53.3 years)
Interventions • Tibolone 1.25 mg/d
• Tibolone 2.5 mg/d
• Estradiol 2 mg/d + norethindrone acetate 1 mg/d
Administered for 24 months
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Roux 2002 (Continued)
Outcomes Menopausal vaginal bleeding
Notes Each participant also received 1 tablet of 500 mg calcium supplement daily
Timing: not specified
Trial location: France
Multi-centre: 66 participating centres
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation (block size of 6)
Allocation concealment (selection bias) Unclear risk Not clear if centralised randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-dummy design
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Self-reported outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Bleeding was evaluated for all randomised women
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk Study sponsored by drug manufacturer
Siseles 1995
Methods Randomised open-label controlled trial
Participants 30 postmenopausal women ≥ 1 year postmenopausal and reporting hot flushes and
other menopausal symptoms (but otherwise healthy). Age range 48 to 62 years
Interventions • Tibolone 2.5 mg/d
• Conjugated oestrogens 0.625 mg/d continuously, medroxyprogesterone 5 mg/d
sequentially for 12 days of each 28-day cycle
Administered for six 28-day cycles
Outcomes Hot flushes, sweating, sleeplessness, irregular bleeding, endometrial hyperplasia
Notes Menopausal symptoms measured through Kupperman Index but results available only
as a graph
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Siseles 1995 (Continued)
Bleeding not evaluable because insufficient information provided
Timing: June to Dec 1990
Trial location: Argentina
Multi-centre: no; single site
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given the nature of the out-
come of interest (endometrial hyperplasia), its
evaluation is likely to be “objective”
Incomplete outcome data (attrition bias)
All outcomes
High risk 6/30 patients excluded from final analyses
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk Financed by drug manufacturer. Study au-
thors’ conflicts of interest not stated
Swanson 2006
Methods Randomised placebo-controlled trial
Participants 396 healthy postmenopausal women (≥ 40 years of age; mean age 52 years) who had
been amenorrhoeic≥ 6 months (women with a uterus only) and who were experiencing
a minimum of 7 moderate to severe hot flashes per day (or 60 per week). In addition,
women had to be within 70% to 140% of their ideal body weight, smoke fewer than 15
cigarettes daily and have tested negative for pregnancy. Mean time since menopause 84
months
Interventions • Tibolone 2.5 mg/d
• Tibolone 1.25 mg/d
• Placebo
Administered for 12 weeks
Outcomes Hot flashes, vaginal dryness, dyspareunia, endometrial hyperplasia, endometrial cancer,
breast cancer
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Swanson 2006 (Continued)
Notes Menopausal symptoms evaluated as mean change from baseline using a non-validated
scale: 1 = mild sensation of heat without perspiration; 2 = moderate sensation of heat
with perspiration, able to continue activity; 3 = severe sensation of heat with sweating,
causing the woman to stop activity
Timing: unclear
Location: United States
Multi-centre: 31 sites
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled. Defined as “double-blind”;
3 daily interventions were compared
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Evaluation of endometrial hyperplasia and can-
cers should not suffer fromdetection bias.Meth-
ods for (and blinding when) diagnosing heart
failure not specified
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5/396 excluded for not receiving any study treat-
ment
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk Financed by the drug manufacturer. Two study
authors were employees of drug manufacturer
Uygur 2005
Methods Parallel-group RCT
Participants 80 postmenopausal women (56 years old), married, with spontaneous menopausal status
≥ 1 year with follicle-stimulating hormone level > 30 mIU/L and no contraindication
to use of HRT, without chronic disease. Participants were not selected on the basis of
sexual function or dysfunction
Interventions • Tibolone 2.5 mg/d (n = 40)
• 0.625 mg continuous conjugated equine oestrogen and 5 mg
medroxyprogesterone acetate (CEE/MPA)/d
Administered for 6 months (n = 40)
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Uygur 2005 (Continued)
Outcomes Vaginal dryness, pain during sexual intercourse as score at baseline and at post treatment
Notes Sexual function measured on a non-validated questionnaire
Timing: unclear
Trial location: Turkey
Multi-centre: no; single site
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants and providers. States “not double
blind”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding, with outcomes evaluated through a questionnaire
Incomplete outcome data (attrition bias)
All outcomes
High risk 8/80 dropped out (2 from tibolone group because of bleeding,
6 from CEE/MPA group - 1 for mastalgia, 1 for menorrhagia,
2 for weight gain, 2 for loss to follow-up)
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest Unclear risk No information provided
Vieira 2009
Methods Randomised placebo-controlled trial
Participants 30 postmenopausal women with systemic lupus erythematosus, between 30 and 65 years
of age (mean age 51.7 years), who had not menstruated for over a year (mean 7.1 years);
had follicle-stimulating hormone (FSH) levels > 20 mIU/mL in 2 (chemiluminescence)
tests performed 30 days apart; had not used anyHRT for≥ 6months; and had presented
with symptoms of hypoestrogenism (night sweats, hot flashes or symptoms of urogenital
atrophy) at inclusion. Other than oral corticosteroids, use of other medications for
treatment of SLE was allowed if doses remained stable for ≥ 3 months before study
outset
Interventions • Tibolone 2.5 mg/d
• Placebo
For 1 year
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Vieira 2009 (Continued)
Outcomes Menopausal symptoms, breast cancer, endometrial cancer, venous thromboembolic
events, mortality from any cause
Notes Data on menopausal symptoms were assessed through Kupperman Index; it is not pos-
sible to derive results on those specific symptoms provided in the protocol
Timing: enrolment between March 2002 and December 2004
Location: Brazil
Multi-centre: no; single site
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk GraphPad StatMate® (Graphpad Software, San
Diego, CA) software programme was used to
randomise participants into 2 groups
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given the nature of outcomes
assessed, their evaluation is likely to be “objec-
tive”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/30 excluded owing to SLE reactivation
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest Unclear risk Not reported
Volpe 1986
Methods Parallel-group RCT
Participants 113 postmenopausal women with menopausal symptoms: 81 were naturally menopausal
(mean age 51 years); 32 were post hysterectomy and oophorectomy (mean age 41 years)
Last menstrual period 1 to 5 years previously
Excluded women who had received hormone preparations during preceding 8 weeks or
in whom oestrogen therapy was contraindicated
Dropouts: 11/15 in placebo group dropped out by 6 months
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Volpe 1986 (Continued)
Interventions Tibolone 2.5 mg daily (n = 27)
vs
• Placebo (n = 15)
• Oestrogen: oestriol (E) 2 to 4 mg/d (n = 21)
• HT (total n = 50)
◦ Conjugated oestrogens (CEE) 0.625 mg/d for 21 days + norethisterone
(NET) 5 mg/d on days 12 to 21 (n = 15)
◦ CEE + cyproterone acetate (CPA) 12.5 mg/d from day 1 to day 10 (n = 15)
◦ Oestradiol valerate (EV) 2 mg/d for 21 days + sequential NET (n = 10)
◦ EV 2 mg/d for 21 days + CPA 12.5 mg/d from day 1 to day 10 (n = 10)
All for 6 cycles
Outcomes Hot flushes, scored as follows: 0 = absent, 3 = mild, 6 = moderate, 9 = severe
No comparative data on AEs were reported. Endometrial hyperplasia was reported, but
no histology was done in the placebo group
Notes Menopausal symptoms measured on a non-validated questionnaire
Timing: unclear
Trial location: Italy
Multi-centre: no; single site
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States “randomly allocated”. Baseline characteristics of groups
not mentioned
Allocation concealment (selection bias) Unclear risk Method not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No information about blinding provided. Blindness unlikely at
least for providers/researchers (it is a placebo-controlled trial)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Histology assessment blinded, but symptoms evaluated through
a questionnaire; unlikely that providers/researchers were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk High attrition in placebo group (11/15), numbers assessed for
hot flushes in active groups not reported
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest Unclear risk No information provided about conflicts of interest. Non-vali-
dated measure used for VM symptoms
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Wender 2004
Methods Randomised double-blind placebo-controlled trial
Participants 40 healthy postmenopausal women, mean age 55 years, mean time since natural
menopause 5 to 7.7 years, mean BMI 26 kg/m2
Interventions • Tibolone 2.5 mg/d
• Placebo
For 1 year
Outcomes Endometrial thickness, endometrial cancer, uterine bleeding
Notes Timing: not specified
Location: Brasil
Single centre
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk page 424: “the tibolone and the placebo
tablets and bottles looked identical; the
bottles were identified with numbers from
1 to 40. The correspondence between the
numbers and the group to which the par-
ticipant belonged was not disclosed until
the end of the study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk page 424: “all ultrasonographic exams were
performed at the Hospital’s Gynecology
and Obstetrics Service by the same opera-
tor, who was blinded to information con-
cerning participant groups. […] “ The ma-
terial was analysed twice by 2 pathologists
who were also blinded to participant infor-
mation”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for withdrawal given: 3 partici-
pants/group withdrew from the study
• Placebo: 1 owing to dizziness, 2
owing to intense climacteric symptoms
that did not improve
• Tibolone: 1 moved to another city, 2
because of missing appointments
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Wender 2004 (Continued)
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest Unclear risk No details given
Winkler 2000
Methods Randomised controlled trial
Participants 62 healthy postmenopausal women, between 45 and 70 years of age (mean age 54 years)
, spontaneous menopause with last menstrual period ≥ 36 months before enrolment or
artificial menopause (hysterectomy and/or oophorectomy) with FSH level > 30 IU/L
(mean time since menopause 8.5 years)
Interventions • Tibolone 2.5 mg/d
• Oestradiol 2 mg/d + oestriol 1 mg/d + norethindrone acetate 1 mg/d
Administered for 24 weeks
Outcomes Vaginal bleeding/spotting (defined as requiring > 1/just 1 tampon/d), hot flushes, sweat-
ing
Notes Menopausal symptoms measured as frequency but number of participants evaluated is
unclear
Timing: Feb 1995 to 1996
Location: Germany
Multi-centre: no; participants were selected from private practices of 2 specialists in
Germany
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided. Concern because participants
were selected from private practices of 2 specialists
Allocation concealment (selection bias) Unclear risk No information provided. Concern because participants
were selected from private practices of 2 specialists
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not specified, but given self-assessment of the outcome
of interest (vaginal bleeding/spotting), its evaluation is
likely to be “objective”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All womenwith a uterus were evaluated for vaginal bleed-
ing/spotting
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Winkler 2000 (Continued)
Selective reporting (reporting bias) Unclear risk Study protocol not available
Conflict of interest High risk Financed by the drug producer. One study author was
an employee of the drug producer
Wu 2001
Methods Randomised controlled trial
Participants 48 healthy postmenopausal women (52 years old), postmenopausal for 12 to 36 months
(confirmation by FSH > 40 mIU/mL and oestradiol < 20 pg/mL), with ≥ 1 climacteric
symptom according to the Greene Climateric Scale
Interventions • Tibolone 2.5 mg/d
• 0.625 mg conjugated equine oestrogen and 5 mg medroxyprogesterone acetate
(CEE/MPA)/d
Administered for 3 months
Outcomes Menopausal symptoms (assessed using Greene’s Climateric Scale), attitudes of sexuality
(assessed using McCoy Sex Scale), unscheduled bleeding
Notes Timing: not clear
Not clear if multi-centre or not
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Randomly selected pairs of 2 women were allocated to
treatment groups
Allocation concealment (selection bias) Unclear risk No information given
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
High risk 12/48 dropped out, but reasons given
Selective reporting (reporting bias) Unclear risk Study protocol not available
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Wu 2001 (Continued)
Conflict of interest High risk Study sponsored by the manufacturer. Study authors de-
clare that they have no conflicts of interest
Ziaei 2010
Methods Randomised controlled trial
Participants 150 healthy postmenopausal women (mean age at menopause: 49 years), 45 to 60 years
of age (mean age 52 years), whose last menstrual period was more than a year ago with
plasma 17β-oestradiol < 35 pg/mL
Interventions • Tibolone 2.5 mg plus a Cal + vit D tablet (500 mg/200 IU)
• 0.625 mg conjugated equine oestrogen and 2.5 mg medroxyprogesterone acetate
(CEE/MPA) plus 1 Cal+D tablet (500 mg/200 IU)
Administered for 6 months
Outcomes Vaginal bleeding (requiring > 1 sanitary napkin per day), vaginal spotting (requiring just
1 sanitary napkin per day), vaginal dryness, vasomotor symptoms, lubrication and pain
during sexual intercourse, as scored at baseline and at post treatment
Notes An arm with 50 women who received only 1 Cal + D tablet (500 mg + 200 IU) was not
considered
Timing: unclear
Location: Iran
Multi-centre: only 2 sites (in Tehran)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list of random numbers
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not specified whether blind/double-blind trial. All
women received Ca + vit D but 1 control group did not
receive active treatments; no dummy placebo mentioned
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Only blood samples stated to have been assessed in
blinded fashion (corresponding outcome is not of inter-
est for this review)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 5/150 lost to follow-up for bleeding outcomes; 20/150
(13%) for vasomotor symptoms
Selective reporting (reporting bias) Unclear risk Study protocol not available
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Ziaei 2010 (Continued)
Conflict of interest Low risk Publicly financed; study authors state no competing in-
terests
ADLS: Almedica Drug Labeling System
AE: adverse event.
BKMI: Blatt-Kupperman menopausal index.
BMD: bone mineral density.
BMI: body mass index.
CE: conjugated oestrogen.
CEE: conjugated equine oestrogen.
ETTH: Episodic tension-type headache
EV: oestradiol valerate.
FDA: Food and Drug Administration.
FSH: follicle-stimulating hormone.
HRT: hormone replacement therapy.
HT: hormone therapy.
MPA: medroxyprogesterone acetate.
RCT: randomized controlled trial.
SLE: systemic lupus erythematosus.
TIA: transient ischaemic attack.
TVUS: transvaginal ultrasonography.
VM: vasomotor symptoms.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Argyroudis 1997 Not clear whether randomised or not; impossible to contact study author to ask for details on methods
Baksu 2005 Inclusion not apparently limited to women who were experiencing vasomotor symptoms at baseline. No other
outcomes of interest measured
Beardsworth 1999 Study vs no treatment
Berlanga 2003 Inclusion not apparently limited to women who were experiencing vasomotor symptoms at baseline. No other
outcomes of interest measured
Bhattacharya 2008 Results on somatovegetative and urogenital symptoms assessed through score but specific outcomes of interest
to this review not measured
Bhattacharya 2010 Results on somatovegetative and urogenital symptoms assessed through score but specific outcomes of interest
to this review not measured
Bukulmez 2001 Measured no outcomes of interest
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(Continued)
Cagnacci 2004 Measured no outcomes of interest
Cayan 2008 No available data explicitly comparing tibolone vs combined hormone therapy
De Censi 2013 Participants not randomised to tibolone
Fedele 2000 No outcomes of interest measured
Gambacciani 2004 Study vs no treatment
Genazzani 2011 Wrote to study authors to ask for data but received no response
Inan 2005 No outcomes of interest measured
Lundstrom 2011 Ineligible outcomes (breast density)
Nappi 2006b Sexual dysfunction as vaginal health index (not provided for in the protocol)
Onalan 2005 No outcomes of interest measured
Palacios 1995 Compared tibolone vs calcium tablets
Silva 2015 Conference proceeding with no data on outcomes of interest
Simsek 2002 Measured no outcomes of interest
Stefanos 2010 Included participants with regular menstruation
Stevenson 2011 Not an RCT; review with unretrievable full text
Tasic 2011 Measured no outcomes of interest
Yuk 2012 Ineligible outcomes (changes in body composition and body size), unretrievable full text
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D A T A A N D A N A L Y S E S
Comparison 1. Tibolone versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Vasomotor symptoms 7 1657 Std. Mean Difference (Fixed, 95% CI) -0.99 [-1.10, -0.89]
1.1 Tibolone 0.625 mg/d 1 158 Std. Mean Difference (Fixed, 95% CI) -0.05 [-0.46, 0.36]
1.2 Tibolone 1.25 mg/day 3 414 Std. Mean Difference (Fixed, 95% CI) -0.83 [-1.06, -0.60]
1.3 Tibolone 2.5 mg/day 7 920 Std. Mean Difference (Fixed, 95% CI) -1.16 [-1.30, -1.03]
1.4 Tibolone 5 mg/day 1 165 Std. Mean Difference (Fixed, 95% CI) -0.84 [-1.25, -0.43]
2 Unscheduled bleeding 9 7814 Odds Ratio (M-H, Random, 95% CI) 2.79 [2.10, 3.70]
2.1 Tibolone, 2.5 mg/day 8 4186 Odds Ratio (M-H, Random, 95% CI) 2.58 [1.89, 3.52]
2.2 Tibolone, 1.25 mg/day 3 3628 Odds Ratio (M-H, Random, 95% CI) 3.63 [2.37, 5.55]
3 Endometrial cancer 9 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Tibolone, all doses 9 8504 Odds Ratio (M-H, Random, 95% CI) 2.04 [0.79, 5.24]
4 Breast cancer; women without
previous breast cancer
4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Tibolone, all doses 4 5500 Odds Ratio (M-H, Random, 95% CI) 0.52 [0.21, 1.25]
5 Breast cancer; women with
previous breast cancer
2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Tibolone, 2.5 mg/day 2 3165 Odds Ratio (M-H, Random, 95% CI) 1.50 [1.21, 1.85]
6 Venous thromboembolic events
(clinical evaluation)
5 9176 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.37, 1.97]
6.1 Tibolone (all doses) 5 9176 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.37, 1.97]
7 Cardiovascular events 4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Tibolone, all doses 4 8401 Odds Ratio (M-H, Random, 95% CI) 1.38 [0.84, 2.27]
8 Cerebrovascular events; women’s
mean age over 60 years
4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Tibolone (all doses) 4 7930 Odds Ratio (M-H, Random, 95% CI) 1.74 [0.99, 3.04]
9 Mortality from any cause 4 8242 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.79, 1.41]
9.1 Tibolone, 2.5 mg/day 3 3736 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.32, 2.73]
9.2 Tibolone, 1.25 mg/day 1 4506 Odds Ratio (M-H, Random, 95% CI) 0.93 [0.54, 1.59]
10 Insomnia 3 3432 Std. Mean Difference (Fixed, 95% CI) -0.19 [-0.38, -0.00]
10.1 Tibolone, 2.5 mg/day 3 3432 Std. Mean Difference (Fixed, 95% CI) -0.19 [-0.38, -0.00]
11 Vaginal dryness and painful
sexual intercourse
3 3348 Std. Mean Difference (Fixed, 95% CI) -0.66 [-0.90, -0.43]
11.1 Tibolone, 1.25mg/day 1 62 Std. Mean Difference (Fixed, 95% CI) -1.78 [-2.43, -1.13]
11.2 Tibolone, 2.5 mg/day 3 3286 Std. Mean Difference (Fixed, 95% CI) -0.49 [-0.75, -0.24]
12 Vaginal infections 2 7639 Odds Ratio (M-H, Random, 95% CI) 2.50 [1.24, 5.06]
12.1 Tibolone, 2.5 mg/day 1 3133 Odds Ratio (M-H, Random, 95% CI) 1.73 [1.17, 2.55]
12.2 Tibolone, 1.25 mg/day 1 4506 Odds Ratio (M-H, Random, 95% CI) 3.54 [2.61, 4.81]
13 Urinary tract infections 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
13.1 Tibolone, 2.5 mg/day 1 3133 Odds Ratio (M-H, Random, 95% CI) 0.70 [0.46, 1.06]
14 Endometrial hyperplasia 4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
14.1 Tibolone, all doses 4 4518 Odds Ratio (M-H, Random, 95% CI) 1.20 [0.23, 6.25]
15 Sensitivity Analysis - Vasomotor
symptoms without trials with
high risk of attrition bias
4 Std. Mean Difference (Fixed, 95% CI) -0.61 [-0.73, -0.49]
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15.1 Tibolone 0.625 mg/day 1 Std. Mean Difference (Fixed, 95% CI) -0.05 [-0.46, 0.36]
15.2 Tibolone 1.25 mg/day 2 Std. Mean Difference (Fixed, 95% CI) -0.62 [-0.86, -0.38]
15.3 Tibolone 2.5 mg/day 4 Std. Mean Difference (Fixed, 95% CI) -0.65 [-0.80, -0.50]
15.4 Tibolone 5 mg/day 1 Std. Mean Difference (Fixed, 95% CI) -0.84 [-1.25, -0.43]
Comparison 2. Tibolone versus oestrogens
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Vasomotor symptoms 2 108 Odds Ratio (M-H, Random, 95% CI) 1.23 [0.35, 4.34]
2 Insomnia 1 50 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Vaginal dryness and painful
sexual intercourse
1 50 Odds Ratio (M-H, Random, 95% CI) 0.32 [0.01, 8.25]
Comparison 3. Tibolone versus combined HT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Vasomotor symptoms 9 1336 Std. Mean Difference (Fixed, 95% CI) 0.17 [0.06, 0.28]
1.1 Tibolone, 2.5 mg/day 9 1336 Std. Mean Difference (Fixed, 95% CI) 0.17 [0.06, 0.28]
2 Unscheduled bleeding 16 6438 Odds Ratio (M-H, Random, 95% CI) 0.32 [0.24, 0.41]
2.1 Tibolone, 2.5 mg/day 16 4720 Odds Ratio (M-H, Random, 95% CI) 0.34 [0.26, 0.45]
2.2 Tibolone, 1.25 mg/day 2 1718 Odds Ratio (M-H, Random, 95% CI) 0.21 [0.16, 0.26]
3 Endometrial cancer 5 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Tibolone, 2.5 mg/day 5 3689 Odds Ratio (M-H, Random, 95% CI) 1.47 [0.23, 9.33]
4 Breast cancer; women without
previous breast cancer
5 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Tibolone (all doses) 5 4835 Odds Ratio (M-H, Random, 95% CI) 1.69 [0.78, 3.67]
5 Venous thromboembolic events
(clinical evaluation)
4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Tibolone (all doses) 4 4529 Odds Ratio (M-H, Random, 95% CI) 0.44 [0.09, 2.14]
6 Cardiovascular events; all
women’s mean age below 60
years. No data available on
different doses
2 3794 Odds Ratio (M-H, Random, 95% CI) 0.63 [0.24, 1.66]
7 Cerebrovascular events; women’s
mean age below 60 years
4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Tibolone (all doses) 4 4562 Odds Ratio (M-H, Random, 95% CI) 0.76 [0.16, 3.66]
8 Mortality from any cause 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Tibolone, 2.5 mg/day 2 970 Odds Ratio (M-H, Random, 95% CI) 3.05 [0.12, 75.20]
9 Endometrial hyperplasia 5 2846 Odds Ratio (M-H, Random, 95% CI) 0.35 [0.05, 2.21]
9.1 Tibolone, 2.5 mg/day 5 1549 Odds Ratio (M-H, Random, 95% CI) 0.35 [0.04, 3.36]
9.2 Tibolone, 1.25 mg/day 1 1297 Odds Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.48]
10 Vaginal dryness and painful
sexual intercourse
7 1098 Std. Mean Difference (Fixed, 95% CI) 0.02 [-0.12, 0.17]
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10.1 Tibolone, 2.5 mg/day 7 1098 Std. Mean Difference (Fixed, 95% CI) 0.02 [-0.12, 0.17]
11 Sensitivity Analysis - Vasomotor
symptoms without trials with
high risk of attrition bias
4 Std. Mean Difference (Fixed, 95% CI) 0.25 [0.09, 0.41]
12 Sensitivity analysis - vasomotor
symptoms - excluding studies
with attrition bias and using
nonvalidated scales
3 Std. Mean Difference (Fixed, 95% CI) -0.03 [-0.30, 0.23]
13 Vasomotor symptoms - ordered
by duration
9 Std. Mean Difference (Fixed, 95% CI) 0.17 [0.06, 0.28]
13.1 Tibolone, 2.5 mg/day 9 Std. Mean Difference (Fixed, 95% CI) 0.17 [0.06, 0.28]
Analysis 1.1. Comparison 1 Tibolone versus placebo, Outcome 1 Vasomotor symptoms.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 1 Tibolone versus placebo
Outcome: 1 Vasomotor symptoms
Study or subgroup Experimental Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Tibolone 0.625 mg/d
Landgren 2002 129 29 -0.05 (0.21) 6.8 % -0.05 [ -0.46, 0.36 ]
Subtotal (95% CI) 129 29 6.8 % -0.05 [ -0.46, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
2 Tibolone 1.25 mg/day
Hudita 2003 45 17 -3.4 (0.42) 1.7 % -3.40 [ -4.22, -2.58 ]
Landgren 2002 124 29 -0.71 (0.21) 6.8 % -0.71 [ -1.12, -0.30 ]
Swanson 2006 133 66 -0.57 (0.15) 13.4 % -0.57 [ -0.86, -0.28 ]
Subtotal (95% CI) 302 112 21.9 % -0.83 [ -1.06, -0.60 ]
Heterogeneity: Chi2 = 40.77, df = 2 (P<0.00001); I2 =95%
Test for overall effect: Z = 7.12 (P < 0.00001)
3 Tibolone 2.5 mg/day
Benedek-Jaszmann 1987 24 19 -1.04 (0.33) 2.8 % -1.04 [ -1.69, -0.39 ]
Bouchard 2012 164 150 -0.48 (0.11) 24.9 % -0.48 [ -0.70, -0.26 ]
Hudita 2003 41 17 -3.54 (0.44) 1.6 % -3.54 [ -4.40, -2.68 ]
Landgren 2002 139 29 -0.69 (0.21) 6.8 % -0.69 [ -1.10, -0.28 ]
Morais-Socorro 2012 27 30 -3.29 (0.17) 10.4 % -3.29 [ -3.62, -2.96 ]
-4 -2 0 2 4
Favours tibolone Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Experimental Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Swanson 2006 125 66 -0.97 (0.16) 11.8 % -0.97 [ -1.28, -0.66 ]
Ziaei 2010 43 46 -0.68 (0.22) 6.2 % -0.68 [ -1.11, -0.25 ]
Subtotal (95% CI) 563 357 64.4 % -1.16 [ -1.30, -1.03 ]
Heterogeneity: Chi2 = 235.77, df = 6 (P<0.00001); I2 =97%
Test for overall effect: Z = 17.02 (P < 0.00001)
4 Tibolone 5 mg/day
Landgren 2002 136 29 -0.84 (0.21) 6.8 % -0.84 [ -1.25, -0.43 ]
Subtotal (95% CI) 136 29 6.8 % -0.84 [ -1.25, -0.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.00 (P = 0.000063)
Total (95% CI) 1130 527 100.0 % -0.99 [ -1.10, -0.89 ]
Heterogeneity: Chi2 = 305.28, df = 11 (P<0.00001); I2 =96%
Test for overall effect: Z = 18.10 (P < 0.00001)
Test for subgroup differences: Chi2 = 28.74, df = 3 (P = 0.00), I2 =90%
-4 -2 0 2 4
Favours tibolone Favours placebo
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Analysis 1.2. Comparison 1 Tibolone versus placebo, Outcome 2 Unscheduled bleeding.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 1 Tibolone versus placebo
Outcome: 2 Unscheduled bleeding
Study or subgroup tibolone placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone, 2.5 mg/day
Berning 2000 18/35 3/12 3.3 % 3.18 [ 0.73, 13.75 ]
Bouchard 2012 38/166 14/152 11.5 % 2.93 [ 1.52, 5.65 ]
Hudita 2003 7/41 4/17 3.7 % 0.67 [ 0.17, 2.67 ]
Kenemans 2009 (1) 230/1575 107/1558 25.2 % 2.32 [ 1.82, 2.95 ]
Kroiss 2005 (2) 10/35 7/32 5.3 % 1.43 [ 0.47, 4.35 ]
Langer 2006 (3) 107/222 53/235 18.9 % 3.20 [ 2.13, 4.78 ]
Meeuwsen 2002 16/35 4/37 4.5 % 6.95 [ 2.03, 23.83 ]
Wender 2004 0/17 0/17 Not estimable
Subtotal (95% CI) 2126 2060 72.5 % 2.58 [ 1.89, 3.52 ]
Total events: 426 (tibolone), 192 (placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 9.20, df = 6 (P = 0.16); I2 =35%
Test for overall effect: Z = 5.98 (P < 0.00001)
2 Tibolone, 1.25 mg/day
Berning 2000 16/36 2/11 2.6 % 3.60 [ 0.68, 19.07 ]
Cummings 2008 165/1746 45/1773 21.5 % 4.01 [ 2.86, 5.61 ]
Hudita 2003 10/45 3/17 3.5 % 1.33 [ 0.32, 5.58 ]
Subtotal (95% CI) 1827 1801 27.5 % 3.63 [ 2.37, 5.55 ]
Total events: 191 (tibolone), 50 (placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.16, df = 2 (P = 0.34); I2 =7%
Test for overall effect: Z = 5.94 (P < 0.00001)
Total (95% CI) 3953 3861 100.0 % 2.79 [ 2.10, 3.70 ]
Total events: 617 (tibolone), 242 (placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 15.90, df = 9 (P = 0.07); I2 =43%
Test for overall effect: Z = 7.12 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.62, df = 1 (P = 0.20), I2 =38%
0.01 0.1 1 10 100
favours tibolone favours placebo
therapy or modified radical mastectomy) followed by tamoxifen (20mg/day). Mean age: 58
(1) Postmenopausal women with vasomotor symptoms, who had been surgically treated for breast cancer within the previous 5 years
(2) Wwomen with newly diagnosed and histologically confirmed invasive or non-invasive early stage breast cancer (<stage IIb), for which they were to receive surgical
treatment (conservation
(3) Women aged 45-79 years (mean: 59; mean time since menopause: 11 years)
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Analysis 1.3. Comparison 1 Tibolone versus placebo, Outcome 3 Endometrial cancer.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 1 Tibolone versus placebo
Outcome: 3 Endometrial cancer
Study or subgroup favours tibolone placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone, all doses
Bouchard 2012 1/166 0/152 8.7 % 2.76 [ 0.11, 68.37 ]
Cummings 2008 (1) 4/1746 0/1773 10.5 % 9.16 [ 0.49, 170.26 ]
Gallagher 2001 3/511 0/128 10.1 % 1.77 [ 0.09, 34.46 ]
Kenemans 2009 (2) 7/1575 4/1558 59.1 % 1.73 [ 0.51, 5.94 ]
Kroiss 2005 (3) 0/35 0/32 Not estimable
Langer 2006 (4) 1/228 1/243 11.6 % 1.07 [ 0.07, 17.14 ]
Swanson 2006 0/193 0/100 Not estimable
Vieira 2009 (5) 0/15 0/15 Not estimable
Wender 2004 0/17 0/17 Not estimable
Subtotal (95% CI) 4486 4018 100.0 % 2.04 [ 0.79, 5.24 ]
Total events: 16 (favours tibolone), 5 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.38, df = 4 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours tibolone favours placebo
therapy or modified radical mastectomy) followed by tamoxifen (20mg/day). Mean age: 58
(1) Included women aged 60-85 (mean 68) and was mainly aimed at assessing the effects of tibolone on bone loss and fractures
(2) Postmenopausal women with vasomotor symptoms, who had been surgically treated for breast cancer within the previous 5 years
(3) Women with newly diagnosed and histologically confirmed invasive or non-invasive early stage breast cancer (<stage IIb), for which they were to receive surgical
treatment (conservation
(4) Women aged 45-79 years (mean: 59; mean time since menopause: 11 years)
(5) Postmenopausal women with systemic lupus erythematosus; mean age: 52
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Analysis 1.4. Comparison 1 Tibolone versus placebo, Outcome 4 Breast cancer; women without previous
breast cancer.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 1 Tibolone versus placebo
Outcome: 4 Breast cancer; women without previous breast cancer
Study or subgroup tibolone placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone, all doses
Cummings 2008 (1) 6/2249 19/2257 60.1 % 0.32 [ 0.13, 0.79 ]
Langer 2006 4/286 4/287 32.6 % 1.00 [ 0.25, 4.05 ]
Swanson 2006 1/258 0/133 7.3 % 1.56 [ 0.06, 38.44 ]
Vieira 2009 (2) 0/15 0/15 Not estimable
Subtotal (95% CI) 2808 2692 100.0 % 0.52 [ 0.21, 1.25 ]
Total events: 11 (tibolone), 23 (placebo)
Heterogeneity: Tau2 = 0.12; Chi2 = 2.40, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours tibolone favours placebo
(1) Included women aged 60-85 (mean 68) and was mainly aimed at assessing the effects of tibolone on bone loss and fractures
(2) Postmenopausal women with systemic lupus erythematosus; mean age: 52
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Analysis 1.5. Comparison 1 Tibolone versus placebo, Outcome 5 Breast cancer; women with previous
breast cancer.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 1 Tibolone versus placebo
Outcome: 5 Breast cancer; women with previous breast cancer
Study or subgroup tibolone placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone, 2.5 mg/day
Kenemans 2009 (1) 237/1556 165/1542 100.0 % 1.50 [ 1.21, 1.85 ]
Kroiss 2005 (2) 0/35 0/32 Not estimable
Subtotal (95% CI) 1591 1574 100.0 % 1.50 [ 1.21, 1.85 ]
Total events: 237 (tibolone), 165 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.74 (P = 0.00019)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
favours tibolone favours placebo
therapy or modified radical mastectomy) followed by tamoxifen (20mg/day). Mean age: 58
(1) Postmenopausal women with vasomotor symptoms, who had been surgically treated for breast cancer within the previous 5 years
(2) Women with newly diagnosed and histologically confirmed invasive or non-invasive early stage breast cancer (<stage IIb), for which they were to receive surgical
treatment (conservation
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Analysis 1.6. Comparison 1 Tibolone versus placebo, Outcome 6 Venous thromboembolic events (clinical
evaluation).
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 1 Tibolone versus placebo
Outcome: 6 Venous thromboembolic events (clinical evaluation)
Study or subgroup tibolone placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone (all doses)
Cummings 2008 (1) 5/2249 9/2257 58.4 % 0.56 [ 0.19, 1.66 ]
Gallagher 2001 0/618 0/149 Not estimable
Kenemans 2009 (2) 5/1575 3/1558 34.1 % 1.65 [ 0.39, 6.92 ]
Landgren 2002 2/597 0/143 7.6 % 1.20 [ 0.06, 25.23 ]
Vieira 2009 (3) 0/15 0/15 Not estimable
Total (95% CI) 5054 4122 100.0 % 0.85 [ 0.37, 1.97 ]
Total events: 12 (tibolone), 12 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.45, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours tibolone favours placebo
(1) Included women aged 60-85 (mean 68) and was mainly aimed at assessing the effects of tibolone on bone loss and fractures
(2) Postmenopausal women with vasomotor symptoms, who had been surgically treated for breast cancer within the previous 5 years
(3) Postmenopausal women with systemic lupus erythematosus; mean age: 52
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Analysis 1.7. Comparison 1 Tibolone versus placebo, Outcome 7 Cardiovascular events.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 1 Tibolone versus placebo
Outcome: 7 Cardiovascular events
Study or subgroup favours tibolone placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone, all doses
Cummings 2008 (1) 27/2249 20/2257 73.9 % 1.36 [ 0.76, 2.43 ]
Jacobsen 2012 (2) 1/92 1/97 3.2 % 1.05 [ 0.07, 17.12 ]
Kenemans 2009 (3) 4/1575 2/1558 8.7 % 1.98 [ 0.36, 10.83 ]
Langer 2006 5/286 4/287 14.2 % 1.26 [ 0.33, 4.74 ]
Subtotal (95% CI) 4202 4199 100.0 % 1.38 [ 0.84, 2.27 ]
Total events: 37 (favours tibolone), 27 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 3 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours tibolone favours placebo
(1) Included women aged 60-85 (mean 68) and was mainly aimed at assessing the effects of tibolone on bone loss and fractures
(2) Women aged > 70, assessing the effects of tibolone on bone loss in postmenopausal women
(3) Postmenopausal women with vasomotor symptoms, who had been surgically treated for breast cancer within the previous 5 years
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Analysis 1.8. Comparison 1 Tibolone versus placebo, Outcome 8 Cerebrovascular events; women’s mean
age over 60 years.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 1 Tibolone versus placebo
Outcome: 8 Cerebrovascular events; women’s mean age over 60 years
Study or subgroup tibolone placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone (all doses)
Cummings 2008 (1) 28/2249 13/2257 71.5 % 2.18 [ 1.12, 4.21 ]
Jacobsen 2012 (2) 1/92 2/97 5.3 % 0.52 [ 0.05, 5.86 ]
Kenemans 2009 (3) 5/1575 5/1558 20.2 % 0.99 [ 0.29, 3.42 ]
Kubista 2007 (4) 1/51 0/51 3.0 % 3.06 [ 0.12, 76.88 ]
Subtotal (95% CI) 3967 3963 100.0 % 1.74 [ 0.99, 3.04 ]
Total events: 35 (tibolone), 20 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.31, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.053)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours tibolone favours placebo
spread and any endocrine or enzyme modulator therapy was stopped at least 3 months before randomisation. Mean age: 65
(1) Included women aged 60-85 (mean 68) and was mainly aimed at assessing the effects of tibolone on bone loss and fractures
(2) Women aged > 70, assessing the effects of tibolone on bone loss in postmenopausal women
(3) Postmenopausal women with vasomotor symptoms, who had been surgically treated for breast cancer within the previous 5 years
(4) Postmenopausal women with initially stage I or II, oestrogen receptor positive (ER+) previously untreated, core-biopsy proven, invasive breast cancer without evidence
of metastatic
99Short-term and long-term effects of tibolone in postmenopausal women (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.9. Comparison 1 Tibolone versus placebo, Outcome 9 Mortality from any cause.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 1 Tibolone versus placebo
Outcome: 9 Mortality from any cause
Study or subgroup tibolone placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone, 2.5 mg/day
Kenemans 2009 (1) 72/1575 63/1558 70.1 % 1.14 [ 0.80, 1.61 ]
Langer 2006 (2) 0/286 2/287 0.9 % 0.20 [ 0.01, 4.17 ]
Vieira 2009 (3) 0/15 0/15 Not estimable
Subtotal (95% CI) 1876 1860 71.0 % 0.94 [ 0.32, 2.73 ]
Total events: 72 (tibolone), 65 (placebo)
Heterogeneity: Tau2 = 0.30; Chi2 = 1.25, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 0.11 (P = 0.91)
2 Tibolone, 1.25 mg/day
Cummings 2008 (4) 26/2249 28/2257 29.0 % 0.93 [ 0.54, 1.59 ]
Subtotal (95% CI) 2249 2257 29.0 % 0.93 [ 0.54, 1.59 ]
Total events: 26 (tibolone), 28 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Total (95% CI) 4125 4117 100.0 % 1.06 [ 0.79, 1.41 ]
Total events: 98 (tibolone), 93 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.54, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
0.01 0.1 1 10 100
favours tibolone favours placebo
(1) Postmenopausal women with vasomotor symptoms, who had been surgically treated for breast cancer within the previous 5 years
(2) Included women aged 45-79 (mean 59)
(3) Postmenopausal women with systemic lupus erythematosus; mean age: 52
(4) Included women aged 60-85 (mean 68) and was mainly aimed at assessing the effects of tibolone on bone loss and fractures
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Analysis 1.10. Comparison 1 Tibolone versus placebo, Outcome 10 Insomnia.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 1 Tibolone versus placebo
Outcome: 10 Insomnia
Study or subgroup Experimental Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Tibolone, 2.5 mg/day
Bouchard 2012 66 152 0.2 (0.45) 4.6 % 0.20 [ -0.68, 1.08 ]
Kenemans 2009 1575 1558 -0.17 (0.11) 76.4 % -0.17 [ -0.39, 0.05 ]
Meeuwsen 2002 39 42 -0.36 (0.22) 19.1 % -0.36 [ -0.79, 0.07 ]
Total (95% CI) 1680 1752 100.0 % -0.19 [ -0.38, 0.00 ]
Heterogeneity: Chi2 = 1.38, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours tibolone Favours placebo
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Analysis 1.11. Comparison 1 Tibolone versus placebo, Outcome 11 Vaginal dryness and painful sexual
intercourse.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 1 Tibolone versus placebo
Outcome: 11 Vaginal dryness and painful sexual intercourse
Study or subgroup Experimental Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Tibolone, 1.25mg/day
Hudita 2003 45 17 -1.78 (0.33) 13.2 % -1.78 [ -2.43, -1.13 ]
Subtotal (95% CI) 45 17 13.2 % -1.78 [ -2.43, -1.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.39 (P < 0.00001)
2 Tibolone, 2.5 mg/day
Hudita 2003 41 17 -1.88 (0.34) 12.5 % -1.88 [ -2.55, -1.21 ]
Kenemans 2009 1575 1558 -0.35 (0.18) 44.5 % -0.35 [ -0.70, 0.00 ]
Ziaei 2010 47 48 -0.13 (0.22) 29.8 % -0.13 [ -0.56, 0.30 ]
Subtotal (95% CI) 1663 1623 86.8 % -0.49 [ -0.75, -0.24 ]
Heterogeneity: Chi2 = 20.00, df = 2 (P = 0.00005); I2 =90%
Test for overall effect: Z = 3.84 (P = 0.00013)
Total (95% CI) 1708 1640 100.0 % -0.66 [ -0.90, -0.43 ]
Heterogeneity: Chi2 = 33.16, df = 3 (P<0.00001); I2 =91%
Test for overall effect: Z = 5.54 (P < 0.00001)
Test for subgroup differences: Chi2 = 13.17, df = 1 (P = 0.00), I2 =92%
-2 -1 0 1 2
Favours tibolone Favours placebo
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Analysis 1.12. Comparison 1 Tibolone versus placebo, Outcome 12 Vaginal infections.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 1 Tibolone versus placebo
Outcome: 12 Vaginal infections
Study or subgroup tibolone placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone, 2.5 mg/day
Kenemans 2009 (1) 72/1575 42/1558 48.6 % 1.73 [ 1.17, 2.55 ]
Subtotal (95% CI) 1575 1558 48.6 % 1.73 [ 1.17, 2.55 ]
Total events: 72 (tibolone), 42 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.77 (P = 0.0056)
2 Tibolone, 1.25 mg/day
Cummings 2008 (2) 186/2249 56/2257 51.4 % 3.54 [ 2.61, 4.81 ]
Subtotal (95% CI) 2249 2257 51.4 % 3.54 [ 2.61, 4.81 ]
Total events: 186 (tibolone), 56 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 8.14 (P < 0.00001)
Total (95% CI) 3824 3815 100.0 % 2.50 [ 1.24, 5.06 ]
Total events: 258 (tibolone), 98 (placebo)
Heterogeneity: Tau2 = 0.23; Chi2 = 8.17, df = 1 (P = 0.004); I2 =88%
Test for overall effect: Z = 2.55 (P = 0.011)
Test for subgroup differences: Chi2 = 8.15, df = 1 (P = 0.00), I2 =88%
0.01 0.1 1 10 100
favours tibolone favours placebo
(1) Postmenopausal women with vasomotor symptoms, who had been surgically treated for breast cancer within the previous 5 years
(2) Included women aged 60-85 (mean 68) and was mainly aimed at assessing the effects of tibolone on bone loss and fractures
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Analysis 1.13. Comparison 1 Tibolone versus placebo, Outcome 13 Urinary tract infections.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 1 Tibolone versus placebo
Outcome: 13 Urinary tract infections
Study or subgroup tibolone placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone, 2.5 mg/day
Kenemans 2009 (1) 40/1575 56/1558 100.0 % 0.70 [ 0.46, 1.06 ]
Subtotal (95% CI) 1575 1558 100.0 % 0.70 [ 0.46, 1.06 ]
Total events: 40 (tibolone), 56 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.088)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours tibolone favours placebo
(1) Postmenopausal women with vasomotor symptoms, who had been surgically treated for breast cancer within the previous 5 years
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Analysis 1.14. Comparison 1 Tibolone versus placebo, Outcome 14 Endometrial hyperplasia.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 1 Tibolone versus placebo
Outcome: 14 Endometrial hyperplasia
Study or subgroup tibolone placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone, all doses
Cummings 2008 (1) 2/1746 1/1773 47.2 % 2.03 [ 0.18, 22.43 ]
Gallagher 2001 3/511 1/128 52.8 % 0.75 [ 0.08, 7.27 ]
Kroiss 2005 (2) 0/35 0/32 Not estimable
Swanson 2006 0/193 0/100 Not estimable
Subtotal (95% CI) 2485 2033 100.0 % 1.20 [ 0.23, 6.25 ]
Total events: 5 (tibolone), 2 (placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours tibolone favours placebo
therapy or modified radical mastectomy) followed by tamoxifen (20mg/day). Mean age: 58
(1) Included women aged 60-85 (mean 68) and was mainly aimed at assessing the effects of tibolone on bone loss and fractures
(2) Women with newly diagnosed and histologically confirmed invasive or non-invasive early stage breast cancer (<stage IIb), for which they were to receive surgical
treatment (conservation
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Analysis 1.15. Comparison 1 Tibolone versus placebo, Outcome 15 Sensitivity Analysis - Vasomotor
symptoms without trials with high risk of attrition bias.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 1 Tibolone versus placebo
Outcome: 15 Sensitivity Analysis - Vasomotor symptoms without trials with high risk of attrition bias
Study or subgroup
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Tibolone 0.625 mg/day
Landgren 2002 -0.05 (0.21) 8.2 % -0.05 [ -0.46, 0.36 ]
Subtotal (95% CI) 8.2 % -0.05 [ -0.46, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
2 Tibolone 1.25 mg/day
Landgren 2002 -0.71 (0.21) 8.2 % -0.71 [ -1.12, -0.30 ]
Swanson 2006 -0.57 (0.15) 16.0 % -0.57 [ -0.86, -0.28 ]
Subtotal (95% CI) 24.2 % -0.62 [ -0.86, -0.38 ]
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 5.06 (P < 0.00001)
3 Tibolone 2.5 mg/day
Bouchard 2012 -0.48 (0.11) 29.8 % -0.48 [ -0.70, -0.26 ]
Landgren 2002 -0.69 (0.21) 8.2 % -0.69 [ -1.10, -0.28 ]
Swanson 2006 -0.97 (0.16) 14.1 % -0.97 [ -1.28, -0.66 ]
Ziaei 2010 -0.68 (0.22) 7.4 % -0.68 [ -1.11, -0.25 ]
Subtotal (95% CI) 59.5 % -0.65 [ -0.80, -0.50 ]
Heterogeneity: Chi2 = 6.44, df = 3 (P = 0.09); I2 =53%
Test for overall effect: Z = 8.35 (P < 0.00001)
4 Tibolone 5 mg/day
Landgren 2002 -0.84 (0.21) 8.2 % -0.84 [ -1.25, -0.43 ]
Subtotal (95% CI) 8.2 % -0.84 [ -1.25, -0.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.00 (P = 0.000063)
Total (95% CI) 100.0 % -0.61 [ -0.73, -0.49 ]
Heterogeneity: Chi2 = 15.31, df = 7 (P = 0.03); I2 =54%
Test for overall effect: Z = 10.14 (P < 0.00001)
Test for subgroup differences: Chi2 = 8.58, df = 3 (P = 0.04), I2 =65%
-2 -1 0 1 2
Favours tibolone Favours placebo
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Analysis 2.1. Comparison 2 Tibolone versus oestrogens, Outcome 1 Vasomotor symptoms.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 2 Tibolone versus oestrogens
Outcome: 1 Vasomotor symptoms
Study or subgroup Tibolone Oestrogens Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gupta 2013 (1) 4/25 3/25 61.4 % 1.40 [ 0.28, 7.00 ]
Mendoza 2002 2/29 2/29 38.6 % 1.00 [ 0.13, 7.62 ]
Total (95% CI) 54 54 100.0 % 1.23 [ 0.35, 4.34 ]
Total events: 6 (Tibolone), 5 (Oestrogens)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours tibolone Favours oestrogens
(1) Symptomatic patients (no menopausal symptoms) with surgical menopause 3 days earlier
Analysis 2.2. Comparison 2 Tibolone versus oestrogens, Outcome 2 Insomnia.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 2 Tibolone versus oestrogens
Outcome: 2 Insomnia
Study or subgroup Tibolone Oestrogens Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gupta 2013 (1) 0/25 0/25 Not estimable
Total (95% CI) 25 25 Not estimable
Total events: 0 (Tibolone), 0 (Oestrogens)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours tibolone Favours oestrogens
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(1) Symptomatic patients (no menopausal symptoms) with surgical menopause 3 days earlier
Analysis 2.3. Comparison 2 Tibolone versus oestrogens, Outcome 3 Vaginal dryness and painful sexual
intercourse.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 2 Tibolone versus oestrogens
Outcome: 3 Vaginal dryness and painful sexual intercourse
Study or subgroup Tibolone Oestrogens Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gupta 2013 (1) 0/25 1/25 100.0 % 0.32 [ 0.01, 8.25 ]
Total (95% CI) 25 25 100.0 % 0.32 [ 0.01, 8.25 ]
Total events: 0 (Tibolone), 1 (Oestrogens)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours tibolone Favours oestrogens
(1) Symptomatic patients (no menopausal symptoms) with surgical menopause 3 days earlier
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Analysis 3.1. Comparison 3 Tibolone versus combined HT, Outcome 1 Vasomotor symptoms.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 3 Tibolone versus combined HT
Outcome: 1 Vasomotor symptoms
Study or subgroup Experimental Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Tibolone, 2.5 mg/day
Elfituri 2005 50 50 -0.04 (0.2) 7.9 % -0.04 [ -0.43, 0.35 ]
Hammar 1998 210 212 0.41 (0.1) 31.6 % 0.41 [ 0.21, 0.61 ]
Hammar 2007 222 241 0 (0.09) 39.0 % 0.0 [ -0.18, 0.18 ]
Ko¨k u¨ 2000 19 19 1.62 (0.54) 1.1 % 1.62 [ 0.56, 2.68 ]
Mendoza 2002 29 26 0.37 (0.76) 0.5 % 0.37 [ -1.12, 1.86 ]
Nappi 2006a 20 20 -0.37 (0.32) 3.1 % -0.37 [ -1.00, 0.26 ]
Polisseni 2013 42 44 0.47 (0.22) 6.5 % 0.47 [ 0.04, 0.90 ]
Wu 2001 24 24 -0.19 (0.29) 3.8 % -0.19 [ -0.76, 0.38 ]
Ziaei 2010 43 41 0.13 (0.22) 6.5 % 0.13 [ -0.30, 0.56 ]
Total (95% CI) 659 677 100.0 % 0.17 [ 0.06, 0.28 ]
Heterogeneity: Chi2 = 23.99, df = 8 (P = 0.002); I2 =67%
Test for overall effect: Z = 2.96 (P = 0.0030)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
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Analysis 3.2. Comparison 3 Tibolone versus combined HT, Outcome 2 Unscheduled bleeding.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 3 Tibolone versus combined HT
Outcome: 2 Unscheduled bleeding
Study or subgroup tibolone combined HT Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone, 2.5 mg/day
Al-Azzawi 1999 31/111 67/105 6.9 % 0.22 [ 0.12, 0.39 ]
Archer 2007 163/806 347/813 9.7 % 0.34 [ 0.27, 0.42 ]
Doren 1999 13/47 29/49 4.9 % 0.26 [ 0.11, 0.62 ]
Elfituri 2005 3/50 4/50 2.2 % 0.73 [ 0.16, 3.46 ]
Hammar 1998 71/210 124/213 8.4 % 0.37 [ 0.25, 0.54 ]
Hammar 2007 75/241 107/257 8.7 % 0.63 [ 0.44, 0.92 ]
Huber 2002 75/208 109/213 8.5 % 0.54 [ 0.36, 0.79 ]
Ko¨k u¨ 2000 4/23 5/21 2.4 % 0.67 [ 0.15, 2.94 ]
Langer 2006 107/222 153/232 8.6 % 0.48 [ 0.33, 0.70 ]
Mendoza 2002 3/44 25/89 3.0 % 0.19 [ 0.05, 0.66 ]
Nappi 2006a 2/20 3/20 1.6 % 0.63 [ 0.09, 4.24 ]
Nijland 2009 48/199 145/201 8.0 % 0.12 [ 0.08, 0.19 ]
Roux 2002 9/75 13/37 4.3 % 0.25 [ 0.10, 0.66 ]
Winkler 2000 4/16 10/20 2.5 % 0.33 [ 0.08, 1.39 ]
Wu 2001 2/16 6/16 1.8 % 0.24 [ 0.04, 1.43 ]
Ziaei 2010 14/49 28/47 4.9 % 0.27 [ 0.12, 0.64 ]
Subtotal (95% CI) 2337 2383 86.5 % 0.34 [ 0.26, 0.45 ]
Total events: 624 (tibolone), 1175 (combined HT)
Heterogeneity: Tau2 = 0.15; Chi2 = 45.13, df = 15 (P = 0.00007); I2 =67%
Test for overall effect: Z = 7.82 (P < 0.00001)
2 Tibolone, 1.25 mg/day
Archer 2007 105/792 346/813 9.6 % 0.21 [ 0.16, 0.26 ]
Roux 2002 7/76 12/37 3.9 % 0.21 [ 0.07, 0.60 ]
Subtotal (95% CI) 868 850 13.5 % 0.21 [ 0.16, 0.26 ]
Total events: 112 (tibolone), 358 (combined HT)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 12.81 (P < 0.00001)
0.01 0.1 1 10 100
favours tibolone favours combined HT
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(. . . Continued)
Study or subgroup tibolone combined HT Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 3205 3233 100.0 % 0.32 [ 0.24, 0.41 ]
Total events: 736 (tibolone), 1533 (combined HT)
Heterogeneity: Tau2 = 0.17; Chi2 = 61.01, df = 17 (P<0.00001); I2 =72%
Test for overall effect: Z = 8.62 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.28, df = 1 (P = 0.01), I2 =86%
0.01 0.1 1 10 100
favours tibolone favours combined HT
Analysis 3.3. Comparison 3 Tibolone versus combined HT, Outcome 3 Endometrial cancer.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 3 Tibolone versus combined HT
Outcome: 3 Endometrial cancer
Study or subgroup favours tibolone combined HT Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone, 2.5 mg/day
Archer 2007 0/1308 1/1320 33.4 % 0.34 [ 0.01, 8.26 ]
Elfituri 2005 0/49 0/49 Not estimable
Hammar 1998 1/218 0/219 33.3 % 3.03 [ 0.12, 74.73 ]
Ha¨nggi 1997 0/23 0/39 Not estimable
Langer 2006 1/228 0/236 33.3 % 3.12 [ 0.13, 76.95 ]
Subtotal (95% CI) 1826 1863 100.0 % 1.47 [ 0.23, 9.33 ]
Total events: 2 (favours tibolone), 1 (combined HT)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.22, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours tibolone favours combined HT
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Analysis 3.4. Comparison 3 Tibolone versus combined HT, Outcome 4 Breast cancer; women without
previous breast cancer.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 3 Tibolone versus combined HT
Outcome: 4 Breast cancer; women without previous breast cancer
Study or subgroup tibolone combined HT Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone (all doses)
Archer 2007 10/1528 8/1626 69.4 % 1.33 [ 0.52, 3.38 ]
Hammar 1998 1/218 0/219 5.9 % 3.03 [ 0.12, 74.73 ]
Hammar 2007 0/284 1/285 5.9 % 0.33 [ 0.01, 8.22 ]
Ha¨nggi 1997 2/35 0/70 6.4 % 10.52 [ 0.49, 225.34 ]
Langer 2006 4/286 1/284 12.5 % 4.01 [ 0.45, 36.14 ]
Subtotal (95% CI) 2351 2484 100.0 % 1.69 [ 0.78, 3.67 ]
Total events: 17 (tibolone), 10 (combined HT)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.34, df = 4 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours tibolone favours combined HT
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Analysis 3.5. Comparison 3 Tibolone versus combined HT, Outcome 5 Venous thromboembolic events
(clinical evaluation).
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 3 Tibolone versus combined HT
Outcome: 5 Venous thromboembolic events (clinical evaluation)
Study or subgroup favours tibolone combined HT Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone (all doses)
Al-Azzawi 1999 1/119 0/116 23.9 % 2.95 [ 0.12, 73.14 ]
Archer 2007 0/1598 3/1626 28.1 % 0.15 [ 0.01, 2.81 ]
Hammar 2007 0/284 1/285 24.0 % 0.33 [ 0.01, 8.22 ]
Huber 2002 0/250 1/251 24.0 % 0.33 [ 0.01, 8.22 ]
Subtotal (95% CI) 2251 2278 100.0 % 0.44 [ 0.09, 2.14 ]
Total events: 1 (favours tibolone), 5 (combined HT)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.95, df = 3 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours tibolone favours combined HT
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Analysis 3.6. Comparison 3 Tibolone versus combined HT, Outcome 6 Cardiovascular events; all women’s
mean age below 60 years. No data available on different doses.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 3 Tibolone versus combined HT
Outcome: 6 Cardiovascular events; all women’s mean age below 60 years. No data available on different doses
Study or subgroup tibolone combined HT Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Archer 2007 2/1598 2/1626 24.1 % 1.02 [ 0.14, 7.23 ]
Langer 2006 (1) 5/286 9/284 75.9 % 0.54 [ 0.18, 1.64 ]
Total (95% CI) 1884 1910 100.0 % 0.63 [ 0.24, 1.66 ]
Total events: 7 (tibolone), 11 (combined HT)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours tibolone favours combined HT
(1) Included women aged 45-79 (mean 59)
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Analysis 3.7. Comparison 3 Tibolone versus combined HT, Outcome 7 Cerebrovascular events; women’s
mean age below 60 years.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 3 Tibolone versus combined HT
Outcome: 7 Cerebrovascular events; women’s mean age below 60 years
Study or subgroup tibolone combined HT Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone (all doses)
Archer 2007 0/1598 3/1626 28.1 % 0.15 [ 0.01, 2.81 ]
Hammar 1998 0/218 1/219 24.0 % 0.33 [ 0.01, 8.23 ]
Huber 2002 1/250 0/251 24.0 % 3.02 [ 0.12, 74.59 ]
Nijland 2009 1/199 0/201 24.0 % 3.05 [ 0.12, 75.20 ]
Subtotal (95% CI) 2265 2297 100.0 % 0.76 [ 0.16, 3.66 ]
Total events: 2 (tibolone), 4 (combined HT)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.91, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours tibolone favours combined HT
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Analysis 3.8. Comparison 3 Tibolone versus combined HT, Outcome 8 Mortality from any cause.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 3 Tibolone versus combined HT
Outcome: 8 Mortality from any cause
Study or subgroup tibolone combined HT Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone, 2.5 mg/day
Langer 2006 0/286 0/284 Not estimable
Nijland 2009 1/199 0/201 100.0 % 3.05 [ 0.12, 75.20 ]
Subtotal (95% CI) 485 485 100.0 % 3.05 [ 0.12, 75.20 ]
Total events: 1 (tibolone), 0 (combined HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours tibolone favours combined HT
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Analysis 3.9. Comparison 3 Tibolone versus combined HT, Outcome 9 Endometrial hyperplasia.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 3 Tibolone versus combined HT
Outcome: 9 Endometrial hyperplasia
Study or subgroup favours tibolone combined HT Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tibolone, 2.5 mg/day
Archer 2007 0/671 1/660 33.5 % 0.33 [ 0.01, 8.05 ]
Baracat 2002 0/40 1/45 33.0 % 0.37 [ 0.01, 9.25 ]
de Aloysio 1998 (1) 0/24 0/23 Not estimable
Ha¨nggi 1997 0/23 0/39 Not estimable
Siseles 1995 0/13 0/11 Not estimable
Subtotal (95% CI) 771 778 66.5 % 0.35 [ 0.04, 3.36 ]
Total events: 0 (favours tibolone), 2 (combined HT)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
2 Tibolone, 1.25 mg/day
Archer 2007 0/637 1/660 33.5 % 0.34 [ 0.01, 8.48 ]
Subtotal (95% CI) 637 660 33.5 % 0.34 [ 0.01, 8.48 ]
Total events: 0 (favours tibolone), 1 (combined HT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
Total (95% CI) 1408 1438 100.0 % 0.35 [ 0.05, 2.21 ]
Total events: 0 (favours tibolone), 3 (combined HT)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
0.01 0.1 1 10 100
favours tibolone favours combined HT
(1) Patients with uterine leiomyomas
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Analysis 3.10. Comparison 3 Tibolone versus combined HT, Outcome 10 Vaginal dryness and painful sexual
intercourse.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 3 Tibolone versus combined HT
Outcome: 10 Vaginal dryness and painful sexual intercourse
Study or subgroup Experimental Control
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Tibolone, 2.5 mg/day
Hammar 1998 210 212 0.09 (0.1) 53.4 % 0.09 [ -0.11, 0.29 ]
Huber 2002 158 166 -0.07 (0.34) 4.6 % -0.07 [ -0.74, 0.60 ]
Ko¨k u¨ 2000 23 21 0.64 (1.01) 0.5 % 0.64 [ -1.34, 2.62 ]
Nappi 2006a 20 20 0.11 (0.32) 5.2 % 0.11 [ -0.52, 0.74 ]
Osmana ao lu 2006 54 53 -0.18 (0.19) 14.8 % -0.18 [ -0.55, 0.19 ]
Uygur 2005 38 34 -0.33 (0.24) 9.3 % -0.33 [ -0.80, 0.14 ]
Ziaei 2010 47 42 0.21 (0.21) 12.1 % 0.21 [ -0.20, 0.62 ]
Total (95% CI) 550 548 100.0 % 0.02 [ -0.12, 0.17 ]
Heterogeneity: Chi2 = 5.07, df = 6 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 Tibolone versus combined HT, Outcome 11 Sensitivity Analysis - Vasomotor
symptoms without trials with high risk of attrition bias.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 3 Tibolone versus combined HT
Outcome: 11 Sensitivity Analysis - Vasomotor symptoms without trials with high risk of attrition bias
Study or subgroup
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Elfituri 2005 -0.04 (0.2) 16.1 % -0.04 [ -0.43, 0.35 ]
Hammar 1998 0.41 (0.1) 64.3 % 0.41 [ 0.21, 0.61 ]
Nappi 2006a -0.37 (0.32) 6.3 % -0.37 [ -1.00, 0.26 ]
Ziaei 2010 0.13 (0.22) 13.3 % 0.13 [ -0.30, 0.56 ]
Total (95% CI) 100.0 % 0.25 [ 0.09, 0.41 ]
Heterogeneity: Chi2 = 8.71, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 3.13 (P = 0.0017)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
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Analysis 3.12. Comparison 3 Tibolone versus combined HT, Outcome 12 Sensitivity analysis - vasomotor
symptoms - excluding studies with attrition bias and using nonvalidated scales.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 3 Tibolone versus combined HT
Outcome: 12 Sensitivity analysis - vasomotor symptoms - excluding studies with attrition bias and using nonvalidated scales
Study or subgroup
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Elfituri 2005 -0.04 (0.2) 45.1 % -0.04 [ -0.43, 0.35 ]
Nappi 2006a -0.37 (0.32) 17.6 % -0.37 [ -1.00, 0.26 ]
Ziaei 2010 0.13 (0.22) 37.3 % 0.13 [ -0.30, 0.56 ]
Total (95% CI) 100.0 % -0.03 [ -0.30, 0.23 ]
Heterogeneity: Chi2 = 1.66, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.80)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
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Analysis 3.13. Comparison 3 Tibolone versus combined HT, Outcome 13 Vasomotor symptoms - ordered
by duration.
Review: Short-term and long-term effects of tibolone in postmenopausal women
Comparison: 3 Tibolone versus combined HT
Outcome: 13 Vasomotor symptoms - ordered by duration
Study or subgroup
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Tibolone, 2.5 mg/day
Polisseni 2013 0.47 (0.22) 6.5 % 0.47 [ 0.04, 0.90 ]
Wu 2001 -0.19 (0.29) 3.8 % -0.19 [ -0.76, 0.38 ]
Nappi 2006a -0.37 (0.32) 3.1 % -0.37 [ -1.00, 0.26 ]
Ziaei 2010 0.13 (0.22) 6.5 % 0.13 [ -0.30, 0.56 ]
Hammar 2007 0 (0.09) 39.0 % 0.0 [ -0.18, 0.18 ]
Hammar 1998 0.41 (0.1) 31.6 % 0.41 [ 0.21, 0.61 ]
Mendoza 2002 0.37 (0.76) 0.5 % 0.37 [ -1.12, 1.86 ]
Ko¨k u¨ 2000 1.62 (0.54) 1.1 % 1.62 [ 0.56, 2.68 ]
Elfituri 2005 -0.04 (0.2) 7.9 % -0.04 [ -0.43, 0.35 ]
Total (95% CI) 100.0 % 0.17 [ 0.06, 0.28 ]
Heterogeneity: Chi2 = 23.99, df = 8 (P = 0.002); I2 =67%
Test for overall effect: Z = 2.96 (P = 0.0030)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
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Table 1. Details on RCTs assessing vasomotor symptoms requiring additional data or analysis before data synthesis
Study Comparator Outcome measure Information
available
Notes Results for meta-
analysis
SMD
Al-Azzawi 1999 HT Presence of va-
somotor symp-
toms, severity
mea-
sured by Greene
menopausal
6 HRT and 9 ti-
bolone pa-
tients were with-
out symptoms at
base-
line. 67 HRT
Contacted study
authors, no reply
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Table1. Details onRCTs assessing vasomotor symptoms requiring additional data or analysis beforedata synthesis (Continued)
symptoms scale and 58 tibolone
patientswere free
at month 3
Baracat 2002 HT Total score:
mean number of
hot flushes per
day multiplied
by severity score
Means plotted as
bar chart in Fig-
ure 1.
Baseline, 11 for
tibolone (n = 40)
, 12 for control
(n = 45).
At 3 months, 1.8
for tibolone and
1.5 for control.
At 13 months,
0.2 for both
Would
have to impute
SDs - ‘no signifi-
cant difference’
Unclear how to
do this, given the
available info
Unable to find
contact details
Benedeck-
Jaszmann 1987
Placebo 0 to 3 severity
score
12 months
From Fig 1:
Mean
P: 1.6
T: 0.6
SD
P: 1
T: 0.9
N
P: 19
T: 24 (assuming
30 per arm to
start, not explic-
itly stated)
Extracted from
figure
Mean
P: 1.6
T: 0.6
SD
P: 1
T: 0.9
N
P: 19
T: 24
SMD: -1.
0384784 SE: 0.
3268612
Bouchard 2012 Placebo Severity score Calculate 12
week values
P: 1.59
T: 1.16
Sample sizes of
150 (P) and 164
(T)
Wk 12
Use SD from
sample size calc,
which is in line
with other stud-
ies
P: Mean 1.59
SD 0.9
N = 150
T: Mean 1.16
SD: 0.9
N = 164
SMD: -0.
4766282
SE: 0.1145686
Egarter 1996 HT Severity of hot
flushes (mod-
ified Kupperman
Index)
Baseline mean
C: 2.1
T: 2.2
6 months
C: 0.4
T: 0.4
‘N/S’
N = 34 (C)
N = 62 (T)
Impute SD - un-
clear how to
Contacted study
authors: no reply
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Table1. Details onRCTs assessing vasomotor symptoms requiring additional data or analysis beforedata synthesis (Continued)
Hammar 2007 HT Number of hot
flushes
Week 48, base-
line mean
of both groups 6,
follow-up mean
≤ 1
Baseline SD
C: 4.40
T: 4.37
N = 241 (C)
N = 222 (T)
Use baseline SDs
(these appear
reasonable, given
Landgren 2002)
C:mean 1, SD4.
40;
N = 241
T: mean 1, SD 4.
37
N = 222
SMD: 0.00
SE: 0.09302624
Hudita 2003 Placebo (3 -arm
study)
5-point
severity scale for
hot flushes
Week 24
P: 3
T: 1.25 mg: 0.2
T: 2.5mg: 0.1
N = 34
N = 45
N = 41
P < 0.01 for both
compared with
placebo
Split con-
trol group size
between 2 arms
Used P value to
calculate SD
Get implausible
answers. Used
known value in-
stead (e.g. Ham-
mar 1998)
Mean
P: 3
T: 1.25 mg: 0.2
T: 2.5 mg: 0.1
N
N = 34/2 = 17
N = 45
N = 41
SD
P: 0.63
T: 1.25: 0.87
T: 2.5: 0.87
1.25
SMD: -3.
4009511
SE: 0.4175209
2.5
SMD: -3.
5375963
SE: 0.4371477
Kokcu 2000 HT Occurrence of
hot flushes
OR: 4.16 (0.75
to 22.9)
2/19 have symp-
toms in C
12/19 have
symptoms in T
SMD: 1.
6236743
SE: 0.5369759
Landgren 2002 Placebo (5-arm
study)
Frequency of hot
flushes
Read means and
SEs at 12 weeks
from Figure 1
Mean
P = 5.2
T 0.625 = 5
T 1.25 = 2.1
T 2.5 = 1.8
T 5.0 = 1.6
Standard error
P = 0.37
T 0.625 = 0.37
T 1.25 = 0.40
T 2.5 = 0.43
T 5.0 = 0.37
Ns (calculated as
all evaluable
- dropouts -this
assumes dropout
Read means and
SEs from Figure
1
Calculated SDs
using SEs and
sample sizes
Split placebo
group size in 4
113/4 = 28.25
Mean
P = 5.2
T 0.625 = 5
T 1.25 = 2.1
T 2.5 = 1.8
T 5.0 = 1.6
SD
P = 3.93
T 0.625 = 4.20
T 1.25 = 4.45
T 2.5 = 5.07
T 5.0 = 4.31
N (calculated as
all evaluable -
dropouts - this
assumes dropout
occurred after
1st measurement
0.625
SMD: -0.
04792794
SE: 0.20552850
1.25
SMD: -0.
7077526
SE: 0.2102005
2.5
SMD: -0.
6912512
SE: 0.2076033
5.0
SMD: -0.
8437215
SE: 0.2097448
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Table1. Details onRCTs assessing vasomotor symptoms requiring additional data or analysis beforedata synthesis (Continued)
occurred after
1st measurement
at week 4)
P = 113
T 0.625 = 129
T 1.25 = 124
T 2.5 = 139
T 5.0 = 136
at week 4)
P = 28.25
T 0.625 = 129
T 1.25 = 124
T 2.5 = 139
T 5.0 = 136
Mendoza 2002 HT Flushes subscore
of the Modified
Kupperman In-
dex, 0 to 2 score
Number (%) re-
duced
Have number
and percentage
that improved in
terms of vasomo-
tor symptoms af-
ter 1 year
Have 2 possible
control groups -
choose the best
performing
to give a conser-
vative estimate
25/26 reduced in
control group
27/29 reduced in
T groups
Cal-
culate odds ratio
for reduced va-
somotor symp-
toms. Turn this
into an SMD for
combination
(27/2)/(25/1) =
0.54
SE log(OR) =
Sqrt(1/27+1/
2+1/25+1/1)
= 1.26
OR for improve-
ment: OR = 0.54
SE(log(OR)) =
1.26
(so T worse)
SMD: 0.
3734461
SE: 0.7610917
Nappi 2006a HT Vasomotor
symptoms (0 to
3 severity score)
At 6 months
Means from Fig-
ure 4
C: 1.75
T: 1.5
P value for treat-
ment term in
ANOVAgiven as
‘P < 0.4’
N = 20 in both
groups
As-
sume ANOVA P
value is 0.4 and
work out SDs as
though this was a
t-test
Gives SD
of 0.657, assum-
ing same in both
groups
SMD: -0.
3729492
SE: 0.3189649
Ross 1999 HT Greene Climac-
teric Scale sub-
score
Nothing usable.
Only present 1 of
6 relevant com-
parisons because
it is almost sig-
nificant. Do not
present 3 month
score
Siseles 1995 HT Kupperman In-
dex
No information
given for vaso-
Have con-
tacted study au-
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Table1. Details onRCTs assessing vasomotor symptoms requiring additional data or analysis beforedata synthesis (Continued)
motor subscale thors, no reply
Swanson 2006 Placebo (3-arm
study)
Number of hot
flushes per day
Median change
from baseline at
week 12
-5.5 P
-9.7 T 2.5
-8.3 T 1.25
P < 0.001 for T
2.5 vs P
P < 0.003 for T
125 vs P
N
P: 133
T 2.5: 125
T 1.25: 133
Actually, mean
changes at week
12 and P values
given in abstract
T 2.5 vs P
-10.14 vs -5.85,
P < 0.001
T 1.25 vs P,
week12
-8.32
P < 0.003
Use reported val-
ues and calculate
as
for t-tests. Split
placebo group in
half
Will have to im-
pute SDs and fi-
nal scores,
as changes can-
not be pooled
with final scores
if SMDs are used
For base-
line, takemedian
of values from
Hammar
2007 and Land-
gren 2002
6,6,8,8,8,9,9.7
Mean 7.
8. Too low - Fig-
ure 2 shows large
changes. Say, 10
P: 10 - 5.85 = 4.
15
T 2.5: 10 - 10 =
0
T 1.25: 10 - 8.32
= 1.68
SDs too large
when calculated
from t-test. Use
values from Lan-
gren:
P: 3.93
T 2.5: 5.07
T 1.25: 4.45
Mean
P: 10 - 5.85 = 4.
15
T 2.5: 10 - 10 =
0
T 1.25: 10 - 8.32
= 1.68
SD
P: 3.93
T 2.5: 5.07
T 1.25: 4.45
N
P: 66
T 2.5: 125
T 1.25: 133
1.25
SMD: -0.
5741771133
SE: 0.1532927
2.5
SMD: -0.
9661562
SE: 0.1599848
Vieira 2009 Placebo Kupperman In-
dex
Only overall
Kupperman In-
dex shown
Have con-
tacted study au-
thors, no reply
Volpe 1986 Placebo
HT
0 to 9 score, with
0 = absent, 3 =
mild, 6 = moder-
ate, 9 = severe
Can
extract means for
24 weeks
for tibolone arm,
No
real way to cal-
culate SD from
info in the pa-
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Table1. Details onRCTs assessing vasomotor symptoms requiring additional data or analysis beforedata synthesis (Continued)
Unclear whether
intermediate
scores are possi-
ble
placebo arm and
each of several
HT arms, which
have been par-
tially combined,
from Figure 1 in
the paper
per, and the scale
is different from
those used in
other studies (so
not reasonable to
use one from an-
other study)
Wender 2004 Placebo Kupperman In-
dex
Only overall
Kupperman In-
dex shown
Have con-
tacted study au-
thors, no reply
Table 2. Details on RCTs assessing vaginal dryness requiring additional data or analysis before data synthesis
Study Comparator Outcome measure Information
available
Method used Results for meta-
analysis
SMD
Hudita 2003 Placebo (3-arm
study)
0 to 4 scale From figure
Week 24
P: 2.6
T 1.25 mg: 1
T 2.5 mg: 0.9
N = 34/2 = 17
N = 45
N = 41
Split con-
trol group size
between 2 arms
Use known value
from other study
for SD
Use those from
Nappi 2006a
SD
T: 0.89
HT: 0.89
Mean
P: 2.6
T 1.25 mg: 1
T 2.5 mg: 0.9
N
N = 34/2 = 17
N = 45
N = 41
SD
P: 0.89
T 1.25: 0.89
T 2.5: 0.89
1.25mg
SMD: -1.
7751711
SE: 0.3262804
2.5mg
SMD: -1.
8843965
SE: 0.3373802
Kenemans 2009 Placebo Vaginal dryness
as binary
P: 33/1558
T: 19/1575
Convert OR to
SMD
P: 33/1558
T: 19/1575
Swanson 2006 Placebo (3-arm
study)
0 to 3 score Mean change
from baseline at
week 12
P: -0.2
T 2.5: -0.26
T 1.25: -0.39
N
P: 133
T 2.5: 125
T 1.25: 133
Split con-
trol group size
between 2 arms
Calculate
finalmeans using
base-
line and change
- but no baseline
values given
Would also need
to use SDs from
another study
Cannot use
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Table 2. Details on RCTs assessing vaginal dryness requiring additional data or analysis before data synthesis (Continued)
Huber 2002 HT Vaginal dryness
as binary
HT: 7/166
T: 6/158
Convert OR to
SMD
HT: 7/166
T: 6/158
SMD: -0.
06613757
SE: 0.34411866
Kokcu 2000 HT Vaginal dryness
as binary
HT: 0/21
T: 1/23
Convert OR to
SMD
HT: 0/21
T: 1/23
SMD: 0.
6382727
SE: 1.0064298
Ziaei 2010 HT and placebo Vaginal dryness
as binary
Also, lubrication
scores 1 to 5,
higher is better -
can reverse signs
of mean differ-
ences
HT: 20/42
T: 33/47
P: 37/48
Mean
HT: 4.93
T: 4.58
P: 3.65
SD
HT: 1.95
T: 1.26
P: 1.81
Use the continu-
ous data
Calculate
and reverse sign,
so that greater =
increased vaginal
dryness
HT: 20/42
T: 33/47
P: 37/48
Using OR to
SMD
vs HT
SMD: 0.
5774306 0.
2691251
vs placebo
SMD -0.
5904427
SE: 0.2096301
Using lubrica-
tion scores
vs HT:
SMD after
switching sign:
0.2138954
SE: 0.2129393
vs placebo: SMD
after
switching sign: -
0.1313959 SE:
0.2185150
Nappi 2006a HT Vaginal dryness
0 to 3 score
From Fig-
ure 4, mean at 6
months
Mean
T: 0.7
HC: 0.6
SD: can read SE
off Figure 4 and
calculate SD
N = 20 both
groups
SD: can read SE
off Figure 4 and
calculate SD
T: 0.89
HT: 0.89
Mean
T: 0.7
HC: 0.6
SD
T: 0.89
HT: 0.89
N = 20
SMD: 0.
1101248
SE: 0.3164674
Uygur 2005 HT 7-point scale
with -3 as wors-
ened a lot and 3
as improved a lot
6 months
Mean (higher is
better)
HT: 0
T: 0.56
N
P < 0.05 given.
Assume P = 0.
05 and calcu-
late SD, assum-
ing equal in 2
groups:
Mean (higher is
better)
HT: 0
T: 0.56
N
HT: 34
SMD af-
ter sign change: -
0.3258676 0.
2376236
127Short-term and long-term effects of tibolone in postmenopausal women (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Details on RCTs assessing vaginal dryness requiring additional data or analysis before data synthesis (Continued)
HT: 34
T: 38
Gives SD = 1.7 T: 38
Sd=1.7 for both
A P P E N D I C E S
Appendix 1. Gynaecology and Fertility (GF) Specialised Register search strategy
Formerly known as the Menstrual Disorders and Subfertility database (MDSG)
Inception until 14.10.15
KeywordsCONTAINS “climacteric ”or “menopausal” or “*Menopause” or “postmenopausal” or “postmenopause” or “perimenopausal”
or “perimenopause” or “vasomotor” or “hot flashes” or “hot flushes” or “night sweats” or “night time awakenings” or Title CONTAINS
“climacteric ”or “menopausal” or “*Menopause” or “postmenopausal” or “postmenopause” or “perimenopausal” or “perimenopause”
or “vasomotor” or “hot flashes” or “hot flushes” or “night sweats” or “night time awakenings”
AND
Keywords CONTAINS “tibolone” or “Livial” or Title CONTAINS “tibolone” or “Livial” (289 hits)
Appendix 2. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
Database: EBM Reviews - Cochrane Central Register of Controlled Trials (Ovid platform)
From inception until 14.10.15
1 exp climacteric/ or exp menopause/ or exp menopause, premature/ or exp perimenopause/ or exp postmenopause/ (5805)
2 (climacteric or menopaus$).tw. (5145)
3 (postmenopaus$ or perimenopaus$).tw. (10135)
4 exp Hot Flashes/ (514)
5 (hot flush$ or hot flash$).tw. (1247)
6 vasomotor.tw. (1057)
7 or/1-6 (14853)
8 (tibolone or tibilone).tw. (430)
9 17 hydroxy.tw. (29)
10 17 alpha.tw. (149)
11 (boltin or livial).tw. (44)
12 (liviella or tibofem).tw. (0)
13 xyvion.tw. (0)
14 (org od 14 or org od 4).tw. (26)
15 17 beta hydroxy$.tw. (8)
16 or/8-15 (625)
17 7 and 16 (399)
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Appendix 3. MEDLINE(R) search strategy
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
From inception to 14.10.15
1 exp climacteric/ or exp menopause/ or exp menopause, premature/ or exp perimenopause/ or exp postmenopause/ (52515)
2 (climacteric or menopaus$).tw. (41594)
3 (postmenopaus$ or perimenopaus$).tw. (47307)
4 exp Hot Flashes/ (2625)
5 (hot flush$ or hot flash$).tw. (3908)
6 vasomotor.tw. (11184)
7 or/1-6 (100994)
8 (tibolone or tibilone).tw. (912)
9 17 hydroxy.tw. (553)
10 17 alpha.tw. (5521)
11 (boltin or livial).tw. (66)
12 (liviella or tibofem).tw. (0)
13 xyvion.tw. (0)
14 (org od 14 or org od 4).tw. (44)
15 17 beta hydroxy$.tw. (1658)
16 or/8-15 (8186)
17 randomized controlled trial.pt. (414057)
18 controlled clinical trial.pt. (91918)
19 randomized.ab. (335509)
20 placebo.tw. (173417)
21 clinical trials as topic.sh. (179333)
22 randomly.ab. (242103)
23 trial.ti. (147798)
24 (crossover or cross-over or cross over).tw. (66140)
25 or/17-24 (1025496)
26 (animals not (humans and animals)).sh. (4035803)
27 25 not 26 (944593)
28 7 and 16 and 27 (391)
Appendix 4. Embase search strategy
Database: Ovid Embase
From inception until 14.10.15
1 exp “menopause and climacterium”/ or exp climacterium/ or exp early menopause/ or exp menopause/ or exp postmenopause/
(94150)
2 (climacteric or menopaus$).tw. (56667)
3 (postmenopaus$ or perimenopaus$).tw. (61730)
4 vasomotor.tw. (12794)
5 exp hot flush/ (12544)
6 (hot flush$ or hot flash$).tw. (5365)
7 or/1-6 (145116)
8 exp Tibolone/ (2591)
9 (tibilone or tibolone).tw. (1219)
10 (boltin or livial).tw. (425)
11 17 beta hydroxy$.tw. (488)
12 17 hydroxy.tw. (573)
13 17 alpha.tw. (2144)
14 (liviella or tibofem).tw. (25)
15 xyvion.tw. (7)
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16 (org od 14 or org od 4).tw. (105)
17 or/8-16 (5728)
18 Clinical Trial/ (851552)
19 Randomized Controlled Trial/ (385597)
20 exp randomization/ (68366)
21 Single Blind Procedure/ (21090)
22 Double Blind Procedure/ (124054)
23 Crossover Procedure/ (44662)
24 Placebo/ (264312)
25 Randomi?ed controlled trial$.tw. (124841)
26 Rct.tw. (18429)
27 random allocation.tw. (1456)
28 randomly allocated.tw. (23397)
29 allocated randomly.tw. (2061)
30 (allocated adj2 random).tw. (738)
31 Single blind$.tw. (16431)
32 Double blind$.tw. (155332)
33 ((treble or triple) adj blind$).tw. (491)
34 placebo$.tw. (221733)
35 prospective study/ (309654)
36 or/18-35 (1510043)
37 case study/ (34071)
38 case report.tw. (292028)
39 abstract report/ or letter/ (940292)
40 or/37-39 (1259859)
41 36 not 40 (1470095)
42 7 and 17 and 41 (979)
Appendix 5. PsycINFO search strategy
Database: Ovid PsycINFO
From inception until 14.10.15
1 exp menopause/ (3151)
2 (climacteric or menopaus$).tw. (4257)
3 (postmenopaus$ or perimenopaus$).tw. (2524)
4 vasomotor.tw. (1224)
5 or/1-4 (6700)
6 (tibilone or tibolone).tw. (33)
7 (boltin or livial).tw. (3)
8 (liviella or tibofem).tw. (0)
9 xyvion.tw. (0)
10 (org od 14 or org od 4).tw. (0)
11 17 hydroxy.tw. (34)
12 17 alpha.tw. (27)
13 17 beta hydroxy$.tw. (6)
14 or/6-13 (99)
15 5 and 14 (30)
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Appendix 6. CINAHL search strategy
Database: Ovid CINAHL
From inception until 13.12.07
S28 S9 AND S26 AND S27 (80)
S27 S10 OR S11 OR S12 OR S13 OR S14 (593)
S26 S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 (921,449)
S25 TX allocat* random* (4,096)
S24 (MH “Quantitative Studies”) (12,613)
S23 (MH “Placebos”) (8,922)
S22 TX placebo* (32,488)
S21 TX random* allocat* (4,096)
S20 (MH “Random Assignment”) (38,014)
S19 TX randomi* control* trial* (78,710)
S18 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or
(tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) ) (739,304)
S17 TX clinic* n1 trial* (166,477)
S16 PT Clinical trial (76,624)
S15 (MH “Clinical Trials+”) (179,629)
S14 TX 17 beta hydroxy (5)
S13 TX (boltin or livial) (16)
S12 TX 17 alpha (314)
S11 TX 17 hydroxy* (251)
S10 TX (tibilone or tibolone) (147)
S9 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 (21,930)
S8 TX climacteri* (1,622)
S7 TX (postmenopaus* or perimenopaus*) (13,847)
S6 TX menopaus* (11,430)
S5 TX hot flash* (1,998)
S4 TX hot flush* (465)
S3 TX vasomotor (1,060)
S2 (MM “Postmenopause”) (3,318)
S1 (MM “Climacteric”# OR #MM “Perimenopause”# OR #MM “Perimenopausal Symptoms”# OR #MM “Menopause+”# OR #
MM “Hot Flashes”# (8,921)
Database: Ebsco CINAHL
From inception until 14.10.15
# Query Results
S28 S9 AND S26 AND S27 82
S27 S10 OR S11 OR S12 OR S13 OR S14 645
S26 S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR
S22 OR S23 OR S24 OR S25
990,143
S25 TX allocat* random* 4,464
S24 (MH “Quantitative Studies”) 13,814
S23 (MH “Placebos”) 9,427
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(Continued)
S22 TX placebo* 34,772
S21 TX random* allocat* 4,464
S20 (MH “Random Assignment”) 39,802
S19 TX randomi* control* trial* 93,467
S18 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl*
n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*)
or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1
mask*) )
789,912
S17 TX clinic* n1 trial* 175,948
S16 PT Clinical trial 78,685
S15 (MH “Clinical Trials+”) 192,364
S14 TX 17 beta hydroxy 5
S13 TX (boltin or livial) 18
S12 TX 17 alpha 338
S11 TX 17 hydroxy* 281
S10 TX (tibilone or tibolone) 153
S9 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 23,371
S8 TX climacteri* 1,799
S7 TX (postmenopaus* or perimenopaus*) 14,679
S6 TX menopaus* 12,192
S5 TX hot flash* 2,163
S4 TX hot flush* 484
S3 TX vasomotor 1,147
S2 (MM “Postmenopause”) 3,604
S1 (MM “Climacteric”) OR (MM “Perimenopause”) OR (MM
“Perimenopausal Symptoms”) OR (MM “Menopause+”) OR
(MM “Hot Flashes”)
9,562
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WH A T ’ S N E W
Last assessed as up-to-date: 15 October 2015.
Date Event Description
23 November 2016 Review declared as stable We have made this a stable review as further evidence is unlikely to change its
conclusions
H I S T O R Y
Protocol first published: Issue 6, 2010
Review first published: Issue 2, 2012
Date Event Description
15 September 2016 New search has been performed Updated version
15 September 2016 New citation required but conclusions have not
changed
Thirteen new studies (Baracat 2002; Benedek-
Jaszmann 1987; Bouchard 2012; Gupta 2013;
Jacobsen 2012; Mendoza 2000; Morais-Socorro 2012;
Okon 2005; Polisseni 2013; Ross 1999; Uygur 2005;
Volpe 1986; Wender 2004) added and additional data
included for one study (Langer 2006). Two reports of
the same study (Ziaei 2010) amalgamated. Total of 46
studies in updated review
20 September 2010 New search has been performed Contact details updated.
9 February 2010 Amended made corrections according to Editorial Board’s re-
quests
23 March 2006 New citation required and major changes Substantive amendment
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Vittorio Basevi: performed previous work that was the foundation of the current study; participated in conceiving the review and in
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texts.
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Roberto D’Amico: participated in conceiving the statistical methods of the review and in protocol development; participated in study
screening; provided statistical support.
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EmilioMaestri: performed previous work that was the foundation of the current study; participated extensively in conceiving the review
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texts.
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• Cochrane Gynaecology and Fertility Group, New Zealand.
Provided feedback and support during the whole review process; provided bibliographic support
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Title: We changed the protocol title (“Tibolone for menopausal symptoms”) to “Short-term and long-term effects of tibolone in
postmenopausal women”, because the review is focused mostly on the long-term safety of tibolone (in particular for the incidence of
breast and endometrial cancer and of cardiovascular events, which were included among the primary outcomes - see next paragraph), in
addition to its efficacy for symptoms. Protocol criteria allowed the inclusion of RCTs testing tibolone also inwomenwithoutmenopausal
symptoms, as far as safety data were reported; in fact, the largest trial in the review tested the effects of tibolone in osteoporotic women.
Therefore, the title “Tibolone for menopausal symptoms” would have been misleading. The new title is consistent with Cochrane
editorial policies, using the [Intervention] in OR for [participant group/location] structure, as proposed in the Cochrane Handbook
for Systematic Reviews of Interventions (Table 4.2.a: Structure for Cochrane review titles). Moreover, “short-term and long-term effects”
helps to suggest that the goal is to review short-term and especially long-term safety, in addition to symptom improvement in the short
term.
Outcomes: Given the importance of safety in the objectives of the review, we followed reviewers’ suggestions to include major adverse
events (breast cancer, endometrial cancer, venous thromboembolic events, cardiovascular events, cerebrovascular events and mortality
from any cause) as primary outcomes, along with reduction in symptoms and shifting genital symptoms (excluding vaginal bleeding
because it may also be a drug-related adverse event) as secondary outcomes. We evaluated cardiovascular and cerebrovascular events
separately and added endometrial hyperplasia as a secondary outcome. We no longer considered irregular menstrual periods.
In previous versions of the review, we applied the criterion that To be eligible for inclusion in the review, studies had to report useable
data on one of more of the outcomes listed below (in our list of included outcomes), although we did not explicitly state this. In line with
current Cochrane methods, we now include all studies that measured our outcomes of interest, even if they were not reported in a
useable format.
Statistical methods: We did not fully anticipate at the protocol stage the variation in reporting of the primary outcome, vasomotor
symptoms, and so, some of themethods for combining these data in meta-analysis (explained in theMethods section) are necessarily post
hoc and data driven in nature. Although we believe we have reached the most appropriate conclusion given the available information,
another review team may have made different decisions in relation to the analysis and could plausibly have arrived at a different
conclusion. We have attempted to make our methods transparent, so that the competent reader may determine their suitability for
herself.
Aside from data on vasomotor symptoms, vaginal dryness and sleep (as explained in the Methods section), we did not combine
outcomes by using the fixed-effect model (as stated in the protocol); we used the random-effects model instead, because it takes
population heterogeneity into better account. We considered that two of the major RCTs (Cummings 2008; Kenemans 2009) studied
very heterogeneous populations (women who had had breast cancer and osteoporotic women, respectively), whose characteristics differ
widely from women taking hormonal therapies for postmenopausal symptoms. A recent textbook (Borenstein 2009) highlights (page
86): “The selection of a model must be based solely on the question of which model fits the distribution of effect sizes, and takes account
of the relevant source(s) of error.When studies are gathered from the published literature, the random-effects model is generally a more
plausible match”.
Subgroup analyses: As two of the largest RCTs selected very specific populations, it was considered informative to present, together
with a full analysis set, results on breast cancer distinguishing patients who had already had breast cancer from those who had not, and
distinguishing results on cardiovascular and cerebrovascular events for patients under and over 60 years of age. As stated in the protocol,
we also considered subgroup analyses based on methodological risks of bias components and duration of treatment. We eventually did
not perform these, given the lack of studies in most of the strata.
We took the “multi-centre” item out of the risk of bias tables because participation of more centres in an RCT should mainly increase
its external rather than internal validity. However, we kept this information in the “Notes” items under Characteristics of included
studies.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Breast Neoplasms [chemically induced; prevention & control]; Dyspareunia [drug therapy]; Estrogen Receptor Modulators [adverse
effects; ∗therapeutic use]; Estrogen Replacement Therapy [adverse effects; ∗methods]; Hot Flashes [∗drug therapy]; Neoplasm Recur-
rence, Local [chemically induced]; Norpregnenes [adverse effects; ∗therapeutic use]; Postmenopause [∗drug effects]; Stroke [chemically
induced]; Sweating [drug effects]; Uterine Hemorrhage [∗drug therapy]
MeSH check words
Aged; Female; Humans; Middle Aged
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